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ABSTRACT
Subtractive hybridisation is a powerful method for isolating and identifying
rare genes with an expression pattern restricted to specific cell types. Five novel
cDNA clones were isolated and identified from a differentiated glial subtractive
library. They were shown to be specific to the nervous system by Northern blotting
analysis. In situ hybridisation (ISH) studies were carried out on cultured glial cells
to determine if any of the clones were expressed by specific glial cell types.
Oligodendrocytes were identified by the monoclonal antibody 04 and astrocytes
were identified with an anti-GFAP monoclonal antibody.
Clone OL0755, one of the novel brain specific clones identified, was chosen
for further investigation. Two cDNA clones, believed to be full length, were
obtained by hybridisation screening of a rat cDNA library. Clone OL0755-A is 2.7
kb and encodes a protein of approximately 60 kD. Clone OL0755-B is 2 kb in size
and encodes a protein of approximately 50 kD. Sequence analysis showed these
clones to be two alternatively spliced forms of a common gene. An antibody
(Ab755) raised against a 23 amino acid N-terminus peptide common to both clones
(EASFVQTTMALGLPSKKASSRNV) identifies two proteins with the predicted
sizes, 50 kD and 60 kD. Both the mRNAs and the proteins are developmentally
regulated. Both mRNAs increase in abundance in the postnatal rat brain peaking at
postnatal day 21 (P21). Expression of the smaller, more abundant protein also
increases during development peaking at P21 while the larger protein is less
abundant and downregulates slightly with age. Neither protein is phosphorylated or
N-glycosylated. ISH studies on P21 rat brain sagittal sections with clone OL0755
(common to both OL0755-A and OL0755-B) showed a very strong neuronal pattern
of expression but also a weaker expression in glial cells which was confirmed by
ISH on rat optic nerves and which was consistent with the ISH studies on cultured
glial cells. The appearance of these proteins in both glial cells and neurons during
the active phase of myelination suggests a possible role in this process either as a
structural component or as part of a signalling mechanism between the cell types.
xi
CHAPTER 1. INTRODUCTION
The nervous system of higher vertebrates is a network of electrically
conducting cells which relays information in a very fast and efficient manner
between the brain and all parts of the body. It divides into two parts: the central
nervous system (CMS) which is composed of the brain and spinal cord and the
peripheral nervous system (PNS) which encompasses the rest of the body. The
electrically conducting cells which relay the information are the neurons. These
cells have long processes, called axons, extending from their cell bodies which
transmit the information as electrical impulses. Interconnected neurons form
networks of routes for the information to travel around the body to and from the
brain. A group of cells in close proximity to the neuronal networks, called the
neuroglia, play a supporting role for the neurons.
1.1 Myelination
Many axons in the CNS and PNS of vertebrates are ensheathed by a
multilayered myelin membrane which acts as an electrical insulator. In
unmyelinated nerve fibres a nerve impulse is propagated as an action potential which
travels aiong the axon as a wave of membrane depolarisation. A myelin sheath
insulates the axon from the extracellular fluid and prevents the transport of ions
across the axonal membrane. This creates a region of high electrical resistance. An
action potential can therefore only be generated at nodes of Ranvier. These are small
regions of unmyelinated axon in contact with the extracellular fluid which are
present at intervals along the axon between the myelin sheaths. The action potential
jumps as an electrical current from one node to the next. This very fast form of
impulse propagation is therefore known as saltatory conduction (from the Latin
saltare, to jump). Equivalent conduction velocities in unsheathed axons are only
possible if axonal diameter increases since the rate of impulse transmission in
unmyelinated fibres is proportional to the square of the fibre diameter. Therefore to
increase the rate of conduction four-fold, a fibre diameter must increase 4- = 16
times. Only an enormous unmyelinated invertebrate axon (e.g. squid giant axons)
with a diameter of 1mm can approach a conduction velocity of 100 meters per
second achieved by a myelinated human axon with diameter of 20 qm. Also, since
ion exchange only occurs at nodes of Ranvier and not all over the membrane,
myelinated fibres use less than 1% of the energy required by unmyelinated fibres to
conduct an impulse. Therefore since myelination permits several hundred axons in
the space of one squid giant axon each achieving high conduction velocities at low
energy cost, this insulation material is extremely important to the nervous system by
minimising the space it requires whilst maximising impulse velocities.
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In the CNS the cells responsible for producing this insulation material are the
oligodendrocytes. Oligodendrocytes are one of the main types of macroglia, a
subgroup of the neuroglia, and they have sole responsibility for producing and
maintaining the myelin sheaths. (The oligodendrocytes counterpart in the PNS is the
Schwann cell). This relationship between oligodendrocytes and neurons was
recognised as early as 1900 by Holmgren and by Cajal in 1919 (Cajal, 1919;
Holmgren, 1900) who suggested that the neuroglia might have an insulator function.
This idea was later substantiated by the student of Ramon y Cajal, del Rio Hortega
(del Rio Hortega, 1928). The sheath is produced from the extended processes of
oligodendrocytes which flatten and widen as myelin membrane forms and envelops
sections of nearby axons. These sections of myelinated axon are the internodes,
interspersed by the nodes of Ranvier which allow saltatory conduction of impulses
along the nerve. Some single oligodendrocytes have been shown to extend as many
as 50 processes each myelinating individual internodes on multiple axons at the one
time (Pfeiffer et al., 1993). Compaction of the myelin occurs as the membrane
spirals around the axon. The cytoplasm is extruded from the process causing
adjacent plasma membrane surfaces to become apposed. This results in a
characteristic multilamellar structure. Apposition of cytoplasmic faces of plasma
membrane forms the major dense line and a thinner intraperiod line results from
apposed extracellular membrane faces. Some axons may be ensheathed by over 90
compacted bilayers (Lemke, 1986). The distances between nodes of Ranvier vary
with axonal diameter, thinner axons have shorter internodes and generally axons
with diameters of less than ljxm are not myelinated. Hence axon calibre seems to be
an important element in determining myelination (Raine, 1984; Voyvodic, 1989).
Figure 1.1 schematically demonstrates myelination of an axon.
Asou and colleagues (Asou et al., 1994) observed by time lapse photography
the initial events of this process of myelination. They showed that the axon is
contacted several times by an oligodendrytic process which terminates with a
lamellipodium that was seen to 'ruffle'. Eventually the terminal part of the process
became much thicker and apparently anchored to the axon. This was followed by
rotation of the process around the axon. Transitory junctional complexes between
oligodendrocyte processes and axons were observed by Sims and colleagues (Sims
et al. 1988). It is thought that these may stabilise and help to guide the myelin
forming process around the perimeter of the axon. Their existence must be
transitory to allow the inner spiralling oligodendrocyte process to proceed. Coated
vesicles were also observed in the axonal cytoplasm or fused with the axolemma and
may be responsible for the addition or removal of the specialised junctional
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Figure 1.1 Schematic representation of myelination of a neuronal axon by
oligodendrocytes.
A. Longitudinal view demonstrating nodes of Ranvier which allow saltatory
conduction of the impulse along the axon. Sheaths of myelin envelop the internodal
regions. (Figure from Understanding Biology by Raven and Johnson. Published by
Times Mirror Mosby)
B. Transverse view of an axon ensheathed by compact myelin demonstrating the
major dense line formed by apposing cytoplasmic faces of myelin membrane and the
thinner intraperiod line resulting from apposed extracellular membrane faces.

















B. Myelination - Transverse view intraperiod line of
membrane at the sites of adhesion between axon and myelinating process. (Sims et
al., 1988). At least one full rotation of myelin membrane occurs before compaction
commences (Wiggins et al., 1988). Under normal conditions the absence of
compaction with advanced rotation is rare, except in cases of myelin disorders.
The mvelination of nerves first appeared during evolution in Gnathostomata
(Waehneldt et al., 1986). The Agnatha. which include hagfish and lamprey, posses
glial cells which intimately surround nerve axons but myelin formation is not
observed (Bullock et al., 1984). It is suggested that the acquisition of myelin
forming glia occurred 400-450 million years ago during the lower Silurian period,
unless the ancestral forms of hagfish already possessed this capacity in the upper
Cambrian period (approximately 520 million years ago) but then later lost it
(Waehneldt et al., 1986). Spiral myelination and the expression of characteristic
myelin proteins appears to parallel vertebrate evolution since the complexity of the
composition of proteins in CNS myelin increases significantly during the transition
from fishes to tetrapods in keeping with the 'old evolutionary theme of simplicity to
complexity' (Waehneldt et al., 1986) (see Figure 1.2).
1.2 Components of CNS myelin
The process of myelination involves the production of myelin specific
components by the oligodendrocyte. Like all biological membranes, myelin is
composed of lipids and proteins. Approximately 70% of myelin (dry weight)
consists of lipids, of which 32% are glycolipids, particularly galactocerebroside and
sulphatide, its sulphated analogue. 26% is cholesterol and 42% are phospholipids
(Pfeiffer et al., 1993). This high lipid content makes myelin highly suitable for its
role as an electrical insulator of nerve fibres.
Galactocerebroside is synthesised by UDP-galactose ceramide
galactosyltransferase (CGT). Bosio and colleagues (Bosio et al, 1996) have
generated a null mutant mouse deficient in this enzyme which consequently
completely lacks galactocerebroside and its sulfated analogue sulfatide in both the
CNS and PNS myelin lipid bilayers. The velocity of nerve conduction in
homozygous mutant mice is reduced to that of unmyelinated axons indicating a
severely altered ion permeability of the lipid bilayer. The impaired insulator
function is entirely due to the lack of the main glycolipids, galactocerebroside and
sulfatide, and is not compensated for by other lipids. The severe dysmyelinosis
causes body tremor, loss of locomotor activity and death.
Galactocerebroside and sulfatide are important in the structure and stability
of the myelin lipid bilayer in three ways (Bosio et al., 1996). Firstly, they contribute
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to the tight packing of the hydrophobic core domain, the fluidity of which is adjusted
by the presence of cholesterol. Secondly, strong interactions with proteins such as
myelin basic protein (MBP) and proteolipid protein (PLP) contribute to the tight
compaction of the multilayer membrane system. Thirdly, a dense network of
hydrogen bonds between cholesterol and other lipid components may contribute to
the impermeabilty of the lipid bilaver to ions and therefore its insulation properties.
Therefore in a mutant mouse lacking galactocerebroside and sulfatide, cholesterol
and highly unsaturated phospholipids are the main constituents of the myelin
membrane resulting in increased fluidity and ion permeability and therefore
decreased insulating properties and saltatory conduction (Bosio et ah, 1996).
Defects in other enzymes involved in lipid metabolism cause many disorders
of the nervous system in humans. One group is the Adrenoleucodystrophies (ALD),
some of which are X-linked recessive disorders. They are characterised by the
accumulation of very-long-chain saturated fatty acids in all lipid containing ussues
and body fluids and arise from defective very-long-chain fatty acyl-CoA synthetase
activity in peroxisomes resulting in an accumulation of membrane like cytoplasmic
inclusions in brain tissue (Wanders et al„ 1988).
Proteins are less abundant than lipids in myelin. It has been suggested that
approximately 30% of myelin (dry weight) consists of protein (Pfeiffer et al., 1993).
The number of major proteins in myelin is relatively small. PLP comprises 50% of
the protein mass, followed by MBP which comprises 30-40% in CMS myelin. 2',3'-
cyclic 3'-phosphohydrolase (CNPase) forms approximately 5% and myelin
associated glycoprotein (MAG) forms less than 1% of myelin protein (Dubois-Dalcq
et ah, 1986: Pfeiffer et al., 1993). There are other minor proteins also present (e.g.
myelin/oligodendrocyte glycoprotein (MOG)) and additional ones are continually
being identified. Some of these proteins are believed to have specific roles in the
formation and maintenance of the myelin sheath. Studies utilising mutant mice or
knockouts have aided the elucidation of some of these roles. Described below are
the best characterised proteins of CNS myelin with a discussion of their possible
functions.
1.2.1 MBP
The myelin basic proteins (MBPs) are a family of small, exceptionally basic,
membrane proteins localised at the major dense line of compact myelin (Oppenheim,
1996). They are thought to mediate compaction between adjacent cytoplasmic
membrane surfaces. In the CNS MBP constitutes 30-40% of myelin protein but only
5-15% of PNS myelin protein (Lees and Brostoff, 1984). A single 32 kb gene for
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MBP located on chromosome 18 (Roach et al., 1985) in both rats and mice encodes
for at least six related proteins which are the products of alternative RNA splicing.
Five of the protein variants have molecular weights of 14. 17, 18.5, 20 and 21.5 kD.
A sixth form closely related to the 17 kD variant is indistinguishable on SDS
polyacrvlamide gels (SDS PAGE) and -so avoided identification for some time
(Lemke. 1988). In humans there are at least four different forms present. Therefore
MBP is an example of a gene which is spliced differently in different species (Roth
et al., 1987). Transcription of the gene occurs from a discrete promoter beginning
during the first week of postnatal development, at a time coincidental with the onset
of myelination (Zeller et al., 1985). Newly translated proteins are modified by
phosphorylation (Lemke, 1988; Sutcliffe. 1987).
MBP is found diffusely distributed throughout the cytoplasm of
oligodendrocytes in the early stages of myelination but then transfers to the cell
processes and compact myelin as myelination progresses (Omlin et al.. 1982; Zeller
et al., 1985). Since MBPs exhibit a strong but non-specific affinity for membranes
due to their high positive charge, mechanisms have evolved for transporting MBP
mRNAs to regions where myelin compaction is occurring. This ensures the correct
targeting of MBP polypeptides to their final destination. Ainger et al. observed
distinct patterns of MBP mRNA movement in cultured oligodendrocytes following
microinjection of labelled MBP mRNA (either with digoxygenin or a fluorophore)
(Ainger et al.. 1993). Immediately after injection the mRNAs formed into granules
which associated with the cytoskeletal matrix and were not released by extraction
with non ionic detergent. These granules then demonstrated a sustained directional
movement along oligodendrocyte processes, closely associated with microtubules
traversing the cytoplasm. At branch points there was oscillatory motion and at the
cell periphery where the processes terminated the granules demonstrated random
circular movements. It is suggested that microtubule based motor proteins e.g.
kinesins are involved in the active transport of mRNAs along processes but
microfilament based motors e.g. myosin I may be involved in localising the mRNAs
at the cell periphery.
Recently Pedraza and colleagues investigated observations of MBP
expression in the nuclei of immature oligodendrocytes (Pedraza et al., 1997). They
show that MBP isoforms containing exon II, which are highly expressed in
developing oligodendrocytes, are actively transported into the cell nucleus by a
process which is temperature and energy dependent and may be regulated by
phosphorylation. It is very unusual for a membrane protein to be targeted to the
nucleus. Suggestions implicate that these MBPs have a role in initiating regulatory
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mechanisms which coordinate the process of mvelination. This hypothesis is
supported by observations of the shiverer mutant mouse whose MBP gene is
nonfunctional (Roach et al.. 1985). The absence of MBP protein is associated with
reduced expression of other unrelated myelin proteins (Ganser and Kirschner, 1980).
The shiverer mutant is phenotvpicallv characterised by a generalised tremor
first appearing at postnatal day 12 (PI2) and thereafter worsening until premature
death between P50 and PI00 (Chernoff. 1981: Hogan and Greenfield. 1984). It is
caused by the deletion of a large proportion of the MBP gene. The entire gene from
a point approximately 12 kb downstream from exon 1 is missing (Roach et al..
1983). This MBP deletion seems to be the sole cause of the shiverer phenotype.
Levels of MBP are reduced to less than 1% of wild type (Popko et al.. 1987) and
CNS myelin is largely absent. When myelin is present it is as abnormal whorls of
cytoplasm filled membranes tightly compacted at intraperiod lines but uncompacted
at major dense lines (Privat et al.. 1979. Kirschner and Ganser, 1980). PNS myelin
is less affected than CNS appearing almost structurally and functionally normal
(Kirschner and Ganser. 1980). Insertion of the entire normal MBP gene into the
genome of mutant mice causes the shiverer phenotype to be reversed in resultant
transgenics expressing the introduced transgene (Readhead et al., 1987). The
phenotype is also reversed in transgenics expressing a cDNA encoding the 14 kD
MBP isoform (Kimura et al.. 1989).
An independent autosomal recessive mutation, myelin deficient (md), is
allelic to shiverer (Doolittle and Schweilkart. 1977: Hogan and Greenfield. 1984).
The lifespan of these mutants is shorter than normal mice but longer than shiverer
mice of the same genetic background. They also exhibit a classic shivering
phenotype with tremors and convulsions which generally cause death at around 90
days. The CNS is severely hypomyelinated with approximately 2% of normal MBP
RNA levels (Roch et al., 1986). With increasing age the amount of compact myelin
increases in the CNS as do MBP protein levels but normal levels are never reached.
A defect in the regulation of the MBP gene exists and these md mice also have
several copies of the MBP gene, some with large rearrangements (Popko et al.,
1987). Mice have been produced with graded amounts of myelin by the introduction
of one or more copies of an MBP transgene which have facilitated studies of the role
of MBP in myelination (Popko et al. 1987).
1.2.2 PLP
Proteolipid protein (PLP) is a major integral membrane protein of CNS
myelin constituting about 50% of total protein. It is hydrophobic and has a possible
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structural role in mediating interactions between opposing extracellular membrane
surfaces in compact myelin. There is severe disruption of myelin compaction and a
lack of the intraperiod line in Pip gene 'knock out' mice (Boison and Stoffel, 1994).
PLP is encoded by a single gene located on chromosome X (Willard and
Riordan, 1985). Its sequence is highly conserved during evolution with 99%
sequence homology in rats, cows and humans which suggests a strong
structure/function relationship for PLP (Lemke. 1988: Sutcliffe, 1987). The PLP
gene encodes several mRNA isoforms and thus it is known as a complex
transcriptional unit. DM20 is a truncated form of PLP which arises by alternative
splicing mechanisms. It differs from PLP by a deletion of 105 bp (Nave et al.,
1987). In addition to these two main protein isoforms. each displays 5' and 3'
heterogeneity (Kamholz et al., 1992; Milner et al.. 1985). In the mouse there are two
major transcriptional start sites. Transcriptional activation from the proximal site is
favoured in the PNS in contrast to initiation from the distal site in oligodendrocytes.
3' heterogeneity arises from the alternate use of three polyadenylation sites present
in exon 7 giving rise to three PLP mRNAs of 3.2. 2.4 and 1.6 kb in the adult mouse.
The precise role of DM20 is as yet unknown but it is predominantly
expressed during embryonic development. Experiments by Montague and Griffiths
(Montague and Griffiths, 1997) recently have shown that between embryonic day 12
(El2) and E16 in mice DM20 is the predominant form, present at a ratio of 3:1.
From E17 to postnatal day 1 (PI) there is a shift in the ratio with both protein
isoforms being equally expressed. After PI the ratio shifts again towards
predominant expression of PLP at a ratio of 3:1. This relationship is maintained
throughout adulthood and is therefore used as a recognised marker for post mitotic
oligodendrocytes. Peak protein synthesis, in line with myelination. occurs several
days after the basic proteins. PLP proteins are synthesised on membrane bound
ribosomes in the oligodendrocyte cell body. This is followed by microtubule
dependent delivery and insertion into the plasma membrane (Dubois-Dalcq et al..
1986). The protein has several membrane spanning domains but it does not utilise a
cleaved amino-terminal signal peptide for insertion into the membrane as other
integral membrane proteins do (Lemke, 1988; Sutcliffe, 1987). Signals present in
internal domains of the molecule must be involved instead (Weimbs and Stoffel,
1992). Post-translationally the polypeptide backbone is acylated with fatty acids.
Acylation occurs only as the protein begins entry into the myelin sheath and appears
completed before it enters the compact myelin domains (Coleman et al.. 1982;
Townsend et al, 1982).
Mammalian DM20 has significant sequence similarity to related molecules in
primitive fish (DMa, P and y) and in mice (M6a and b) (Yan et al., 1993). There is
significant sequence identity of DMa to channel lining regions of glutamate and
acetylcholine receptors so it has been proposed that DM20 may act as an adhesive
pore in myelin membrane (Kitagawa et al., 1993). Adhesive pores composed of
DM20 oligomers may line up, couple myelin membranes and form channels
spanning the compact myelin lamellae. This may provide physiological
communication between the extracellular space at the outer surface of the myelin
sheath and the axonal membrane that is covered. A selectively porous sheath might
also allow ion passage across the myelin lamellae. Putative transmembrane
segments of PLP/DM20 are amphipathic as are corresponding regions in known
channel proteins (Popot et al., 1991).
The PLP gene is the target of a host of mutations. Many single base
missense changes are found to cluster within the putative membrane spanning region
of the gene and contribute to multiple forms of Pelizaeus-Merzbacher disease (PMD)
in humans. Partial and complete deletions, insertions, frame shifts and duplications
also cause the disease (Hodes et al., 1993; Seitelberger, 1995). Jimpy is a defect in
the PLP gene caused by a point mutation at the splice acceptor site immediately
preceding the 5th exon (Nave et al., 1987). This mutant has a severely
hypomyelinated central nervous system with degeneration and premature cell death
of oligodendrocytes during development. Rumpshaker is a mouse mutant resulting
from a point mutation within the M4 membrane domain (Fanarraga et al., 1992;
Griffiths et al., 1990). This mutant also has severe hypomyelination which is more
severe in the brain than the spinal cord and its optic nerve axons are completely
unmyelinated. Rumpshaker mice, however have nearly normal lifespans unlike their
jimpy cousins (Lemke, 1993). It has been suggested that PLP plays a role in
oligodendrocyte development and survival as well as in the stabilisation of the
myelin structure.
1.2.3 MAG
Myelin associated glycoprotein (MAG) is a minor transmembrane
glycoprotein and is a member the immunoglobulin superfamily (Arquint et al.,
1987). It is localised in oligodendrocytes to the periaxonal membrane immediately
adjacent to the axon and is also found in non-compacted areas of the myelin sheath
but is absent from compact myelin (Martini and Schachner, 1986). MAG has been
detected in the processes of cultured oligodendrocytes at an age corresponding to
P10 in vivo, a time before either MBP or PLP are expressed (Dubois-Dalcq et al.,
1986). This protein is present at relatively low levels, constituting less than 1% of
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myelin protein.
MAG is encoded by a single gene on mouse chromosome 7 (Barnton et al.,
1987). It is a heavily glycosylated glycoprotein and has two polypeptide forms (72
and 67 kD) which are produced by alternative splicing mechanisms. Only the larger
protein is expressed during the initial stages of myelination. The smaller protein is
expressed in adults when myelination is almost complete and it has a shorter
cytoplasmic domain than its larger counterpart (Frail and Braun, 1983). Small MAG
is the major isoform in the adult CNS (Pedraza et al., 1991).
In vitro studies using anti-MAG antibodies or antisense strategies (Owens
and Bunge, 1991) suggested that absence of functional MAG would result in severe
defects of myelination. However mice with null mutations of the Mag gene develop
apparently normal myelin sheaths of normal thickness and periodicity. In a few
CNS fibres the cytoplasmic collar is not present or it contains abnormal organelles.
Also the myelin present is redundant and the periaxonal space is enlarged. These
defects are associated with a tremor and reduced motor activity (Li et al., 1994).
Another study found no clinical phenotype in a Mag null mutant mouse (Montag et
al., 1994) but CNS fibres showed a decreased periaxonal cytoplasmic collar and
multiple myelin sheaths were present around some axons. The lack in phenotypical
abnormalities, such as tremor, in these mice was ascribed to an increased expression
of the cell adhesion molecule N-CAM (Montag et al, 1994).
MAG has features of a cell adhesion molecule such as the carbohydrate
determinant HNK-1 which is common to molecules proposed to mediate cell-cell
interactions e.g. NCAM and LI (McGarry et al., 1983). MAG also contains the Arg-
Gly-Asp tripeptide which mediates binding of many matrix adhesion molecules to
their receptors (Salzer et al., 1987). For example, the cell receptors for fibronectin
(Pytela et al., 1985b), vitronectin (Pytela et al., 1985a) and osteopontin (Oldberg et
al., 1986) have been shown to interact with Arg-Gly-Asp sequences on these
extracellular matrix proteins. MAG has been shown to mediate neuron-
oligodendrocyte and oligodendrocyte-oligodendrocyte adhesion in vitro which is
subsequently blocked by an anti MAG antibody which recognises an extracellularly
localised epitope (Poltorak et al., 1987). Of the two isoforms only the larger
protein is phosphorylated, primarily at serine residues, and it is suggested that this
has significance in the regulation of oligodendrocyte-neuron interactions (Edwards et
al., 1988b). Thus evidence suggest that MAG may have a role to play in
coordinating the recognition and interaction of oligodendrocyte processes with axons
and in preventing interactions with existing myelin.
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1.2.4 CNPase
2',3'-cyclic nucleotide 3'-phosphohydrolase (CNPase) enzymatic activity
was first demonstrated in bovine spleen (Whitfield et al.. 1955) and pancreas (Davis
and Allen, 1956). It hvdrolvses 2'.3'-cyclic nucleotides to give 2'-nucleotides and
can be induced by cyclic AMP (McMorris. 1983). It exists as a dimer with two
catalytically active enzyme forms (Mueller et al.. 1981) produced by alternative
splicing of mRNAs (Bemier et al.. 1987). It has been detected in a variety of tissues
including neuronal cell lines, cultured astrocytes, adrenal medulla, rat liver
mitochondria and serum but its high specific activity in myelin of both the peripheral
and central nervous systems has resulted in its use as a biochemical marker for
myelin and more specifically for the myelin forming glial cells since by comparison
its activity is extremely low in astrocytes (Kurihara and Tsukada, 1967; Podulso and
Norton, 1972). CNPase is found throughout the developing oligodendrocyte cell
body but is more concentrated at the cell periphery adjacent to the plasma membrane
and in elongated oligodendrocyte processes (Braun et al.. 1988). In myelin CNPase
is excluded from compact lamellar domains but is present within the cytoplasmic
channels that traverse the sheath (Trapp et al.. 1988; Brunner et al., 1989). It is an
accumulating component of myelin appearing early in oligodendrocyte development
followed later by MAG. MBP and PLP expression (McMorris, 1983; Vogel and
Thompson, 1988). Translation occurs on free ribosomes (Gillespie et al., 1986;
Karin and Waehneldt. 1985) and the amount of translatable RNA increases with
myelination. Both isoforms of the enzyme are also developmentally regulated in
parallel (Edwards and Braun. 1988a).
1.2.5 MOG, MOSP, MOBP and OMgp
Myelin/oligodendrocyte glycoprotein (MOG) is a unique member of the
immunoglobulin superfamily expressed specifically in the CNS (Gardinier et al.,
1992). Immunoelectron microscopy has localised this protein to the processes of
oligodendrocytes and the external surface of the myelin sheath in adult rats
(Linington et al., 1988). MOG expression parallels other myelin proteins peaking at
PI5-25 in rats, a period of active myelination but expression lags two days behind
MBP possibly suggesting a function in completion and maintenance of the myelin
sheath (Gardinier et al., 1992). MOG has been shown to be a primary target
autoantigen in autoimmune encephalomyelitis in Lewis rats and so may act as an
autoantigen in the pathogenesis of some demyelinating diseases such as multiple
sclerosis in humans (Adelmann et al., 1995).
Myelin/oligodendrocyte specific protein (MOSP) is specifically expressed in
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CNS myelin and oligodendrocytes of higher vertebrates and is recognised by the
monoclonal antibody CE1 (Dyer et al., 1991). MOSP initially appears at P4-5 about
1-2 days after the appearance of galactocerebroside and sulfatide (Mu and Dyer,
1994). This coincides with the time when oligodendrocytes are elaborating
processes and just beginning to form membrane sheets. It is a 48 kD protein which
remains on the surface of cultured oligodendrocytes but becomes associated with
cytoplasmic microtubules following antibody binding (Dyer et al., 1991). This
suggests a role in membrane/cytoskeleton interactions during the extension of
growing processes and the formation of the myelin sheath. Its expression on the
surface of cultured oligodendrocytes also suggest that it may serve as an antigenic
target in demyelinating diseases (Dyeret al., 1991).
Myelin-associated/oligodendrocytic basic protein (MOBP) was identified by
a subtractive cDNA screening approach (Schaeren-Wiemers et al., 1995; Yamamoto
et al., 1994). It has several isoforms produced by alternative splicing which are
identical at their N-termini but differ at their C-termini. MOBP expression is
exclusive to the CNS (Yamamoto et al., 1994). Expression in rat optic nerve
oligodendrocytes occurs later than MBP and PLP but coincides exactly with the
onset of myelin compaction suggesting a possible role in the last stages of
myelination and maintenance of the myelin sheath (Holz et al, 1996).
Oligodendrocyte myelin glycoprotein (OMgp) is a membrane protein specific
to oligodendrocytes and CNS myelin (Mikol and Stefansson, 1988). The gene is
located to chromosome 17 in humans (Mikol et al., 1990b). Its function is unknown
but it is a member of a protein family characterised by leucine-rich repeats (Mikol et
al., 1990a).
1.3 Are other cell types involved in myelination?
The other major macroglial cell type is the astrocyte characterised by
intermediate filaments which are largely composed of polymers of GFAP (glial
fibrilliary acidic protein). GFAP is a specific marker for these cells in the CNS
(Bignami et al., 1972). Astrocytes are found ubiquitously throughout the CNS and
are thought to be the most abundant glial cell type. They exhibit different properties
depending on anatomical location. In grey matter protoplasmic astrocytes have fine
delicate processes but display little immunoreactivity for GFAP. In white matter
fibrous astrocytes have thicker processes with low but detectable immunoreactivity
for GFAP (Lee and Brosnan, 1997).
Astrocytes have a number of functions in vivo including the formation of
physical barriers within the nervous system. Cells resembling fibrous astrocytes
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contribute to glial limiting membranes (glial limitans) (Miller and Raff, 1984). The
processes of specialised astrocytes put feet on blood vessels forming the perivascular
sheath and can induce endothelial cells to form tight junctions (Janzer and Raff,
1987). This suggests that glial cells are responsible for inducing the capillary and
venule endothelial cells in the CNS to form the blood brain barrier. Astrocytes are
also part of the physical barrier separating the CNS and the pia-arachnoid membrane,
the CNS-CSF (cerebral spinal fluid) barrier (Lee and Brosnan, 1997).
Fibrous astrocytes have been observed to interact directly with neurons by
extending processes to the exposed regions of axon between myelin sheaths at the
nodes of Ranvier where saltatory conduction occurs. Their role is possibly one of
nourishing the adjacent axon and stabilisation of local ion concentrations (Ffrench-
Constant and Raff, 1986). Astrocytes are known to secrete growth factors which act
on developing oligodendrocytes (Noble and Murray, 1984). There is also some
indirect evidence that astrocytes are responsible for forming glial scarring in CNS
white matter. Following injury a glial scar forms which is composed of intermediate
filament bundles generated by increased levels of GFAP, vimentin and nestin. The
intermediate filament network at the scar area is very compact and it has been
proposed that the glial scar acts as a physical barrier to neurite outgrowth (Hatten et
al., 1991). Nestin, like GFAP, is an intermediate filament protein which forms an
easily recognisable cytoskeletal network, a general characteristic of intermediate
filaments (Lendahl et al., 1990). The protein is predominantly present in CNS
progenitor cells and expression is downregulated in the adult nervous system
(Dahlstrand et al., 1995). In addition to normal expression during development, the
nestin gene can be reactivated in situations of stress or induced proliferation
(Dahlstrand et al., 1992). After injury to the nervous system nestin is induced in the
CNS. Nestin expression is strikingly and rapidly upregulated in astrocytes of an
injury area and its induction lasts for at least 13 months leaving a longlasting
molecular imprint of the damage (Frisen et al., 1995). Antisense GFAP RNA has
been shown to inhibit GFAP synthesis in astrocytes and so this technique may be
useful for regulating the astrogliosis immediately following CNS injury by delaying
the gliotic reaction and formation of the physical barrier, thus enabling neurons and
oligodendrocytes to re-establish a functional environment (Yu et al., 1991).
Two types of GFAP+ astrocytes have been identified in cultures of
developing rat optic nerve based on morphology, growth characteristics and their
labelling with ligands. Type 1 astrocytes have a fibroblast like morphology,
proliferate in culture and do not bind tetanus toxin or the A2B5 antibody (Raff et al.,
1983). Type 2 astrocytes have a process bearing morphology similar to
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oligodendrocytes, divide infrequently in culture and bind tetanus toxin and the A2B5
antibody (Raff et al., 1983). Expression of both A2B5 and GFAP is a useful marker
in this culture system for type 2 astrocytes, which also share a progenitor cell stage
with oligodendrocytes in vitro (see 1.4). In developmental studies, these markers
were used to identify astrocyte subtype in cultures from optic nerves taken
throughout development. Miller et al: observed that only type 1 astrocytes
(GFAP+/A2B5~) were present at the time equivalent to birth and they reached stable
levels by P15. Type 2 astrocytes (GFAP+/A2B5+) did not appear until the second
postnatal week after PI5, corresponding to a time after oligodendrocytes have begun
myelination. Type 2 astrocytes contributed to more than 65% of astrocytes in
cultures of adult nerve (Miller et al., 1985). A third type of astrocyte has been
identified in cultures of striatum and spinal cord, which express GFAP and the GD3
ganglioside (Vaysse and Goldman, 1992). This cell type is clonally distinct from
type 1 and type 2 astrocytes. These lineage distinctions described may have little
applicability to astrocytes throughout the CNS in vivo since to date there are no
lineage specific subtype markers which encompass both in vivo and in vitro
astrocytes. Astrocytes are extremely heterogeneous not only when comparing
astrocytes from different brain regions but also when comparing cells from the same
brain region (Lee and Brosnan, 1997).
During development a caudal to rostral gradient of GFAP expression by
astrocytes can be followed which correlates with overall brain maturation. GFAP
mRNA is first seen at El6 in the glial limitans of the ventral hind brain but peak
expression at P15 is localised to the deep white matter tracts of the cerebellum,
corpus callosum and certain hippocampal tracts. This is reduced in adults (Landry et
al., 1990). The expression of GFAP mRNA in the developing brain is consistent
with a pattern of at least two waves of astrocyte development. The differentiation of
interfascicular glia in both white and grey matter occurs first followed by the
appearance of astrocytes in white matter tracts once myelination has been initiated
(Landry et al., 1990). A similar pattern of two waves of astrocyte development was
observed by Miller et al in the developing rat optic nerve, as described above. The
correlation of astrocyte development with the onset of myelination implicates a role
by astrocytes in this process during development of nervous system.
1.4 A closer look at myelination
Myelination at first glance appears deceptively simple. Apparently few
major components contribute to the elegant structure of the myelin sheath which so
effectively fulfils its role as an electrical insulator, thus enabling the body to function
13
in a coordinated manner. Yet the details of the process are still extremely poorly
understood and many workers continue to explore the gaps of knowledge striving to
piece together a full picture of understanding.
1.4.1 What causes an oligodendrocyte to extend processes which will myelinate
neuronal axons?
Mature multipolar oligodendrocytes are located in brain white matter as rows
of myelinating cells between nerve fibres. In grey matter they are either associated
with myelinated axons or exist as non-myelinating satellite cells. They are
characterised by their expression of galactocerebrosides (GC) and the lack of
vimentin or any other class of intermediate filaments. These mature cells develop
from small, rounded, bipolar progenitor cells which express vimentin in their
cytoplasm and gangliosides on their cell surface recognised by the A2B5
monoclonal antibody. Such a progenitor cell can be isolated in vitro and will
differentiate in the presence of foetal calf serum (FCS) into a GFAP expressing type
2 astrocyte (A2B5+' GFAP+) or into an oligodendrocyte (A2B5~, GC+) when FCS
is not present. This bipotential progenitor cell therefore became known as the
oligodendrocyte-type 2 astrocyte (0-2A) progenitor (Raff et al., 1983) and in vitro
studies on it have consequently provided many insights into how the development of
oligodendrocytes is regulated. In vivo the tetrasialogangliosides which bind the
A2B5 antibody are also present on neurons (Eisenbarth et ah, 1979), but the optic
nerve which has been described as the simplest part of the CNS does not contain
neuronal cell bodies and so A2B5 is a useful marker for these progenitor cells
present (Miller et al., 1985).
Previously there has been some debate about whether type 2 astrocytes
develop from 0-2A progenitor cells in vivo, although it is now generally thought to
be unlikely. The optic nerves of newts posses a single type of glial cell which
functions as both an astrocyte, with glial filaments and forming a glial limiting
membrane, as well as an oligodendrocyte which myelinates the axons. In the spinal
cord of the newt, however, these two functions are performed by different cell types.
This suggests that there is a possible phylogenetic relationship between type 2
astrocytes and oligodendrocytes (Raff et al., 1983). However since there is no
conclusive evidence that 0-2A cells give rise to type 2 astrocytes in vivo, the 0-2A
cells are now referred to as oligodendrocyte progenitors in vivo.
Cell lines of glial progenitor cells, however, do appear able to generate both
oligodendrocytes and astrocytes in vivo as well as in vitro in response to their
environment. Following the transplantation of cells of the CG4 cell line into areas of
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adult rat spinal cord white matter which had been permanently depleted of glial cells
by local X-irradiation and/or injection with 0.1% ethidium bromide, both myelin
forming oligodendrocytes and GFAP+ astrocytes were identified within the lesion
(Franklin et ah, 1995). The CG4 cell line was obtained from cultures of 0-2A
progenitor cells which had been maintained in the presence of mitogens secreted by
neuronal B104 cell line (Louis et al., 1992). The origin of the glial cells within the
spinal cord lesion was confirmed by retroviral incorporation of the lacZ marker gene
and hence demonstrated that CG4 cells have the potential to differentiate along both
glial pathways in an in vivo environment (Franklin et al., 1995). This indicates that
clonal glial progenitor (0-2A) cell lines are able to manifest differentiation
bipotentiality within a pathological environment that does not appear to occur during
normal development (Skoff, 1990). This has obvious implications in the repair of
damaged CNS.
1.4.2 How do 0-2A progenitor cells decide which glial pathway to take?
Progenitor cells are able to switch from the astrocyte pathway to the
oligodendrocyte pathway after one or two days but not after three days in culture, so
cell division and hence DNA replication is not a requirement for 0-2A progenitors to
choose which glial pathway to differentiate along (Temple and Raff, 1985). Since
type 2 astrocytes occur in culture in the presence of FCS it seems that some factor
mimicked by FCS induces this choice of pathway and the oligodendrocyte pathway
must therefore be a constitutive one. There is evidence to suggest that ciliary
neurotrophic factor (CNTF) released by type 1 astrocytes has such an inducing effect
on type 2 astrocytes (Raff, 1989).
1.4.3 Markers of the oligodendrocyte lineage.
The expression of myelin constituents and the process of myelination both
occur as a consequence of the differentiation of 0-2A progenitors into
oligodendrocytes. Antibodies raised against the various myelin proteins are used to
follow their sequential appearance and hence the stages of oligodendrocyte
development. The monoclonal antibodies 01 and 04 recognise developmentally
regulated cell surface antigens which are specific to cells of the oligodendrocyte
lineage. 04 is a marker for sulfatide and seminolipid and 01 recognises
galactocerebrosides (Sommer and Schachner, 1981). The ordered and partially
overlapping expression of A2B5, 04 and GC/01 markers distinguishes 3 consecutive
phenotypically defined stages of the oligodendrocyte lineage in vitro. 1) Bipolar
A2B5+, 04", GC/01" glial precursor cell, the 0-2A progenitor. 2) multipolar A2B5+,
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04+, GC/01" progenitor. 3) complex process bearing 04+, GC/01+ oligodendrocyte
(Dubois-Dalcq, 1987) which goes on to express the myelin proteins, CNP, MOSP,
MB P. MAG. PLP and MOBP as it begins to produce myelin membrane (See Figure
1.3).
Other serological markers for cells of the oligodendrocyte lineage include the
monoclonal antibody A007 which has a developmental expression pattern identical
to that for 04 (Knapp. 1991). Both antibodies recognise the proligodendroblast
antigen (POA) which is expressed by A007 and 04 positive oligodendrocyte
progenitors before the appearance of sulfatide and galactocerebroside. It seems
likely therefore that both antibodies either recognise the same epitope, or different
epitopes on the same molecule, or two epitopes of two different molecules expressed
at the same time (Bansal et al., 1992). The monoclonal antibody 2B10 labels a cell
surface molecule specifically expressed by cells of the oligodendrocyte lineage, first
appearing as early as embryonic day 14 in rat spinal cord. Its abundance decreases
during myelination but remains steady in adulthood. This molecule is not, however,
a myelin-associated protein since it is not detected in purified myelin fractions (Zhou
et al., 1995). The monoclonal antibody Rip selectively stains mature
oligodendrocytes, their processes and myelin in the adult CNS. It is exceptional in
that it allows the long cytoplasmic processes to be traced back to a parent
oligodendroglia somata (Friedman et al., 1989). When Rip is used in double
labelling experiments with an antibody to carbonic anhydrase II (CAII), two
biochemically and morphologically distinct populations of oligodendrocytes are
identified. Rip+, CAH+ oligodendrocytes support numerous myelin sheaths for
small diameter axons, while Rip+, CAII" oligodendrocytes support fewer myelin
sheaths for large diameter axons, hence there are two types of oligodendrocytes
myelinating large and small diameter fibres (Butt et al., 1995).
1.4.4 Oligodendrocyte progenitor migration.
Oligodendrocyte progenitor cells are highly motile as demonstrated by time
lapse cinematography of progenitor cells in the rat optic nerve (Small et al., 1987).
Small et al. deduced that these progenitors are the only cells of the oligodendrocyte
lineage capable of migration. They were observed moving in the direction of their
bipolar processes and on division the two new cells migrated in opposite directions.
On differentiation their migration ceased. During development of the rat optic nerve
oligodendrocyte progenitor cells first appeared only after axons had reached the
chiasm at approximately embryonic day 15 (E15). At E17 they were distributed
throughout the nerve in a highly graded fashion with less than 0.4% in the retinal
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Figure 1.3 Schematic representation of the rodent oligodendrocyte lineage in vitro.
The sequential appearance of stage-specific antigens is indicated as the cell
morphology changes resulting from differentiation. During differentiation the
bipolar progenitor cell extends many processes which become highly branched and
eventually produce sheets of myelin membrane which would normally envelop
























segment. 2.4% in the middle segment and 6.5% in the chiasmal segment of the optic
chiasm. By birth a steep gradient still existed but now 18% of progenitors occurred
in the retinal segment. 31% in the middle and 51% in the chiasmal segment. This
gradient diminished during the first nine days after birth. Small and colleagues
deduced that the oligodendrocyte progenitor cells migrated into the optic nerve from
the brain guided by the axons. The neuroepithelial cells forming the optic stalk
therefore only give rise to astrocytes (Small et ah. 1987). It is this ability of rapid
movement over long distances by these small motile progenitor cells which ensures
that all axons that need to be myelinated are catered for.
1.4.5 What controls the timing of oligodendrocyte cell development?
It is possible to culture oligodendrocytes in vitro which express myelin
proteins e.g. MBP and PLP without the presence of neurons or other cell types. This
suggests therefore that development of these cells must partly be intrinsic (Dubois-
Dalcq et al., 1986; Temple and Raff. 1985; Knapp et al.. 1987; Yim et al., 1986).
However, there are also many factors which contribute to the regulation of
oligodendrocyte development.
The sequential appearance of type 1 astrocytes (A2B5~, GFAP+) first
appearing in the rat optic nerve at El6. oligodendrocytes (GC+) appearing at birth
and type 2 astrocytes (A2B5+, GFAP+) between P7 and P10 (Miller et al., 1985)
suggest that astrocytes may be part of these regulatory mechanisms. Type 1
astrocytes "have been shown to promote progenitor motility and inhibit premature
differentiation in culture. The effect is produced when 0-2A cells are cultured in
medium which "has been conditioned by astrocytes but does not occur when the
astrocytes are previously treated with antibodies against platelet derived growth
factor (PDGF) (Raff et al., 1988). PDGF reproduces the effect on 0-2A cells when
it replaces astrocyte conditioned medium and again the effect is blocked by an
antibody against PDGF (Noble et al., 1988). Cultures of purified type 1 astrocytes
have been shown to secrete PDGF as well as synthesise PDGF mRNA (Richardson
et al., 1988). When astrocyte conditioned medium is fractionated by gel filtration
the mitogenic activity on 0-2A cells is found in the same fraction as radiolabeled
PDGF (Richardson et al., 1988) and since PDGF has also been shown to be present
in the developing rat optic nerve (Pringle et al., 1989). evidence implicates PDGF as
a molecule promoting progenitor motility and proliferation.
It has been hypothesised that PDGF derived from type 1 astrocytes drives an
intrinsic clock which times oligodendrocyte development by counting the number of
times a progenitor cell divides before spontaneously differentiating into a multipolar
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oligodendrocyte (Raff et al., 1988; Raff et al., 1985). Most progenitor cells have
similar cell cycle times dividing every 1-2 days in culture but their proliferative
capacity varies from cell to cell. In an experiment when progenitor cells were
isolated from PI and P7 rat optic nerve, clone sizes ranging from 2-150 cells were
produced. Separated sister cells always underwent a similar number of cell divisions
before differentiation but the number of divisions varied from pair to pair (Temple
and Raff, 1986). Hence the mitotic clock hypothesis suggests that there is a fixed
maximum number of cell divisions that a progenitor cell can undergo before
differentiation but this number varies between cells so that at any one time during
development there are cells present at different developmental stages.
1.4.6 How is the mitotic clock timed?
In development the thyroid gland becomes active and produces thyroid
hormone at around the time of birth coinciding with the first appearance of
oligodendrocytes (Dussault and Ruel, 1987; Miller et al., 1985). Thyroid hormone is
known to influence many types of precursor cell (Barres et al., 1994). In culture the
number of divisions a progenitor cell undergoes before differentiating decreases with
increasing levels of thyroid hormone (Barres et al., 1994). This observation appears
to be consistent with the mitotic clock hypothesis. Glucocorticoids and retinoic acid
have similar effects. The receptors for all these hormones, when complexed with
their substrates, are able to inhibit the activity of the AP-1 transcription factors and
therefore arrest cell division (Diamond et al., 1990; Nicholson et al., 1990). These
transcription factors are formed by the dimerisation of members of the Jun and Fos
protein families and help to mediate the proliferative response to growth factors e.g.
PDGF in many cell types (Ransone and Verma, 1990; Angel and Karin, 1991). The
intrinsic clock may therefore operate by counting the number of cell divisions
promoted by PDGF which are permissible before AP-1 activity is decreased to a
minimum level. As hormone levels increase, the hormone receptors inhibit AP-1
activity by either decreasing the concentrations of c-fos or c-jun, causing a change in
their dimer partners or covalently modifying these proteins. Once AP-1 activity has
fallen below a minimum level further proliferation is prevented and differentiation
may proceed by default (Barres et al., 1994).
1.4.7 Effects of glutamate and cAMP
Other molecules also exert their effects on oligodendrocyte regulation
through transcription factors at the level of gene transcription. Glutamate induces a
rapid and transient expression of the c-fos oncogene in oligodendrocyte progenitor
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cells through AMPA/kainate receptors and promotes progenitor cell proliferation
(Liu and Almazan. 1995). This expression is also dependent on extracellular
calcium influx and downstream activation of phorbal ester-sensitive protein kinase C
(Liu and .Almazan. 1995). Consequently glutamate plays a role in modulating the
growth and differentiation of oligodendrocytes in the CNS. 3', 5'-cyclic AMP
(cAMP) is another molecule able to regulate oligodendrocyte development (Raible
and McMorris, 1993). Analogues of this molecule inhibit proliferation and
accelerate the rate of differentiation by progenitor cells in mixed glial cultures which
have been established from 1 day old rat cerebrum (Raible and McMorris, 1989,
1990). This suggests that cAMP also increases the rate of induction of the
expression of myelin components. The inhibition of proliferation and the promotion
of differentiation by cAMP can be uncoupled, hence these two processes are
regulated independently by cAMP (Raible and McMorris. 1993).
1.4.8 Production and deposition of myelin proteins
Not only is the differentiation of progenitor cells into oligodendrocytes
carefully regulated but also, it seems, the production of myelin proteins once the
cells have committed to this change in morphology. Monge and colleagues observed
that in newly formed oligodendrocytes, just after differentiation, GC expression is
followed by MBP and then PLP yet in the myelin sheaths deposition of MBP is
followed by PLP and finally by GC (Monge et ah. 1986). Therefore expression of
these proteins within myelin appears to occur as a second wave following
differentiation and shortly before oligodendrocytes begin the process of myelination
(Monge et al., 1986). There is also a difference in timing between differentiation
and myelination by oligodendrocytes in the optic nerve (Colello et ah. 1995).
Progenitor cells present throughout the length of the rat optic nerve at postnatal day
two (P2) mature into GC+ oligodendrocytes in a chiasm to eye progression, with the
oligodendrocytes near the chiasm expressing MBP and PLP three days before those
near the eye (Colello et ah, 1995). However. Colello and colleagues also reported
that the axonal segments near the eye are ensheathed with myelin before those near
the chiasm and that the signalling for the onset of myelination is independent of the
electrical activity of the axon but correlates with increased axonal diameter (Colello
et al., 1995). They also noted that the proportions of axons near the eye were larger
than axons near the chiasm and suggested that a level of axonal maturity is necessary
before the potential expression of an as yet unknown factor which promotes
myelination is possible. A gradient of this factor would therefore occur in an eye to
chiasm direction thus promoting myelination of axons with a minimum diameter.
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This would be similar to what has been found for PNS axons where axon calibre
appears to be a crucial determinant of whether an axon becomes myelinated
(Vovvodic. 1989). Therefore it seems that the processes of cell differentiation and
the production of myelin by an oligodendrocyte can be uncoupled and regulated
independently according to the requirements of the environment.
Steroid hormones effect myelin synthesis by differentiated oligodendrocytes.
In culture hydrocortisone increases PLP mRNA expression by oligodendrocytes as
well as the synthesis of cerebrosides, both of which are components of myelin
(Podulso et al., 1990). Also the metabolising enzymes for ketone bodies, which are
precursors of lipid synthesis, are induced by hydrocortisone (Robinson and
Williamson. 1980). Lipids are an important component of the myelin sheath
comprising 70% of its dry weight (Pfeiffer et al., 1993).
1.4.9. The role of the cytoskeleton.
The dramatic changes in cell morphology during differentiation and
myelination by an oligodendrocyte are also dependent on the cytoskeleton which
interacts with the plasma membrane to regulate shape and movement. Except for a
transient expression of vimentin oligodendrocytes appear to be devoid of
intermediate filaments (Pfeiffer et al., 1993) but their cytoskeleton is rich in
microtubules (polymers of tubulin) and microfilaments (polymers of actin).
Microtubules are located predominantly in the cell body and major processes of
cultured oligodendrocytes while microfilaments are found enriched in the multiple
fine processes at the cell periphery (Wilson and Brophv, 1989). Both play an
important part in the intracellular sorting and transport of components as the changes
in cellular architecture occur. When a cytoskeletal matrix is purified from rat CNS
myelin by non-ionic detergent extraction, components specific to myelin such as
MBP and CNP are found associated with the cytoskeletal preparations (Gillespie et
al., 1989; Pereyra et al., 1988). This suggests the importance of such interactions
during myelination and the maintenance of the mature myelin sheath.
Gelsolin is an ubiquitous actin binding and microfilament severing protein
predominantly expressed in the CNS by oligodendrocytes (Lena et al., 1994; Tanaka
and Sobue, 1994). There are two major forms of gelsolin, a cytoplasmic and a
secretory form (Kwiatkowski et al., 1986). Recently an alternatively spliced form of
the cytoplasmic gelsolin has been identified which appears to be exclusively
expressed by oligodendrocytes in the CNS (Rogers et al., 1997). Actin-binding
proteins are probably important in the extension of myelinating processes by
oligodendrocytes.
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Microtubule-associated proteins (MAPs) are important in regulating the
dynamics and structure of microtubules (Mandelkow and Mandelkow, 1995) and are
enriched in the CNS. The major types are either structural (MAPI, MAP2, MAP4
and MAP-tau) or are microtubule-based motors such as the kinesins which, as
already mentioned, may be involved :in the transport of MBP mRNAs to the
oligodendrocyte periphery. MAP1B is present in oligodendrocytes but expression is
absent from progenitor cells (A2B5+, 04"). It first appears in proligodendrocytes
(A2B5+, 04+) and precedes the development of the mature oligodendrocyte
phenotype suggesting that interactions between microtubules and MAP IB might
have a role in the formation and stabilisation of developing myelin forming
processes (Vouviouklis and Brophy, 1993). This hypothesis is supported by the fact
that anti-sense oligonucleotides to MAP IB mRNA have a destabilising effect on
oligodendrocyte morphology in culture (Rogers et al.. 1997).
MAP4 is ubiquitous but abundantly expressed in brain oligodendrocytes
(Vouyiouklis and Brophy, 1995). It is expressed at all developmental stages of
oligodendrocytes but does not colocalise with microtubules to the same extent as
MAP IB in mature cells (Vouyiouklis and Brophy, 1995). Therefore it probably
does not have a microtubule stabilising role as proposed for MAP1B. However
since it is ubiquitous and upregulated during oligodendrocyte differentiation at a
time when oligodendrocyte progenitors drop out of mitosis, it has been hypothesised
that MAP4 is involved in regulating microtubule dynamics during the cell cycle
(Olmsted et al., 1989).
MAP2 has two high molecular weight protein forms. MAP2a and MAP2b of
approximately 199 kD and a smaller isoform, MAP2c, of 42 kD (Riederer and
Matus, 1985; Kinaler et al.. 1990). These variants arise from a common gene by
alternative splicing mechanisms (Papandrikopoulou et al., 1989). MAP2c is
abundant at birth but is downreguiated when the high molecular weight MAP2
becomes detectable, so is often referred to as the embryonic form of MAP2
(Reiderer and Matus, 1985). MAP-tau and the high molecular weight form of
MAP2 are not present in cultured oligodendrocytes but MAP-tau has been detected
in astrocytes (Vouyiouklis and Brophy, 1995). A fourth isoform of MAP2 has
recently been identified which is similar to MAP2c but includes an additional repeat
within the microtubule-binding site. It is therefore known as 4-repeat MAP2c or
MAP2d (Vouyiouklis and Brophy, 1995; Doll et al., 1993). Although the specific
functions of the various MAPs in oligodendrocytes are still unknown, their
localisation patterns and expression during oligodendrocyte development suggest
that they have distinct roles in the regulation of the microtubule network during
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differentiation of oligodendrocytes.
1.4.10 How are the number of oligodendrocytes matched to the number of axonal
segments to be myelinated?
The survival of newly formed and mature oligodendrocytes is also regulated
by many factors. Between P8 and' P12 at least 10,000 newly formed
oligodendrocytes, approximately 50% of those generated each day, normally die in
the optic nerve daily. They apparently die as a result of competition for survival
factors which act to inhibit an intrinsic suicide program (Raff, 1992). In culture
PDGF is a survival factor for newly formed oligodendrocytes. When PDGF levels
are increased in the developing rat optic nerve oligodendrocytes cell death is
decreased by up to 90% and the number of oligodendrocytes doubles in 4 days
(Barres et al., 1992). There is an extremely fast rate of clearance of these apoptotic
cells. It takes approximately one hour from when a cell dies to the time it is
phagocytosed and degraded (Raff et al., 1993). Therefore normal oligodendrocyte
death is a mechanism for adjusting the numbers of oligodendrocytes required to
myelinate lengths of axon. In the adult optic nerve there are about 100,000 axons
(Lam et al., 1982) myelinated by around 300,000 oligodendrocytes (Barres et al,
1992).
Survival of oligodendrocytes in the rat optic nerve is also dependent on the
electrical activity of neighbouring axons. If the nerve axons are severed
experimentally oligodendrocytes and astrocytes die (Barres and Raff, 1994). Axonal
withdrawal also causes a downregulation of the major myelin proteins, MBP, PLP
and MAG, at the transcription level in mature oligodendrocytes (Goto et al., 1990).
Experimentally increasing PDGF levels in optic nerve can compensate. Hence
axonal electrical activity is required to stimulate astrocytes to produce and release
PDGF which keeps progenitor cells proliferating and inhibits cell death (Barres and
Raff, 1993).
1.5 Some growth factors which regulate oligodendrocyte development
As has been briefly illustrated the development of oligodendrocytes from
progenitor cells and the consequential production of myelin components are
carefully regulated by a host of different factors. Many growth factors are known to
be secreted by neurons and astrocytes in vivo, so both cell types are potential sources
of molecules influencing oligodendrocyte differentiation and myelination.




PDGF (Platelet derived growth factor) is a disulfide linked dimer of A and B
chains with structure AA, BB or AB depending on its source (Collarini et al., 1991).
Neurons have been shown to express A and or B chains (Yeh et ah, 1991), and
astrocytes to express A chains (Collarini et ah, 1991), but it is unknown if neuron-
derived PDGF contributes to oligodendrocyte development. PDGF binds to
transmembrane receptors with extracellular ligand binding domains and intracellular
tyrosine kinase domains (Reviewed by Collarini et ah, 1991). Unoccupied receptors
are monomeric but binding of PDGF induces dimerisation and activates tyrosine
kinase activity. There are two types of PDGF receptor subunit; a binds both A and
B chains but [3 binds only B chains. 0-2A progenitor cells express predominantly the
a receptor (McKinnon et ah, 1990). PDGF is both a survival factor and a mitogen
for 0-2A progenitor cells. It stimulates 0-2A cell proliferation and prevents
premature differentiation (McKinnon et ah, 1993; McKinnon et ah, 1990) which
later proceeds by default when PDGF and other exogenous signals are removed
(Temple and Raff, 1985). The concentration of PDGF required to promote
oligodendrocyte precursor survival is 200 fold lower than that required to promote
their proliferation and only PDGF-AA efficiently promotes survival (Barres et ah,
1993). Possibly there is a high affinity PDGF receptor which signals survival but
not proliferation.
Following differentiation PDGF receptors are downregulated in maturing
oligodendrocytes (Pringle et ah, 1992). In these postmitotic oligodendrocytes
persisting PDGF mediates an increase in cytosolic Ca^4" which activates c-jun and c-
fos expression. This Ca^+ mediated signalling pathway may cause process
elongation in myelinating oligodendrocytes (Hart et ah, 1989; Pfeiffer et ah, 1993).
1.5.2 bFGF
bFGF (basic fibroblast growth factor) has been purified from many tissues
which have been shown to be FGF sensitive. These include brain, pituitary, retina,
corpus luteum, adrenal gland, kidney, placenta, macrophages, prostate and thymus
(Gospodarowicz et al., 1986). bFGF is a single chain polypeptide composed of 146
amino acids which can also exist in a truncated form missing the first 15 amino
acids. In the brain, pituitary and retina the complete form predominates (Esch et ah,
1985). Acidic FGF is found only in the brain and retina and is 30-100 fold less
potent than bFGF (Bohlen et ah, 1985). Unlike other mitogens FGF is not actively
degraded by cells possibly because the receptor is not tyrosine phosphorylated which
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often assists entry of the receptor into the cell (Gospodarowicz et al.. 1986).
FGF regulates expression of the oncogenes c-fos and c-myc which are also
involved in cell proliferation (Muller et al.. 1984). In cultured oligodendrocytes it
stimulates cell migration, increases the rate of cell proliferation and prevents
differentiation (Gospodarowicz et al.. 1986). When purified 0-2A progenitor cells
were cultured in the presence of very low doses of bFGF there was substantial
differentiation in the presence of continued DNA synthesis, so it is possible to
uncouple the inhibitory effects of bFGF on differentiation from its ability to promote
DNA synthesis (Mayer et al., 1993). bFGF and PDGF are known to cooperate
together to induce 0-2A cell proliferation and control differentiation (Boegler et al.,
1990; McKinnon et al., 1993). The accumulation of PDGFa receptors on
oligodendrocytic lineage cells is characteristic of bFGF signalling (McKinnon et al.,
1990).
bFGF may participate in repair mechanisms of CNS myelin. It induces
strong proliferation of 0-2A cells and slightly increases the number of MBP
expressing oligodendrocytes. It also promotes the reconstruction of myelin-like
membranes but in an uncompacted form (Fressinaud and Vallat, 1994). PDGF is as
potent as bFGF in inducing 0-2A proliferation following injury, but PDGF is better
at inducing the reappearance of more myelin like structures with better compaction
(Fressinaud et al., 1996).
When purified 0-2A progenitor cells are cultured with both PDGF and bFGF
and are therefore maintained in a proliferating state, the POU domain transcription
factor SCIP/Tst-1 is expressed at high levels. This is downregulated when the
growth factors are withdrawn and differentiation commences followed by the
sequential expression of myelin specific proteins (Collarini et al., 1991). SCIP is
expressed in proliferating Schwann cells of the PNS but is down regulated when
they begin to express myelin specific genes (Monuki et al., 1989). It has been
suggested that SCIP is a repressor of myelin gene expression in proliferating
Schwann cells (Monuki et al., 1990) and this may also be the case in proliferating 0-
2A cells. SCIP/Tst-1 is also expressed by other cell lineages in the CNS including
neurons (Collarini et al., 1991) so may be mechanistically involved in the transition
from proliferation to differentiation more generally.
1.5.3 CNTF
CNTF (Ciliary neurotrophic factor) is found in astrocytes in the CNS and
promotes the survival and maturation of cultured oligodendrocytes. It protects
oligodendrocytes from death induced by tumour necrosis factors (apoptosis) but not
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against complement mediated lysis (necrosis) following injury. Thus CNTF plays a
role in the survival of oligodendrocytes during development and its survival effect is
restricted to the apoptotic mode of oligodendrocyte death during development or
following exposure to environmental signals such as cytotoxic cytokines (Louis et
al., 1993). CNTF protein and mRNA are found throughout the brain, mostly
associated with astrocytes (Stoeckli et al., 1989) and the appearance of CNTF
coincides with the time when oligodendrocytes are first generated from 0-2A
progenitors. CNTF is able to induce a transient expression of GFAP in 0-2A
progenitors from the optic nerve and initiate their differentiation into type 2
astrocytes but other signals are required to drive the process to completion (Hughes
et al., 1988; Lillien et al., 1988).
1.5.4 IGF
IGF (Insulin-like growth factors). IGF-I and IGF-II are both potent inducers
of oligodendrocyte development and support the survival of newly formed and
mature oligodendrocytes (Barres et al., 1992; McMorris and Dubois-Dalcq, 1988).
The addition of IGF-I to oligodendrocyte cultures increases the amount of CNP and
CNP mRNA expressed per cell (Mozell and McMorris, 1991; van der Pal et al.,
1988). It also increases the incorporation of sulfate into sulfolipids and increases
myelin production. IGF-I and II and their mRNAs are detected in developing
oligodendrocytes in fetal, neonatal and adult brain. Their pattern of peak expression
corresponds to the major period of oligodendrocyte development (Adamo et al.,
1989). The production of IGF-I, in some cases, by developing oligodendrocytes
which also respond to it (autocrine action) support the theory that oligodendrocyte
development may in part be autoregulatory (Shinar and McMorris, 1995). IGFs also
regulate astrocyte and neuron development (Nielsen et al., 1991; Shemer et al.,
1987).
1.5.5 NT3
NT3 (Neurotrophin 3) promotes the survival of purified 0-2A progenitor cells
in vitro. It collaborates with PDGF to promote the clonal expansion of
oligodendrocyte precursor cells in vitro and to drive the intrinsic clock that times
their development (Barres et al., 1994). Cultured astrocytes and astrocytes purified
from rat optic nerve secrete NT3 and NT3 mRNA has been detected in developing
optic nerve (Elkabes et al., 1993). In vivo NT3 helps stimulate the proliferation of
oligodendrocyte precursor cells and is thus required for normal oligodendrocyte
development (Barres et al., 1994).
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1.5.6 Neuregulins
The neuregulins are a family of soluble and transmembrane protein isoforms
encoded by a single gene. They include glial growth factors (GGFs), neu
differentiation factor (NDF), heregulins and acetylcholine receptor-inducing activity
(ARIA) (Marchionni et al.. 1993). The proteins mediate their effects by binding to
receptor tyrosine kinases of the ErbB family, which are structurally related to the
epidermal growth factor (EGF) receptor (Reviewed by Carraway and Burden, 1995).
It is thought that neuregulins interact with a complex composed of erbB3 and erbB4,
which heterodimerise in various combinations with each other, and erbB2 to effect
subsequent signalling.
The neuregulins are expressed very early in CNS development well before
oligodendrocyte precursors are thought to arise at around E16 in the rat forebrain
(Levine and Goldman, 1988) and they persist at low levels into adulthood (Canoll et
al., 1996). GGF has long been known as a mitogen for Schwann cells and astrocytes
(Brockes et al., 1980) but the mitogenic response is greater in cells of the
oligodendrocyte lineage. This correlates with the increased phosphorylation of
neuregulin receptors in these cells (Canoll et al., 1996). Canoll et al. show that
neuregulin receptors are expressed at various stages of the oligodendrocyte lineage
including 04+/01" progenitor oligodendrocytes and mature 04+/01+
oligodendrocytes. They also show that high levels of GGF reversibly inhibit
differentiation and the lineage commitment of oligodendrocyte progenitors. In
cultures of differentiated oligodendrocytes it causes the loss of 01 and MBP
expression (Canoll et al., 1996). Therefore a role of neuregulins is to promote
oligodendrocyte proliferation whilst preventing premature differentiation.
Neurons are an important source of oligodendroglial mitogens (Barres and
Raff, 1994), releasing soluble factors such as PDGF (Dutly and Schwab. 1991) and
bFGF (Hardy and Reynolds, 1993) and stimulating proliferation via contact-
dependent factors (Chen and DeVries, 1989). Cortical neurons express high levels
of GGF during development (Chen et al.. 1994). GGF and other neuregulins may
also function as axolemma-associated mitogens as is the case for Schwann cells.
Norlund et al. described the partial purification of a 50 kD protein from brain
membrane preparations which is mitogenic for both Schwann cells and
oligodendrocytes and may correspond to GGF (Norlund et al.. 1992). Axolemma
-associated factors inhibit the differentiation of oligodendrocytes and promote their
proliferation (Zajicek and Compston, 1994). During CNS development the
neuregulin receptors on oligodendrocytes may be down regulated or other factors
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released by astrocytes may overcome this inhibition, thus promoting differentiation
(Canoll et al., 1996).
Based on in situ hybridisation experiments, neurons and cells of the sub-
ventricular zone (SVZ) appear to be major sources of neuregulins in the developing
and adult CNS (Corfas et al., 1995). In addition astrocytes also synthesise these
proteins (Pinkas-Kramarski et al., 1994). The exact identity of the cells expressing
neuregulins in the SVZ is unknown but this is a region containing mostly glial
progenitor cells in the early postnatal period. This suggests that neurons and glia are
important sources of neuregulins during CNS development (Canoll et al., 1996).
1.6 Oligodendrocyte progenitors in the adult nervous system.
During development, as previously discussed, oligodendrocytes develop
from oligodendrocyte progenitor cells but in the adult nervous system, where the
turnover of oligodendrocytes and astrocytes is extremely slow, do they still arise
from the same progenitor cells which are just maintained in situ until required?
Progenitor cells which replace the myelinating population as it slowly turns over
have been isolated from adult optic nerve and spinal cord and have been analysed in
vivo (Wolswijk and Noble, 1989; Engel and Wolswijk, 1996). These adult
progenitor cells have different characteristics in culture from their perinatal
counterparts. Both the adult and perinatal 0-2A progenitor cells are labelled with the
A2B5 antibody but adult cells also label with 04 which recognises only a
subpopulation of perinatal progenitors (Wren et al., 1992). Adult progenitors are
vimentin negative, proliferate and differentiate more slowly than perinatal cells and
are susceptible to the lytic effects of complement, unlike perinatal 0-2A cells
(Wolswijk and Noble, 1989; Wren et al, 1992; Engel and Wolswijk, 1996).
By one month after birth oligodendrocyte progenitor cells have disappeared
from optic nerve and are not detectable in cultures from adult optic nerves (Wolswijk
and Noble, 1989). Hence this progenitor cell population has a limited lifespan.
They are replaced by the adult progenitor cells which are fist detected at P7 and can
still be identified in optic nerves from one year old rats (Wolswijk et al., 1990). The
adult progenitor cell arises from a subpopulation of the perinatal cells as
demonstrated in culture when, after an initial proliferation period driven by type 1
astrocytes, 0-2A cells isolated from the optic nerve will generate an oligodendrocyte
precursor cell which differs from the 0-2A cell (Wren et al., 1992). This new cell
demonstrates characteristics of the adult progenitor cell. The generation of
oligodendrocytes in vitro from these adult progenitor cells occurs by asymmetric
division and differentiation so that there is constant renewal of these precursors
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(Wren et al., 1992). Hence they behave as a type of stem cell. Adult progenitor
cells also express other properties of stem cells such as their long cell cycle times
(Wolswijk et al.. 1990: Wolswijk and Noble. 1989; Wolswijk et al.. 1991) and the
ability to generate differentiated progeny as well as self renewal throughout life
(Wren et al., 1992).
It was previously believed that perinatal progenitor cells divided
symmetrically in vitro eventually resulting in self extinguishment (Raff et al., 1988;
Temple and Raff, 1986). This is indeed true when 0-2A progenitor cells derived
from perinatal rat optic nerve are cultured in the presence of astrocytes which secrete
factors promoting oligodendrocyte differentiation. However, recently it was noted
that in cultures derived from E15 rat brain, oligodendrocytes were generated by
asymmetric division and differentiation of progenitor cells and that the extent of
oligodendrocyte generation but not the probability was modulated by extrinsic
factors such as thyroid hormone (T3) (Ibarrola et al.. 1996). A new hypothesis has
therefore been formed suggesting that the initial generation of oligodendrocytes is
generally by asymmetric division and differentiation of progenitor cells and that this
is a cell intrinsic property. The extent of differentiation can be modulated by cell
extrinsic factors e.g. T3, CNTF and NT-3. An intrinsic clock measures the mitotic
lifespan of the progenitor cells and when the time ends, if environmental signals
permit, most cells will become oligodendrocytes. A second pathway may also exist
to generate adult progenitor cells (Ibarrola et al.. 1996).
The adult 0-2A progenitor cell described above is detected in normal nervous
tissue, but is it also able to replace damaged oligodendrocytes following injury?
This seems an unlikely possibility considering its susceptibility to the lytic effects of
complement which are activated as a consequence of injury and induction of the
immune system. A progenitor cell was identified in lesioned areas of adult cat optic
nerve which differed from adult 0-2A cells but had similarities to the perinatal 0-2A
progenitor cell (Carroll and Jennings, 1994). It had fast cell cycle times of
approximately 18 hours, was vimentin positive, highly motile becoming closely
apposed to demyelinated axons, was resistant to the lytic effects of complement
which were highly active in the inflamed region of injury and it differentiated into
oligodendrocytes. This cell possibly arose as a result of division by a putative
resting progenitor cell in the normal optic nerve surrounding the lesion. Such a
readily recruitable and motile progenitor cell which is unaffected by the immune
system has many important implications in myelin repair mechanisms following
injury or demyelination as a result of viral infection, when a rapid response is also
required. Therefore normal adult 0-2A progenitor cells are apparently responsible
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for the general maintenance of the nervous system, replacing cells as and when
required due to general cell turnover. A second faster responding cell type is
recruited in emergency situations when damage to the nervous system must be
minimised. This hypothesis is supported by the fact that when 04+GC" adult
progenitor cells are treated with PDGF:and bFGF. which are both upregulated
following CNS injury (Lotan and Schwarz. 1992). a small population transiently
reverts to a more mitogenicailv active and migratory phenotype with similarities to
the perinatal 0-2A progenitor cell (Wolswijk and Noble, 1992). Normal adult
progenitor cells are found evenly distributed throughout the optic nerve and
represent up to 5% of the normal macroglial population (Fulton et al.. 1992).
Signals from a lesion may cause some of these to revert to a phenotype similar to
perinatal 0-2A progenitor cells and respond to the injury by differentiating into
oligodendrocytes which subsequently repair the damage by remyelination.
1.7 Embryonic origin of glial progenitors.
Oligodendrocyte precursors, the 0-2A progenitor cells are thought to
originate from the neuroectodermal cells of subventricular zones. The earliest
identified precursor cells are proliferative, monopolar cells expressing vimentin
which differentiate into proliferative, migratory, bipolar 0-2A precursor cells
expressing GD3 (Hardy and Reynolds, 1991). GD3 is a major glycolipid component
of the immature vertebrate CNS which is downregulated during early development.
Its expression characterises immature dividing neuroectodermal cells such as the
glial precursors (Goldman et ah. 1984: Goldman and Reynolds. 1996). Vimentin is
a marker for undifferentiated neuroepithelial cells following the closure of the neural
tube (Bignami et al., 1982). The GD3+ 0-2A precursors are located in the
subependymal layers of the 4th ventricle and migrate from there to their final
positions in the brain. As they reach their final destinations they differentiate via a
pro-oligodendrocyte (04+, GC~) into GC expressing oligodendrocytes (04+, GC+)
which then synthesise myelin. Consistent with overall brain development
oligodendrocytes develop in a posterior to anterior gradient in the brain (Hardy and
Reynolds, 1991; Reynolds and Wilkin, 1988).
Studies on spinal cord, one of the first parts of the CNS to be myelinated,
provide evidence to suggest that oligodendrocytes are generated from the ventral half
of the neural tube but it is still controversial whether they also arise from the dorsal
half. It has also been suggested that oligodendrocytes in the spinal cord can develop
from dedifferentiated radial glia (Choi et al., 1983; Hirano and Goldman, 1988).
Expression of the PDGFa receptor (PDGFocR) has been used to identify cells of the
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Figure 1.4 Schematic diagram of the developing vertebrate spinal cord
demonstrating the embryonic origin of oligodendrocytes in the ventral ventricular
zone (VZ) and their subsequent migration dorsally and radially (arrows). FP=floor
plate and NC=notochord. (Figure from Miller, 1996)
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oligodendrocyte lineage (Pringle et al., 1992). Investigations show that PDGFaR+
cells originate at a defined point in the ventricular zone and subsequently migrate
away from there into the surrounding tissue (Pringle and Richardson, 1993). Hall et
al. recently demonstrated that all PDGFaR+ cells in the embryonic rat spinal cord
were oligodendrocyte precursors (Hall et al., 1996). Other studies suggest that
oligodendrocyte precursors arise in the ventral ventricular zone of the embryonic
neural tube from which they spread first over the ventral then over the dorsal halves
of developing white matter (Cameron-Curry and Le Douarin, 1995). In the
developing chick spinal cord oligodendrocyte precursors are specifically labelled
with 04 (Ono et al., 1995). This immunoreactivity appears very early and its
expression is retained throughout cellular maturation. The earliest 04+ cells are
located in the ventral ventricular zone and subsequently migrate into the dorsal
region. In the avian spinal cord Cameron-Curry (Cameron-Curry and Le Douarin,
1995) claims that cells from dorsally located precursors migrate to dorsal and lateral
funiculi and to more ventrally located regions. However when dorsal and ventral
regions of E4 chick spinal cord were cultivated separately significant numbers of
oligodendrocytes failed to develop in dorsal spinal cord cultures but E7 dorsal spinal
cord was found to produce large numbers of oligodendrocytes. Hence there is a
limited period when oligodendrocyte potentiality is restricted to the ventral region.
When E4 dorsal spinal cord microexplants were co-cultivated with notochord
segments or with floor plate tissue, oligodendrocytes were found but when explants
were cultivated alone no oligodendrocytes were detected (Trousse et al., 1995). It
therefore seems that there are cells present in the dorsal spinal cord which can be
induced to differentiate into the oligodendrocyte phenotype by ventrally derived
signals from notochord and floor plate.
Neural crest cells of the dorsal neural tube are multipotent and following
detachment they migrate to diverse locations in the developing embryo where they
give rise to a number of different cell types including neurons, glia, secretory cells of
the peripheral neuroendocrine system, melanocytes, chondrocytes and smooth
myocytes. Hence a homogeneous population of non differentiated cells are
channelled into different developmental pathways (Stemple and Anderson, 1992). In
vitro studies have demonstrated that some multipotent cortical cells are able to self
renew, a property of stem cells (Davis and Temple, 1994), and there is some
evidence for the existence of such cells in vivo (Reid et al., 1995). It is therefore
possible that neurons and glia in the CNS may arise from multipotent founder cells
via restricted progenitor cells.
The development of neurons and oligodendrocytes from a common precursor
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has been demonstrated in vitro (Williams et al., 1991). In cultures of dissociated
embryonic rat cerebral cortex where a small number of cells are infected with a
recombinant retrovirus carrying the lacZ gene and which can be detected by anti-f)-
galactosidase serum and identified by monoclonal antibodies, most precursors
generated either neurons or glia. Some neuronal clones however also included
oligodendrocytes and the proportion of mixed clones increased from El2, a time
before neurogenesis begins in the cortex, until El6, the peak time of neurogenesis
(Miller, 1986), when 18% of neuronal clones also contained oligodendrocytes.
Whether the fate of progenitor cells in vivo is specified intrinsically or through
environmental factors is unknown. However Qian and colleagues have recently
demonstrated that bFGF seems to influence the fate of embryonic cortical stem cells
in vitro (Qian et al, 1997). They demonstrate that when cells from the cortical
ventricular zone are cultured in the presence of low levels of bFGF the predominant
cell fate was neuronal. At higher concentrations of bFGF both neurons and glia
developed. It was suggested that the neuronal lineage was the default pathway of
cell development but when bFGF levels reached a threshold level cells were
produced with the bipotential to generate oligodendrocytes or astrocytes. Formation
of oligodendrocytes was then the default pathway of development with additional
signals required for astrocyte formation. This finding is consistent with recent work
demonstrating how bone morphogenic proteins (BMPs) cause cells which have been
generated from the sub ventricular zone (SVZ), a region arising later from the
ventricular zone, to become astrocytes (Gross et al., 1996). This is associated with
almost complete suppression of neuronal and oligodendrocyte lineage elaboration.
The SVZ progenitor cells were also shown to express BMP-specific type I and type
II receptor subunits and selective BMP ligands indicating either paracrine and/or
autocrine developmental signalling pathways. Therefore the fate choice of
multipotent cortical stem cells is at least partly directed by environmental signals.
1.8 A differentiated glial subtractive library
How can we gain a better understanding of a) the regulation of
oligodendrocyte development from progenitor cells in both the developing nervous
system and in adults, b) how oligodendrocytes get to their correct locations to do
their job, c) how other cells such as astrocytes and neurons are involved and what
exactly they do, and d) whether axons signal to induce myelination in development
and in response to injury and what these signals are? Gaining an understanding in
just some of these areas may also eventually lead to therapies for many disorders and
diseases of the nervous system such as multiple sclerosis in humans. Knowledge
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and understanding at the genetic level could also contribute to the correction of
inherited disorders such as the multiple forms of Pelizaeus-Merzbacher disease
(PMD). The appearance of novel proteins which may also become upregulated- at
particular times of development or in particular situations may implicate their
involvement in particular events. Perhaps by identifying all the pieces involved, the
jigsaw can be constructed.
The total number of genes expressed in the mammalian brain has been
estimated at approximately 30,000 with at least half of them being present
exclusively in brain (Bantle. 1987; Chikaraishi. 1979; Milner, 1983). Systematic
analysis therefore of individual novel brain specific mRNAs potentially offers
important insights into neural function and the composition of the nervous system.
Well over 100 brain specific proteins have already been identified biochemically
through protein purification, by functional assays, or by the isolation and
characterisation of mRNAs from brain cDNA libraries (Sutcliffe, 1988). Many of
these early-identified brain specific proteins are relatively abundant such as the
neurofilament proteins and the major constituents of myelin but many more,
including as yet unidentified proteins, are extremely rare yet may well have
important roles to play in myelin structure, cell-cell interactions, the regulation of
development or in cellular plasticity during development or repair of the nervous
system.
Several powerful methods have been developed to allow the isolation of such
rare and specifically expressed mRNAs. The main techniques are differential
screening of cDNA libraries, differential display and subtractive hybridisation. All
these techniques compare two mRNA populations e.g. from different time points in
development and enable the identification of mRNAs present in one but not the
other. Typically such isolated clones represent genes which alter their expression
during development, or as a consequence of disease, or due to an induction signal.
In differential screening probes are made from the mRNAs of two
populations being compared. They are then used to screen a cDNA library. Clones
which hybridise to one probe but not to the other are isolated and analysed further.
This technique is able to detect relatively abundant transcripts representing
approximately 0.1% of an mRNA population (Ausubel et al., 1992) In differential
display partially random primers are used to amplify a subset of mRNAs expressed
in a given population. These are separated on an acrylamide gel and the bands
between different samples compared. This technique generally targets medium
abundant mRNAs but can yield many false positives (Ausubel et al., 1992) The
third main technique is subtractive hybridisation. A cDNA library representing one
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population is used to remove all sequences which are also present in a second library
representing another population. The resultant subtracted cDNA library contains
cDNA clones which are present exclusively in the second population. Of all three
techniques subtractive cloning is the most sensitive, due to its enriching steps,
enabling detection of rare transcripts forming less than 0.001% of an mRNA
population. It is also the best method for isolating as complete a set of differentially
expressed genes as possible (Ausubel et al. 1992).
A combination of differential screening and subtractive hybridisation has also
proved useful whereby a cDNA library is hybridised with probes which have been
enriched for by subtractive hybridisation (Baba, 1994). A number of interesting
neural proteins identified by subtractive screening include RC3, a calmodulin
binding, protein kinase C substrate which is enriched in the dendrites of forebrain
neurons (Watson, 1990), the retinal degeneration slow gene product (Travis, 1989),
PMP22, the locus of the trembler mouse mutant and the human genetic disorder,
Charcot-Marie-Tooth disease(Patel, 1992; Suter, 1992) and MOBP (Schaeren-
Wiemers et al., 1995).
In the present study clones were isolated from a cDNA library which was the
product of subtractive hybridisation between a library encoding clones expressed by
glial 0-2A progenitor cells and a second library encoding clones expressed by glial
cells which had been allowed to differentiate in culture for three days. Isolated 0-2A
progenitor cells from mixed glial cultures established from neonatal rat brains, were
used to make the first cDNA library. The second cDNA library was prepared from
cells which had differentiated from 0-2A cells in culture for three days. The culture
medium contained low amounts of FCS so the majority of differentiated glia were
oligodendrocytes but some astrocytes were also present. Hence this second library
represented clones expressed by differentiated glia and not just by oligodendrocytes.
Figure 1.5 shows schematically how the subtractive library was constructed
according to the method of Herfort and Garber, 1991. The subtraction was done by
P.J. Brophy using cDNA libraries prepared by C.S. Gillespie. Biotinylated single
stranded cDNA was produced from the progenitor library. The differentiated glial
library was digested with the restriction enzymes NotI and Sail to release the insert
sequences from the pSPORTl plasmid vector. These cDNA fragments were heated
to melt the double strands of DNA into single strands which were then mixed with
the biotinylated single stranded cDNAs of the progenitor library. On cooling
complementary sequences hybridised to each other, so vector sequences common to
both libraries rehybridised, as did common insert sequences. Insert sequences which
were unique to differentiated glia rehybridised with one another. Some unpaired
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Figure 1.5 Schematic diagram demonstrating how the differentiated glial
subtractive library was constructed from two cDNA libraries. A cDNA library
encoding clones expressed by 0-2A progenitor cells was subtracted from a cDNA
library encoding clones expressed by differentiated glial cells. The resulting
subtractive library encodes cDNAs expressed specifically by differentiated glia. For
details see the main text.
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vector and insert fragments were also present. The addition of streptavidin, which
binds to biotin, allowed the removal of all biotin containing cDNAs and therefore
those which were common to both libraries, in the organic phase of a phenol
chloroform extraction. What should remain in the aqueous phase are double
stranded cDNAs encoding sequences specifically expressed by differentiated glia.
These were ligated into the vector pSPORTl and electroporated into E. coli DH12S
to form the differentiated glial subtractive library which has a complexity of
approximately 300,000.
1.9 The proposed study
This differentiated glial subtractive library is now a source of cDNA clones
which are expressed following differentiation into glial cells. Since their expression
must therefore be switched on sometime during the process of differentiation it is
likely that the products of these cDNAs are involved somehow in glial development.
Some of the clones in the library will be expressed exclusively by oligodendrocytes
and therefore may be intrinsically involved in oligodendrocyte development, perhaps
as a structural component of the myelin sheath. Other clones will also be expressed
by different cell types such as astrocytes and neurons and so may be part of the
physical interactions between these cells or as components of signalling mechanisms
between cells. There will also be clones which are expressed in addition by other
cell types outside of the nervous system. These may represent as yet unrecognised
components necessary for more general mechanisms of differentiation exhibited
throughout development.
In this study individual clones were isolated from the subtractive library with
the intention of identifying novel proteins expressed by differentiated glial cells and
with a view to eventually elucidating their role in the developing nervous system.
From this differentiated glial subtractive library five novel clones were isolated
which are expressed specifically by the nervous system. One was chosen for
detailed investigation.
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CHAPTER 2. MATERIALS AND METHODS
2.1 NORTHERN BLOTTING
2.1.1 Extraction of total RNA from rat tissues
DEPC-treated MilliQ dHgO was prepared by the addition of Diethyl
pvrocarbonate (DEPC, Sigma) (500 pi) to MilliQ dHgO (500 ml). After mixing, the
solution was left to stand at RT overnight and then autoclaved.
P10 Wistar rats were sacrificed. Various tissues were rapidly dissected from
the animal using sterile instruments, loosely wrapped in aluminium foil and frozen in
liquid nitrogen. The dissected tissues were stored at -70°C until required.
Tissue samples were homogenised with RNAzol B (Biogenesis,
Bournemouth, England) (approximately 2 mi per 100 mg of tissue) using a few
strokes in a glass-Teflon homogeniser. The resulting homogenate was divided into
aliquots (1 ml) in 1.5 ml Eppendorf tubes on ice. Chloroform (100 |il) was added to
each tube which was then vortexed to mix and left on ice for 5 min. The tubes were
centrifuged at 13,000 g for 15 min at 4°C in a benchtop centrifuge (Biofuge 13,
Heraeus Instruments). The top aqueous phase containing soluble RNA was then
carefully removed to a new Eppendorf tube. An equal volume of phenol/chloroform
(1:1) was added, the tubes vortexed and then centrifuged at 13,000 g for 5 min at
4°C. Again the top aqueous layer was carefully removed to a clean Eppendorf tube
and the phenol/chloroform extraction repeated. This was done until there was no
precipitate of DNA/protein visible at the interphase of the aqueous and organic
phases (2-3 times should be sufficient). To the isolated upper aqueous phase an
equal volume of isopropanol was then added. The tubes were vortexed and left on
ice for 15 min to precipitate the RNA. Centrifugation at 13,000 g for 45 min at 4°C
pelleted the RNA. The supernatant was carefully removed and the pellet washed in
70% ethanol (500 pi). After centrifugation at 13.000 g for 5 min at RT and removal
of the supernatant the pellet was allowed to briefly air dry before being resuspended
in DEPC treated MilliQ dH20.
2.1.2 Spectrophotometry determination of RNA purity and yield
Spectrophotometry measurements (LKB-Ultrospec III. Pharmacia Biotech)
of the RNA samples were used to calculate purity and concentration. Blank readings
to set the references were done on 1 ml of MilliQ dH20 in a quartz cuvette. Sample
readings were done on aliquots of sample RNA (2 pi) diluted 500 times with MilliQ
dH20 to a final volume of 1ml in the cuvette. The optical density (O.D.) of the
samples were measured at 260 nm to estimate nucleic acid content and at 280 nm to
estimate protein content. Purity of the RNA sample is determined by a ratio of
protein to nucleic acid content. A figure of between 1.7 and 2.0 is acceptable.
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2.1.3 Filter preparation for Northern Blotting
For 200 pi of RNA denaturation buffer, which was freshly prepared as
required:-
20 pi lOx MOPS buffer (0.2 M MOPS, 50 mM sodium acetate,
10 mM EDTA; pH 7)
100 pi formamide
40 pi formaldehyde
20 pi ethidium bromide (0.5 mg/ml, w/v)
20 pi DEPC dH20
RNA denaturation buffer (10 pi) was added to an aliquot of RNA (10 pg) in
a 0.5 ml Eppendorf tube. The tubes were incubated at 65°C for 20-30 min to
denature the RNA and then plunged onto ice. After a brief pulse centrifuge, filtered
loading buffer (30% Ficol Type 400 (Pharmacia), 0.25% bromophenol blue) (1 pi)
was added. Samples were run on a 0.8% formaldehyde agarose gel in lx MOPS
buffer at 50 V for 3-4 h. Size standards (0.24-9.5 kb RNA ladder, GIBCO BRL)
were also run on the gel.
For a 0.8% gel:- 4 ml lOx MOPS buffer
1.2 ml formaldehyde
34.8 ml 1% agarose (Seakem, FMC Bioproduct)
(w/v) in MilliQ dH20
The RNA was then transferred onto Hybond-N nylon membrane
(Amersham) under vacuum at 40 mBar for 90 min whilst submerged in 20x SSC (3
M NaCl, 0.3 M trisodium citrate, pH 7). After transfer and before drying, the filter
was briefly viewed with a U.V. light source and the size standards noted with pencil
for reference later. The gels could then be discarded. Once the filters were dry they
were baked in an oven at 80°C for 1.5-2 h and stored at RT until required.
2.1.4 Probe preparation for Northern Blotting
Plasmid DNA was radioactively labelled with [oc-32p] dCTP (Amersham)
using the Random Priming Kit (GIBCO, BRL). Plasmid DNA (25 ng) in a volume
of 10 pi was boiled for 5 min, then plunged onto ice. Then added were ATP, GTP
and TTP (2 pi of each), Random primers buffer (15 pi), dH20 (13 pi), [a-32p]
dCTP (5 pi, equal to 50 pCi) and Klenow fragment (1 pi). The tube was mixed
gently and incubated at 25°C for 1 h before the addition of stop solution (5 pi).
Sheared salmon sperm DNA (lOOpl of a lOmg/ml stock) (Stratagene) was then




The prepared filters were trimmed to a minimum size, rinsed very briefly in
dHqO to remove excess salts and then placed in individual 50 ml universal tubes
with QuikHyb Hybridisation Solution (3 ml) (Stratagene). The filters were pre-
hvbridised at 65°C for 30 min on a rotary oven.
The radioactivelv labelled cDNA probe and salmon sperm DNA were boiled
for 5 min (minimum) and then rapidly added to the pre-hybridising Quikhvb
solution. The filters were left to hybridise with the probes for 1.5 h at 65°C in the
rotary oven.
Filters were then washed at low stringency twice for 10 min in 100 ml of
2xSSC/0.1%SDS with agitation at RT, then at high stringency twice for 30 min in 40
ml of 0.2xSSC/0.1%SDS at 65°C in the rotary oven.
Filters were wrapped in Saran-Wrap while still damp and exposed to
photographic film (Agfa Curix RPI) in a cassette containing an intensifying screen.
Films were developed using chemicals from Kodak; Kodak LX24 X-ray developer
diluted 1:18 with tap water and Kodak Industrex manual fixer diluted 1:4 with tap
water.
2.2 OLIGODENDROCYTE CULTURES
1-2 day old Wistar rats were decapitated and the heads swabbed with 70%
ethanol. The cerebral hemispheres were then quickly removed and placed in a Petri
dish containing approximately 1.5 ml per brain of cold lx Hank's balanced salt
solution without Ca^+ or Mg^+ (HBSS-Ca, Mg). The tissue was dissociated as
much as possible by chopping with scissors and was then forced through a 140 (im
sterile nylon mesh attached to a cut off 10 ml syringe, then through another of 35
(im. (Nybolt, Plastock Assoc., Birkenhead, UK) Each mesh was washed through
with lx HBSS to minimise cell loss.
Cells were harvested by centrifugation at 1000 g for 3 min at RT. The
supernatant was carefully removed and discarded. The pellet was gently
resuspended in Dulbecco's modified Eagle's medium without Glutamine (DMEM)
containing 10% foetal calf serum (FCS) (Flow, UK), penicillin (100 IU/ml) and
streptomycin (100 (ig/ml) (both from ICN). Approximately 10 brains were used to
seed 8x 75cm^ flasks (Costar) which had been coated with 0.1 mg/ml poly-D-lysine
hydrobromide (30-70,000 Mr, Sigma) for 30 min. Each flask contained a final
culture volume of 11 ml. These primary cultures were maintained in a 37°C
incubator with a water saturated atmosphere and 5% C02-
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culture volume of 11 ml. These primary cultures were maintained in a 37°C
incubator with a water saturated atmosphere and 5% C02-
After 3-4 days the medium was replaced with DMEM containing 10% FCS,
penicillin (100 IU/ml), streptomycin (100 |lg/ml) and glutamine (2 mM) (ICN).
After 6-10 days in culture a clearly defined bilayer of cells formed with
phase-dark rounded 0-2A progenitors in the top layer. The flasks were sealed and
pre-shaken at 180 rpm for 2 h at 37°C in an orbital incubator to remove loosely
attached macrophages. The medium was then replaced with fresh DMEM
containing 10% FCS, penicillin (100 IU/ml), streptomycin (100 (ig/ml) and
glutamine (2 mM) and the cultures allowed to equilibriate for at least 2 h in the
incubator at 37°C with a water saturated atmosphere and 5% C02 • Then the flasks
were resealed and shaken at 180 rpm for 18-24 h in the 37°C orbital incubator.
The monoclonal antibody A2B5 (200 pi) was then added to each flask which
was then inverted so that the roof of the flask became the adhesion surface. The
flasks were placed in the incubator for 5-20 min or until the flat cells and remaining
macrophages had adhered, leaving the small round 0-2A progenitor cells coated
with the A2B5 monoclonal antibody in suspension. These cells could then be
removed to a 50 ml universal tube and harvested by centrifugation at 1000 g for 3
min at RT. The pellet was gently resuspended in Defined Medium (+bFGF/-FCS)
(DMEM containing transferrin (50 pg/ml), triiodothyronine (30 nM), NaSelenite (20
nM), D-biotin (10 ng/ml), progesterone (20 nM), putrescine (100 pM), insulin (5
pg/ml), glutamine (4 mM), penicillin (100 IU/ml), streptomycin (100 pg/ml) and
bFGF (2 ng/ml). All supplements were from Sigma except penicillin-streptomycin
and glutamine which were from ICN and bFGF which was from British
Biotechnology, Oxford, UK).
The resuspended cells from 8x 75 cm^ flasks were seeded into 6x 25 cm^
flasks each with 4 ml of medium or 20-30 pi were seeded per 13 mm glass coverslip
(Nol thickness, BDH, UK). Up to 3 coverslips were maintained in 2 ml of medium
in a 35 mm Petri dish.
The seeded progenitor cells were maintained in Defined Medium (+bFGF/-
FCS) in the incubator (37°C, 5% CO2, water saturated atmosphere) for 4 days,
replacing half the medium every 24 h. The medium was then replaced with Defined
Medium (-bFGF/+FCS) (DMEM containing the same supplements as above except
without bFGF but with 1% FCS). The cells were allowed to differentiate in the
presence of FCS for 4 days at 37°C with a water saturated atmosphere and 5% CO2.
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2.3 IN SITU HYBRIDISATION (ISH)
2.3.1 Plasmid DNA preparation
An aliquot (1 pi) of a frozen glycerol stock of XL-1 Blue E.coli cells
containing the plasmid DNA of interest was added to 10 ml of L-broth (Luria Broth
base. Sigma) containing ampicillin (lOOug/ml) in a 50 ml universal tube. The
culture was incubated at 37°C in an orbital incubator (220 rpm) overnight.
The culture was centrifuged in a 30 ml glass corex tube at 9500 rpm for 10
min at 4°C (Sorvall RC 5B. rotor SS-34). The supernatant was discarded and the
pellet resuspended in 1 ml of filter sterilised solution PI (50 mM glucose, 10 mM
EDTA pH 8, 25 mM Tris-HCl pH 8). Then 1 ml of freshly prepared solution P2
(1% SDS, 0.2 M NaOH) was added. The tube was mixed gently and left at RT for 5
min. Then 1ml of solution P3 (29.4 g potassium acetate. 11.5 ml glacial acetic acid.
dHoO to 100 ml, 3 M with respect to potassium and 5 M with respect to acetate) was
added and the tube mixed by inversion. It was then centrifuged at 9500 rpm for 15
min at 4°C (Sorvall RC 5B, rotor SS-34). The supernatant was dispensed into a
clean 30 ml corex tube and 0.8x the volume of isopropanol (2.4 ml) was added.
After leaving on ice for 10 min, the tube was centrifuged at 9500 rpm for 20 min at
4°C. The supernatant was discarded and the pellet resuspended in 0.35 ml of TE (10
mM Tris/HCl pH 7.4, 1 mM EDTA pH 8) buffer. The solution was transferred to a
1.5 ml Eppendorf tube and 0.17 ml of LiCl (15 M) was added. After mixing it was
left to stand at RT for 10 min. Centrifugation at 13,000 g for 15 min at RT pelleted
the RNA. The supernatant was dispensed into a clean Eppendorf tube and 0.5 ml of
phenol/chloroform (1:1) was added. After vortexing to mix and centrifugation at
13,000 g for 5 min at RT, the upper aqueous layer was removed to a clean Eppendorf
tube where O.lx the volume of 3 M Na Acetate. pH 5.5 and 2x the volume of 100%
ethanol were added. After 30 min at -70°C, the tube was centrifuged at 13,000 g for
40 min at 4°C. The supernatant was discarded and the pellet washed with 70%
ethanol (500 (ll). It was then centrifuged at 13,000 g for 5 min at RT. After
discarding the supernatant the pellet was briefly air-dried before resuspending it in
TE buffer (40 |il).
A restriction digest was done on the purified plasmid DNA to confirm the
presence of the correct-sized insert of interest and also to estimate plasmid
concentration. An aliquot (1-2 jil) of the plasmid DNA was mixed with lOx
restriction buffer H (Sure/Cut BufferH, Boehringer Mannheim) and the restriction
enzymes NotI (5 U) (New England Biolabs) and Sail (5 U) (Advanced
Biotechnologies) in a total volume of 10 p.1. The digest was incubated at 37°C for 1-
2 h and then run out on a 1% agarose electrophoresis gel in lx TAE buffer (0.04 M
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Tris-Acatate, 0.00 1M EDTA) at 50 mA to separate the vector (pSPORTl) which
runs at 4 kb and insert DNA bands. A DNA mass/size ladder (Low or High DNA
mass ladders from GIBCO) were used to estimate the size of the insert DNA band
and the plasmid concentration. The plasmid DNA was stored at-20°C. Figure 2.1
shows a diagram of the pSPORTl plasmid and its cloning sites.
2.3.2 Linearisation of plasmid DNA
The plasmid DNA was linearised by digestion with NotI so that transcription
using the T7 promoter would produce sense RNA. Digestion with Sail and then
transcription with the SP6 promoter produced antisense RNA. Transcription with
linearised template DNA prevents the additional transcription of pSPORTl vector
sequence i.e. linearisation ensures that only insert sequence which is the probe of
interest is transcribed.
Plasmid DNA (10 jj.g) was mixed with lOx restriction buffer H (5 jj.1) and
NotI or Sail enzyme (30 U) in a total volume of 50 jil. The digests were incubated at
37°C for 2 h. 50 ul of phenol/chloroform (1:1) were then added. After vortexing
the tubes were centrifuged at 13,000 g for 5 min at 4°C. The top aqueous layer was
removed to a clean Eppendorf tube and O.lx the volume of 3 M NaAcetate, pH 5.5
and 2x the volume of 100% ethanol were added. After mixing, the tubes were put at
-70°C for 30 min and then centrifuged at 13,000 g for 40 min at 4°C. The
supernatant was discarded and the pellet washed in 70% ethanol (500 pil). After
centrifugation at 13,000 g for 5 min at RT, the supernatant was discarded and the
pellet briefly air-dried before it was resuspended in TE buffer (10 p.1). It was stored
at -20°C at this stage.
Assuming 100% recovery the final linearised plasmid concentration should
now be 1 flg/|ll. 1 jil of a 1:10 dilution was run out on a 1% agarose electrophoresis
gel in lx TAE buffer against a standard of known concentration to confirm this and
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Figure 2.1. Map of DNA plasmid vector pSPORTl (Gibco) indicating cloning sites.
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to check that there was no undigested plasmid which could give rise to circular
transcription.
2.3.3 Preparation of riboprobes for ISH
The linearised plasmid DNA was transcribed using the SP6/T7 Transcription
Kit (Boehringer Mannheim, Cat. No. 999 644). The manufacturers instructions were
modified. Linearised DNA (4-5 pg) was incubated with 10 mM ATP, GTP and CTP
(1 pil of each), [35S]-UTP (50 pCi) (ICN Biochemicals Ltd.), lOx buffer (2 pi),
RNase inhibitor (20 U) and SP6 RNA polymerase (10 U) (to produce antisense
RNA) or T7 RNA polymerase (10 U) (to produce sense RNA) in a total volume of
21 pi. The transcription was incubated at 37°C for 30 min. The tubes were then
pulse centrifuged before another aliquot of SP6 or T7 RNA polymerase (10 U) was
added and incubated at 37°C for another 30 min. RNase-free DNase I (20 U) was
added to remove the template DNA. After incubation at 37°C for 15 min and pulse
centrifugation, an equal volume of phenol/chloroform (1:1) was added. The tube
was vortexed to mix and then centrifuged at 13,000 g for 3 min at RT. The top
aqueous layer was removed to a clean Eppendorf tube. The solvent layer was back
extracted by the addition of DEPC dH20 (24 pi). After mixing and centrifuging at
13,000 g for 3 min at RT the top aqueous layer was harvested and combined with the
first. The RNA was precipitated by the addition of 0.5x the volume of 7.5 M
ammonium acetate, pH 5.5 and 2.5x the volume of cold (-20°C) 100% ethanol
followed by 30 min at -70°C.
An aliquot (1 pi) was removed and added to 1 ml of Optiphase 'Hisafe' 3
liquid scintilation cocktail (Wallac). The rest was centrifuged at 13,000 g for 20 min
at 4°C. Another aliquot (1 pi) of the discarded supernatant was added to 1 ml of
scintilation cocktail. The pellet was washed in 70% ethanol (50 pi), centrifuged at
13,000 g for 5 min at RT and then resuspended in DEPC dH20 (100 pi). An aliquot
(1 pi) of this pellet solution was added to 1 ml of scintilation cocktail.
Next, the riboprobe was reprecipitated overnight at -20°C in 0.1 x the volume
of 3 M NaAcetate, pH 5.5 and 2x the volume of 100% ethanol. After centrifuging at
13,000 g for 40 min at 4°C, the supernatant was discarded and the pellet washed
with 70% ethanol. After counting the radioactivity of the 3 samples (Total,
supernatant and pellet), the ammount of incorporated isotope in the transcribed RNA
could be calculated and the volume of 0.01 M DTT in which to resuspend the
riboprobe determined. Calculation for radioactivity incorporation:-
% unincorporated 33S = unincorporated cpm x 100% = 8.5% (e.g.)
Total cpm
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Therefore % incorporated 35s = 100% - 8.5% = 91.5%
91.5% of 50 uCi (the initial ammount added) = 45.75 jiCi
= 45.75 pMol of UTP
(since 1 |iCi = 1 pMol)
1 Moi of dTP = 330 g. Therefore 45.75 x 330 = 15.1 ng
Total RNA = 4 x 15.1 = 60.4 ng
Resuspend the probe at 1 ng/pl/kb
1 ng/ul = 60.4 pi
Riboprobe length = 0.7 kb (e.g.)
Therefore resuspend the probe in 60.4 x 1 = 86.3 Ltl of 0.01 M DTT
0.7
2.3.4 Surface labelling of live oligodendrocytes with antibodies before ISH
Coverslips with cultured oligodendrocytes were rinsed briefly in lx PBS
(phosphate buffered saline) made with MilliQ dHgO. The primary antibody, the
monoclonal antibody 04 (Sommer and Schachner, 1981), was diluted (1:10) in lx
PBS and 2% goat serum and applied to and incubated with the cells in a humid
chamber for 30 min at RT. The coverslips were then rinsed twice for 2 min in lx
PBS before being fixed with freshly prepared 4% paraformaldehyde in 0.1 M
phosphate buffer. pH 7.4 for 5 min at RT. The coverslips were then washed three
times for 5 min in 0.1 M Glycine-HCl in lx PBS, pH 7.4. and then twice for 5 min in
lx PBS. The coverslips were then glued onto glass slides with Loctite glass to glass
glue and exposed to UV light for 10-15 seconds to bond the adhesive. The
secondary antibody was then applied (donkey anti-mouse coupled to TRITC.
Jackson) diluted (1:50) in lx PBS and 2% goat serum. The slides were incubated in
a humid chamber for 30 min at RT in darkness and then washed twice for 2 min in
lx PBS before continuing with the pre-treatment washes.
2.3.5 Preparation of rat brain sections for ISH
A 21 day old Wistar rat was sacrificed, its brain dissected out and frozen in
isopentane at -45°C. Parasagittal cryostat sections of brain (15 um) were mounted
on slides coated with TESPA (3-aminopropyltriethoxysilane) (Sigma) and stored at
-70°C.
2.3.6 Pre-treatment washes
The samples were fixed with 4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4 for 5 min at RT. The fixed material was then acetylated for 10 min at
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RT (to 50 mi of 0.1 M triethanolamine pH 8. 125 jil of acetic anhydride was added,
mixed and quickly poured onto the material). The slides were washed twice for 2
min in lx PBS (made with DEPC dH20) at RT. then for 2 min in 70% ethanol. 2
min in 90% ethanol and twice for 2 min in 100% ethanol. The samples were then
air-dried for approximately 30 min.
2.3.7 Hybridisation
The hybridisation buffer consisted of 50% formamide, 10% dextran sulfate,
lx Denhardts, 20 mM Tris-HCl pH 8. 0.3 M NaCl, 5 mM EDTA. 10 mM sodium
phosphate pH 8. 0.5 mg/ml yeast tRNA and could be stored in aliquots at -20°C.
The riboprobe was diluted lOx with hybridisation buffer containing 10 mM DTT
(i.e. 10 ul riboprobe + 0.9 jil 1M DTT + 89.1 ill hybridisation buffer), heated at
80°C for 2 min and then plunged on ice until used. The denatured riboprobe was
applied to the sample and covered with a sterile coverslip. Then the slides were
placed in a box containing 3MM paper soaked in 50% formamide/5x SSC, the box
was sealed and incubated at 50°C overnight.
2.3.8 Post-hybridisation washes
Following hybridisation the slides were taken through a series of washes.
The first was in 5x SSC, 10 mM DTT (Wash I) at 50°C for 5 min. This was
followed by a wash in 2x SSC, 50% formamide. 0.1 M DTT (Wash II) at 60°C for
20 min. Following this were three washes in 0.5 M NaCl. 10 mM Tris-HCl. 5 mM
EDTA (Wash III) at 37°C. each for 5 min. RNAaseA diluted to 20 jig/ml in Wash
III was then applied to the slides which were incubated at 37°C for 30 min. The
slides were then washed with Wash III at 37°C for 5 min. then Wash II at 65°C for
20 min. This was followed by a 5min wash in 2x SSC at RT and then a 5min wash
in 0. lx SSC at RT.
The slides were then taken through a series of washes to dehydrate the
samples. The first wash was in 0.3 M NHq acetate. 30% ethanol for 2 min at RT.
The second wash was in 0.3 M NHq acetate. 60% ethanol for 2 min at RT. The third
wash was in 0.3 M NH4 acetate, 80% ethanol for 2 min at RT. The fourth wash was
in 0.3 M NH4 acetate, 95% ethanol for 2 min at RT. These washes were followed
by a final wash in 100% ethanol for 2 min at RT. The slides were then air-dried for
at least 30 min. At this stage the dried slides could be exposed to X-ray film




Immunocytochemistry to label intracellular antigenic markers was done at
this stage.
Cultured cells:-
The primary antibody (monoclonal antibody GA5 against GFAP, Boehringer
Mannheim) was diluted 1:5 in blocking buffer (lx PBS/1% goat serum/0.1% (v/v)
Triton-X-100) and applied to the cells which were then incubated in a humid
chamber for 60 min at RT. The slides were washed three times for 5 min in lx PBS
(DEPC) at RT. The secondary antibody (goat anti-mouse coupled to TRITC,
Southern Biotech) diluted 1:50 in blocking buffer was then applied and incubated in
darkness for 30 min in a humid chamber at RT. The slides were washed three times
for 5 min in lx PBS (DEPC) at RT and then air-dried.
Brain sections:-
Sections were blocked for 2 h at RT in lx PBS (DEPC)/0.2% pig skin
gelatin (BDH) (blocking buffer). The primary antibody (mAb GA5 against GFAP,
Boehringer Mannheim) was diluted 1:5 in blocking buffer and applied to the tissue.
A coverslip was placed on top and the slides were incubated in a humid chamber
overnight at 4°C. The slides were then washed three times for 10 min in blocking
buffer before the secondary antibody (goat anti-mouse coupled to TRITC, Southern
Biotech) was applied diluted 1:50 in blocking buffer. The slides were incubated in a
humid chamber for 2 h at RT in darkness and then washed twice for 10 min in
blocking buffer and twice for 10 min in lx PBS before being air-dried.
2.3.10 Emulsion dipping
An aliquot (6 ml) of a glycerol solution made by mixing glycerol (0.14 ml)
and DEPC dH20 (7 ml) was put in a 50 ml universal tube and warmed to 43-45°C.
In a darkroom using only a Kodak orange safe-lamp, emulsion (Nuclear Research
Emulsion, Ilford K-5 (A size) 1355127) was added until the volume was 12 ml and
then dissolved by warming at 43-45°C for 10-15 min. The solution was transferred
to a dipping vessel and then stood in the waterbath for 10 min to allow air bubbles to
rise. Each slide was then dipped into the emulsion and the excess wiped off the
back. The slides were then left in an upright position for excess emulsion to drain
away from the sample and the resultant thin coating to dry (approximately 20 min).
The slides were then placed in a box with sachets of autoclaved silica, sealed with
tape and wrapped in aluminium foil and black plastic to seal them from the light.
The sealed box was left at RT overnight, then at 4°C for 2-3 weeks or as required.
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2.3.11 Development
In the darkroom, as for the emulsion dipping, the slides were dipped in D19
(Kodak) developer (made up according to the manufacturers instructions) for 4 min
at RT, then in stop solution (1% glycerol/1% glacial acetic acid) for 1 min and then
in fix (30% (w/v) thiosulfate) for 3 min. The slides were washed under running tap
water for 20 min and then air-dried.
If immunocytochemistry had been done the slides were mounted with anti-
fade and the coverslips sealed with nail varnish. Otherwise the samples were
counterstained with Ehrlichs heamatoxylin for 20-30 seconds, washed under running
water until clear, dipped twice in acid-alcohol, washed under running water for 3
min, dehydrated for 1 min in 70% ethanol, 90% ethanol then 100% ethanol, dipped
in xylene for 5 min before being mounted with DePeX mounting medium (BDH)
and coverslipped whilst still damp.
2.4 HYBRIDISATION SCREENING OF A CDNA LIBRARY FOR FULL
LENGTH CDNA CLONES
2.4.1 Titration of the cDNA library
NZY Broth (5 ml) (Gibco BRL) containing 0.2% maltose and 100 Jig/ml
ampicillin was innoculated with Y1090-E.coli and incubated at 37°C in an orbital
incubator overnight.
The cDNA library analysed was an oligo dT primed, directionally cloned
(NotI -> Sail), mixed age (1 day, 15 day and 16 weeks) rat brain library in Xgt22A,
prepared by K. Rogers. The library phage were diluted 1:100 with SM buffer (0.58
g NaCl, 0.2 g MgS04.7H20, 5 ml 1 M Tris-HCl pH 7.5, 0.5 ml 2% gelatin, dH20 to
100ml, autoclaved). The diluted phage (1 |il) was added to the Y1090 culture (200
fil) in a 5 ml bijoux and incubated in a 37°C oven for 20 min with swirling every 5
min. 3 ml of Top Agarose (NZY broth + 0.7% agarose) cooled to 48 °C were added
and mixed by inversion before being poured onto a dry small 90 mm NZY agar plate
(NZY broth +1.5% agar). Once the top agarose had set, the plate was incubated at
37°C overnight. The number of recombinant plaques could then be counted and the
titre of the cDNA library established.
2.4.2 Plate preparation for a primary hybridisation screen of the cDNA library
NZY broth (5 ml) containing 0.2% maltose and 100 pg/ml ampicillin was
innoculated with Y1090, as above, and incubated overnight at 37°C in an orbital
incubator. The cDNA library phage were diluted with SM buffer to give the
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appropriate titre required. This required titre e.g. 60,000 plaque forming units (pfu)
per 15 cm plate was added to 500 }ll of the Y1090 culture and incubated at 37°C for
20 min with swirling every 5 min. NZY Top Agarose (7.5 ml) cooled to 48°C was
then added and mixed by gentle inversion before being poured onto a large 15 cm
NZY agar plate. Once set. the plate was .incubated at 37°C overnight to allow the
viral plaques to develop.
2.4.3 Filter lifts
Some of the plaque DNA was blotted onto circular nylon membranes
(Duralon-UV membranes, Stratagene) which were laved onto the NZY-agar plates.
Orientation marks were made on both the nylon membranes and the agar plates for
reference later. The membrane filters were placed, DNA side up, on two layers of
3MM filter paper soaked in denaturation buffer (0.5 M NaOH, 1.5 M NaCl),
ensuring the DNA side did not get wet. They were left for 5 min. The filters were
then placed onto 3MM paper soaked in neutralising buffer (1.5 M NaCl, 0.5 M Tris-
HC1 pH 7.4) in the same fashion and left for 2 min. This neutralising step was
repeated on fresh 3MM paper and again left for 2 min. The filters were then briefly
rinsed in 2x SSC, air-dried and baked in an 80°C oven for 2 h. They could be stored
at RT until required.
2.4.4 Hybridisation of filters with:-
a) 32p labelled cDNA probe
The Ready TO GO DNA Labelling Kit (-dCTP) (Pharmacia) was used to
radioactively label the cDNA probe required. Plasmid DNA (25-50 ng) boiled for 2
min to denature, was added to the reconstituted kit reaction mix with [a-^-P] dCTP
(50 pCi) (ICN) and dH20 to a final volume of 50 jil. The reaction mix was
incubated at 37°C for 30 minutes. 100 |ll of sheared salmon sperm DNA (10 mg/ml)
(Stratagene) was then added to the labelled cDNA probe and boiled for 5 min before
being added to prehybridising filters.
Filters were briefly wet with dH20 and placed in large glass hybridisation
tubes which had been coated with dime thy Idichlorosilane. Rapid Hyb Hybridisation
Buffer (15 ml) (Stratagene) was added to each tube which was then prehybridised at
65°C in a rotary oven for 30 min. On addition of denatured probe the filters were
left to hybridise for 1.5 h at 65 °C.
The filters were then washed at low stringency twice for 10 min in
2xSSC/0.1%SDS at RT with agitation and twice at high stringency for 30 min in
0.2xSSC/0.1%SDS at 65°C in the rotary oven. They were then allowed to dry
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Figure 2.2. Clone OL0755 sequence indicating PCR primers.
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5 ' GCGAGCTTTGTCGAGACCACCATGGCTCTGGGGCTGCCCTCCAAGAAAGC 5 0
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slightly before noting the orientation marks with radioactive ink, wrapping them in
Saran Wrap and exposing them to X-ray film.
bj Digoxvgenin labelled cDNA probe
Primer 9F 5' AAGCATCTTCCCGCAACGTG 3'
Primer 9R 5' TGCCTAATCTCTCCCCACATAGGTA 3'
For primer preparation see 2.6.3.
A 904 bp fragment of the 1.1 kb insert for clone OL0755 was amplified by
PCR using primers 9F and 9R (see Figure 2.2), incorporating digoxygenein labelled
UTP. lOx buffer (5 pi), modified dNTPs (2 mM ATP. GTP, CTP, 1.4 mM TTP) (5
pi), 1 mM digoxvgenin-UTP (3.5 pi) (this gives a ratio of 2 UTP : 1 Digoxygenin-
UTP), 10 mM primer 9F (5 pi), 10 mM primer 9R (5 pi), plasmid DNA of clone
OL0755 diluted 1:500 (1 pi) and Dvnazyme DNA polymerase (1 U) were mixed in a
total volume of 25 pi and overlaid with mineral oil (25 pi). A control PCR reaction
was set up in the same way, except with regular 2 mM dNTPs. Amplification
conditions were:- 29 cycles of denaturation at 94°C for 40 seconds, annealing at
59°C for 1 minute and extension at 72°C for 40 seconds, followed by a final cycle
of denaturation at 94°C for 40 seconds, annealing at 59°C for 1 minute and
extension at 72°C for 7 minutes. The PCR reactions were then run out on a 1%
agarose electrophoresis gel in lx TAE buffer. Digoxygenin incorporated during
amplification retards mobility of the product during electrophoresis as shown in
Figure 2.3, so comparison with the control reaction indicates how successful the
reaction was.
The digoxygenin incorporated PCR product bands were cut out of the gel and
the amplified DNA purified using the Qiaex II gel extraction kit (see 2.5.1 for
details). The purified DNA was eluted first in 30 pi and then in 20 pi (total volume
of 50 pi). An aliquot was mn on a gel against a standard of known concentration to
estimate the concentration of the digoxygenin labelled probe. The probe (2.5 pg)
diluted to 50 pi with TE buffer was mixed with 50 pi of sheared salmon sperm DNA
(10 mg/ml) and denatured at 98°C for 10 min before being added to prehybridising
filters (see 2.4.4a). Filters were left to hybridise for 1.5 h at 65°C, then washed at
low stringency twice for 10 min in 2xSSC/0.1%SDS at RT with agitation and twice
at high stringency for 30 min in 0.2xSSC/0.1%SDS at 65°C in the rotary oven.
Positive plaques were visualised by first washing the filters for 5 min at RT
in 10 ml of Buffer I (0.1 M maleate, 0.15 M NaCl, pH 7.5) with gentle shaking.
They were then incubated with 10 ml of Buffer II (1% Boehringer blocking agent in
Buffer I, w/v) for 40 min at RT with agitation, followed by incubation for 40 min at
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Figure 2.3. Digoxigenin incorporation during PCR amplification of clone OL0755
with primers 9F and 7R. The incorporation of digoxigenin causes a retardation in
mobility of the amplified product on a 1% agarose electrophoresis gel as can clearly







RT in 5 ml of anti-Digoxygenin antibody-AP diluted 1:5000 with Buffer II. Filters
were washed twice for 5 min in 10 ml of Washing Buffer (0.3% Tween 20 in
Bufferl) followed by 2 min in 10 ml of freshly prepared Buffer III (0.1 M Tris-HCl,
0.1 M NaCl, 0.05 M MgCl2, pH 9.5). They were then left in 3 ml of freshly
prepared colour solution (5 ml Buffer III +• 25 til NBT (50 mg/ml. Promega) + 19 jll
BCIB (50 mg/ml. Promega)) in darkness for the colour reaction to develop. The
filters could then be washed under tap water, dried and stored.
Individual plaques containing DNA which had hybridised with the probe
were identified. Plugs were removed from the NZY-agar plates containing the
positive plaques of interest with a cut-off yellow pipette tip and placed in 1.5 ml
Eppendorf tubes with SM buffer (500 jll) and chloroform (50 (ll). These were then
left at RT for at least 4 h to lyse the Y1090 bacteria. The resultant lysate could then
be re-titrated as before (See 2.4.1)
A secondary hybridisation screen could be done but with fewer pfu per small
90 mm NZY-agar plate (approximately 200) which can be used for taking filter lifts
etc. In this way positive plaques of interest are diluted and purified. After 2 or 3
rounds of hybridisation screening it was possible to cleanly isolate a plug from an
NZY-agar plate with a single pure plaque containing a single cDNA clone from the
library.
2.4.5 PCR amplification of plug lysates to confirm the presence of clone
OL0755 sequence
Primer 1 IF 5'AGCTTTGTCCAGACCACCAT3'
Primer 7R 5 'GGCTCGAGCTGTGCTGATS'
For primer preparation see 2.6.3.
lOx buffer (5 |ll), 2 mM dNTPs (5 jll), 5uM primer 1 IF (5jll), 5|lM primer
7R (5|il) and lysate(l |ll) (template) in a total volume of 49.5 jll was overlaid with
mineral oil (50 jll) and heated to 94°C before the addition of Dynazyme DNA
polymerase (1 U). A negative control was prepared with no added template DNA.
Amplification conditions were:- 29 cycles of denaturation at 94°C for 40 seconds,
annealing at 65°C for 1 minute and extension at 72°C for 40 seconds followed by a
final cycle with extension for 7 minutes. An aliquot (10 jll) of the reaction mix was
run out on a 1% agarose electrophoresis gel with a 1 kb size marker. A band of
about 300 bp indicates the amplification of clone OL0755 sequence.
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2.4.6 PCR amplification of plug lysates to estimate extra 5' sequence
Primer 601 5 'GGCACATGGCTGAATATCGA3'
Primer 7R 5 'GGCTCGAGCTGTGCTGAT3'
For primer preparation see 2.6.3.
lOx buffer (5 ul), 2 mM dNTPs (5 ul), 5 llNI primer 601 (5 ill), 5 llM primer
7R (5 pi) and lysate (1 ul) (template) in a total volume of 49.5 ul was overlaid with
mineral oil (50 til) and heated to 94°C before addition of Dvnazyme DNA
polymerase (1 U). A negative control was prepared with no added template DNA.
Amplification conditions were:- 29 cycles of denaturation at 94°C for 40 seconds,
annealing at 62°C for 1 minute and extension at 72°C for 1 minute and 40 seconds
followed by a final cycle with extension for 7 minutes. An aliquot (10 ill) of the
reaction mix was run out on a 1% agarose electrophoresis gel with a 1 kb size
marker to try and estimate how much extra 5' sequence, if any, had been amplified.
2.4.7 Preparation of high titre lysates for purified plaques of interest
After titration of the lysate of the purified plaque of interest, 50,000 pfu per
small 90mm NZY-agar plate were allowed to grow to confluence at 37°C overnight
(see 2.4.2). The plates were then flooded with SM buffer (4 ml) and left at RT with
gentle agitation for at least 6 h. The resultant lysate was removed, aliquoted in
fractions (1 ml) with chloroform (50 ul) and stored at 4°C until required.
2.4.8 Isolation of plasmid DNA
Two aliquots (1 ml each) of high titre lysate were centrifuged at 13.000 g for
5 min at RT, the third was kept as a backup. The supernatant was removed to a
clean Eppendorf tube and 350 jil of 30% PEG (polyethylene glycol) in 3 M NaCl
were added. The tubes were mixed and left on ice for 30 min. After centrifugation
at 13,000 g for 10 min at 4°C the supernatant was discarded. After re-centrifugation
at 13,000 g for 2 min the residual supernatant was discarded. Both pellets were then
resuspended together in 250 u.1 of filter sterilised PSB (10 mM Tris-HCl pH 7.5, 10
mM MgS04, 100 mM NaCl) by gentle pipetting. 5 u.1 of RNAase cocktail (1 mg/ml
RNaseA, 20,000 U/ml RNaseTl; Ambion) and 1.5 pi of DNAasel (1 mg/ml in H2O)
were added, mixed and then incubated at 37°C for 30 min. Then 250 |ll of 0.3 M
Tris-HCl pH 9. 100 mM EDTA. 1.25% SDS (freshly made) were added, mixed and
incubated at 65°C for 10 min. 250 ul of solution P3 (See 2.3.1) were then added,
mixed and left on ice for 5 minutes. After centrifuging at 13,000 g for 2 min at 4°C,
the supernatant was removed to a clean Eppendorf tube and an equal volume of
phenol/chloroform (1:1) was added. Following mixing the tube was centrifuged at
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13,000 g for 5 min at RT. The upper aqueous phase was removed to a clean
Eppendorf tube and the phenol/chloroform extraction repeated. 0.8x the volume of
isopropanol was added to the isolated aqueous phase, mixed and left on ice for 10
min. The tube was then centrifuged at 13,000 g for 5 min at 4°C. The supernatant
was discarded and the pellet washed with 70% ethanol (0.5 ml). Following
centrifugation at 13,000 g for 5 min at RT the pellet was resuspended in TE buffer
(20 pi).
An aliquot (3 pi) of the purified plasmid DNA could then be digested at
37°C with NotI (5 U) and Sail (5 U) in a volume of 10 pi with lOx restriction buffer
H (Boehringer) and run out on a 1% agarose electrophoresis gel in lx TAE buffer to
confirm the presence and size of an insert.
2.5 EXCISION OF INSERT DNA AND LIGATION INTO A SUITABLE
VECTOR FOR SEQUENCING
2.5.1 Purification of excised DNA using QIAEX II Gel Extraction Kit
The released insert DNA from the digested plasmid was cut out of a 1%
agarose gel and purified using the QIAEX II Gel Extraction Kit (Qiagen). Buffer
QX1 was added to the gel fragment in an Eppendorf tube at 3x the volume of the gel
for DNA fragments of 100 bp-4 kb e.g. 300 pi of buffer QX1 was added to 100 mg
of gel. Resuspended QIAEX II (10 pi) was then added and the tube was vortexed
before incubation at 55°C for 10 min. Mixing was repeated every 2 min to keep the
QIAEX II in suspension. Following centrifugation of the sample at 13,000 g for 30
seconds at RT, the supernatant was discarded. The pellet was washed with buffer
QX1 (0.5 ml) to remove agarose contaminants and then centrifuged at 13,000 g for
30 seconds at RT. The supernatant was discarded and the pellet washed twice with
buffer PE (0.5 ml) to remove salts, centrifuging at 13,000 g for 30 seconds at RT
each time. The pellet was then left to dry for 10-15 min, then resuspended in TE
buffer (15 pi) by vortexing. It was left at RT for 5 min to elute the DNA and then
centrifuged at 13,000 g for 30 seconds at RT. The supernatant containing eluted
DNA was removed to a clean Eppendorf tube. Elution of DNA from the QIAEX II
pellet was repeated by the addition of another aliquot of TE buffer (5 pi). Incubation
at RT, centrifugation and removal of the supernatant was repeated as before and the
two eluants were then combined (15 pi + 5 pi).
50
2.5.2 Ligation of purified DNA
The purified Notl/Sall digested insert DNA was ligated into a suitable
plasmid for sequencing e.g. pSPORT I (Gibco). The purified DNA (20 p.1) was
mixed with 5x T4 ligase buffer (6 |J.l), T4 ligase (2 U) and Notl/Sall digested
pSPORT I plasmid (10 ng) in a total volume of 29 p.1. The reaction was incubated at
21°C overnight.
2.5.3 Preparation of XL-1 Blue competent cells
Sterile L-Broth (5 ml) containing tetracycline (5 pg) was inoculated with XL-
1 Blue E.coli bacteria and incubated overnight at 37°C in an orbital incubator (220
rpm).
The culture was diluted 1:50 with L-broth (5 ml) and then incubated at 37°C
in the orbital incubator for 3 h until the optical density (O.D.) reached 0.4-0.7. The
culture was then centrifuged at 2000 rpm for 10 min at RT. The supernatant was
discarded and the pellet gently resuspended in cold, sterile 0.1 M CaCl2 (2.5 ml).
This was left on ice for 20 min with occasional shaking. The cells were then
centrifuged at 2000 rpm for 10 min at RT, the supernatant discarded and the pellet
resuspended in cold 0.1 M CaCl2 (0.5 ml).
2.5.4 Transformation of ligated plasmid into competent XL-1 Blue E.coli
To 100 p.1 of competent cells the entire ligation mix was added. This was
then incubated on ice for 30 min with occasional shaking. The cells were heat
shocked at 42°C for 2.5 min, added to L-Broth (5 ml) and incubated at 37°C in the
orbital incubator (220 rpm) for 1 h. Following centrifugation for 10 min at 2000 rpm
at RT most of the supernatant was discarded before the pellet was resuspended in a
volume of 50 p.1 and spread on X-Gal agar plates. These were prepared from L-broth
(500 ml) containing agar (7.5 g), ampicillin (50 mg), 4% X-Gal (1 ml) and 1 M
IPTG (150 p.1). The plates were incubated overnight at 37°C. White colonies
indicated recombinant bacteria containing plasmids with inserts of interest. Insertion
of new DNA inactivated (3-galactosidase synthesis. X-gal is cleaved by (3-
galactosidase into a product which is bright blue. Since the recombinants did not
have p-galctosidase their plaques appeared colourless (white). These colonies were
picked from the plate and cultured in L-broth (5 ml) containing ampicillin (5 mg) by
incubation at 37°C overnight in the orbital incubator (220 rpm).
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2.5.5 Alkaline lysis to purify the plasmid DNA
An aliquot (0.5 ml) of the culture was mixed with an equal volume of 50%
glycerol (sterile) and stored as a stock at -70°C.
Another aliquot (1.5 ml) of the culture was centrifuged at 13,000 g for 1 min
at RT and the supernatant discarded. The pellet was resuspended in cold solution PI
(See 2.3.1) by vonexing. Freshly prepared solution P2 (See 2.3.1) (200 pi) was
added and mixed by inversion. Cold solution P3 (See 2.3.1) (150 ill) was added and
mixed by vortexing before being left on ice for 5 min. Following centrifugation at
13,000 g for 5 min at 4°C the supernatant was removed to a clean Eppendorf tube
and an equal volume of phenol/chloroform (1:1) was added. The tube was vortexed
and then centrifuged at 13,000 g for 5 min at RT. Addition of 0.1 x the volume of
3M Na acetate. pH 5.5 and 2x the volume of 100% ethanol to the isolated aqueous
phase was followed by 30 min at -70°C. The tube was then centrifuged at 13.000 g
for 40 min at 4°C and the supernatant discarded. The pellet was washed in cold
70% ethanol (0.5 ml) and then centrifuged at 13,000 g for 5 min at RT. After being
briefly air-dried the pellet was resuspended in TE buffer (20 pi) containing RNAase
cocktail (2 pi) (1 mg/ml RNaseA, 20.000 U/ml RNaseTl; Ambion).
An aliquot (1 pi) of the purified plasmid DNA was digested with NotI (5 U)
and Sail (5 U) with lOx buffer H in a final volume of 10 pi at 37°C and then run out
on a 1% agarose electrphoresis gel in lx TAE buffer to confirm the presence of the
insert DNA of interest, before sequencing.
2.6 SEQUENCING OF PLASMID DNA
2.6.1 Sample preparation for sequencing
Template DNA (1.5-2 pg) was taken to a volume of 12 pi with MilliQ dFUO
in an Eppendorf tube. 2 M NaOH (3 pi) was added and the mixture left to incubate
at RT for 10 min. 3 M Na acetate. pH 4.7 (4.5 pi) and MilliQ dFQO (7 pi) were then
added and mixed followed by 100% ethanol (90 pi). The tube was put at -70°C for
20 min and then centrifuged at 13,000 g for 10 min at 4°C. The supernatant was
discarded and the pellet washed with cold 70% ethanol (100 pi). Following
centrifugation at 13,000 g for 2 min at RT, the supernatant was discarded and the
pellet air-dried before being resuspended in MilliQ dFDO (5 pi).
The Sequencing Kit (Pharmacia) was used. Annealing buffer (1 pi) and lpl
of the required primer (5 pM) were added to the resuspended pellet. This reaction
was incubated at 37°C for 20 min and then at RT for 10 min. Meanwhile four tubes
labelled A, G, T and C were set up with A mix, G mix, C mix and T mix
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respectively (1.5 ill). The T7 DNA polymerase (0.5 ul) was diluted with dilution
buffer (1 p.1) and TE buffer (1 pi) (NB this is enough for 2 DNA templates). To each
tube containing template DNA and primer. Labelling mix A (1.5 pi) was added with
[35s]-ATP (0.2 pi), the diluted T7 polymerase (1 ul) and dHoO (0.3 pi) (Total
volume of 10 pi). This reaction mixture was incubated at RT for 4 min. The DNA
template mixture (2.3 pi) was then added to each of the A. G. T and C mix tubes
which were then incubated at 39°C for 5 min. Stop solution (2.5 pi) was added to
each and the samples were stored at -20°C for up to 1 week.
2.6.2 Sequencing gel
A 6% acrylamide, 42% urea (w/v), lx TBE (Tris-HCl, boric acid. EDTA pH
8) 60cm gel was run in lx TBE at 2900 V and 70 W for 30 minutes to warm up.
Once all the samples had been loaded, the gel was run at 2900 V and 60 W until the
desired separation of bands had occured (usually around 3.5 h).
The gel was fixed in 5% methanol/5% acetic acid in dH20 for 20-30 min
before being transferred onto 3MM filter paper and dried under vacuum at 80°C for
1 h. Once dry, the gel was exposed to X-ray photographic film. From the resultant
autoradiograph the sequence of the DNA could be read.
2.6.3 Primer preparation
Primers were synthesised on the PCR Mate Oligonucleotide Synthesiser on
appropriate columns (A, G, T or C columns depending on the desired 3' nucleotide).
Recovery and purification of the synthesised primer must first involve detachment
from the column. The column was flushed with ammonium hydroxide (0.6 ml) and
left in this solution at RT for 20 min before draining into a small bijoux bottle. This
was repeated twice more to produce a total volume of 1.8 ml of primer and
ammonium hydroxide solution. This solution was incubated at 56°C overnight to
complete the breakdown of side chain protecting groups.
An aliquot (200 pi) of the primer/ammonium hydroxide solution was put into
a 1.5 ml Eppendorf tube with butanol (1 ml). The tube was vortexed and then
centrifuged at 13,000 g for 2 min at RT. The supernatant was removed. Another
aliquot (200 (il) of primer/ammonium hydroxide solution and butanol (1 ml) were
added to the pellet. The mixture was vortexed and centrifuged as before. This was
continued until all the primer/ammonium hydroxide solution had been processed and
the primer had been precipitated. The pellet was gyrovapped to remove all traces of
solvent and then resuspended in MilliQ dfbO (0.5 ml).
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Spectrophotometric measurements (LKB-Ultrospec III. Pharmacia Biotech)
of the primer solutions were used to calculate concentration. Readings were done on
aliquots (2 pi) of primer solution diluted 500 times with MilliQ dH20 to a final
volume of 1ml in the cuvette. The optical density (O.D.) was measured at 260 nm to
estimate nucleic acid content. The following formulae were used to calculate
concentration and molarity:-
33 x A260 nm = pg/pl
2
Ll g/ul = Molarity
MW
The molecular weight (MW) of the primer was calculated from its sequence.
The sum of the molar values for each nucleotide was divided by 1.06. The molar
values used were 331.2 for A, 307.2 for C. 347.2 for G and 306.2 for T.
2.7 RAISING A POLYCLONAL ANTIBODY AGAINST A SYNTHETIC
PEPTIDE
2.7.1 Dialysis of KLH (Keyhole Limpet hemocyanin) solution
A 30 cm length of dialysis tubing was boiled for 5 min in MilliQ dH20
containing a small amount of NaHC03 and EDTA. The water was allowed to cool
before the tubing was thoroughly rinsed in fresh MilliQ dH20. One end of the
tubing was knotted twice and 6 ml of KLH solution (10 mg/ml) placed inside. The
tubing was closed with a single knot, placed in 2.5 L of lx PBS at 4°C and left to
dialyse for 2 h. The PBS solution was then replaced with fresh and dialysis
continued at 4°C overnight. The PBS solution was then replaced with 10 mM
potassium phosphate. pH 7 and the dialysis continued for a further 6 h at 4°C. The
dialysed KLH was then removed from the tubing to a 15 ml Corex centrifuge tube
and centrifugea at 8500 rpm for 10 min. The supernatant was removed to a 20 ml
Universal tube.
An aliquot (100 pi) of the KLH solution was diluted to 1 ml with dH20 and
its absorbance at 280 nm measured. This gives an ODU per 100 pi, therefore
multiplying this reading by 10 gives an ODU per ml. Using the standard of 18 ODU
= 10 mg/ml the concentration of the KLH solution was calculated from the ODU
reading.
The dialysed KLH solution was divided into two aliquots (3.5 ml each) and
stored at -45°C.
54
2.7.2 Preparation of a Sephadex G-50 chromatography column
12 g of G-50 Sephadex (Sigma) was swollen at RT for 30 minutes in 0.1 M
potassium phosphate. pH 6. .An excess volume of potassium phosphate was added to
the unswollen sephadex. mixed by swirling and then left to sediment. The mixture
was swirled and left to sediment again before the buffer solution was poured off and
replaced. This process of swirling to mix and sedimentation followed by replacing
of the buffer was repeated a further three times to ensure the removal of all loose
debris. The swollen Sephadex was then poured into a clamped glass column (19 cm
long, 4 cm diameter) and allowed to settle. The column was equilibriated with 0.1
M potassium phosphate, pH 6 (100-150 ml) before being stored at 4°C until
required.
2.7.3 Preparation of MBS activated KLH
12.5 mg of sulfo-MBS (maleimidobenzoic acid N-hydroxysuccinimide) was
dissolved in 10 mM potassium phosphate. pH 7 (2.5 ml) in a 20 ml Universal tube.
When dissolved 3.75 mi (23.85 mg) of diaiysed KLH was added and the tube mixed
on a rotating windmill for 30 min at RT. This reacted sulfo-MBS-KLH was then
applied to the prepared G-50 Sephadex column and eluted with 0.1 M potassium
phosphate, pH 6. After the first 20 ml had eluted through the column fractions (1.5
ml) were collected and their absorbance at 280 nm measured. Six fractions were
pooled together with an average OD/ml = 1.563 and stored at -40°C.
2.7.4 Conjugation of a peptide to activated KLH
A peptide (20 mg) synthesised by Professor Nigel Groome, Oxford Brookes
University, was dissolved in 10 mM HC1 (2 ml) in a 15 ml glass tube. An equal
volume of ether was added, mixed gently and the mixture allowed to separate into
two phases. The lower phase containing the peptide was transferred to a fresh
Universal tube and the pH adjusted to 6 by the dropwise addition of 0.1 M NaOH.
1.5 ml of each peptide was then added to 2.25 ml of activated KLH on ice and
mixed. The tube was then mixed by rotation on a windmill at 4°C overnight.
2 ml of 0.5 M ethanolamine, pH 7 was added and rotation on the windmill
continued for 1 h at 4°C. The conjugated KLH-peptide was then diaiysed twice
against 2 L of lx PBS before storage at -45°C.
2.7.5 Innoculation of rabbits with KLH-peptide
The KLH-peptide (1.5 ml) was emulsified overnight with Freunds complete
adjuvant (2 ml) with shaking at 4°C. Two New Zealand White rabbits were
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innoculated with 0.5 ml in each hind limb and 0.75 ml subcutaneously (Total of 1.75
ml per rabbit).
After 10 days test bleeds were taken. Blood (2-5 ml) was taken from each
animal and placed in a Universal tube. It was left at RT for a few hours to begin to
clot. Ringing with a stick allowed the resultant blood clot to contract away from the
walls of the tube. It was left at 4°C overnight. The resultant serum was then
removed to a 15 ml Corex tube and centrifuged at 8500 rpm for 15 min. The
supernatant was aliquoted and stored at -45°C.
Rabbits either received booster injections or were sacrificed by cardiac
puncture under anaesthesia. The blood collected (usually 50-100 ml) was allowed to
clot, ringed and centrifuged etc. as for the test bleed. The antisera were tested by
Western blotting.
2.8 WESTERN BLOTTING
2.8.1 Preparation of rat brain homogenates for Western blotting
Wistar rats were sacrificed by lethal injection and the brains rapidly dissected
out. A small portion of each brain (approximately 0.25 cm^ in size) including some
tissue from the cerebellum and cerebral hemispheres was homogenised in sterile lx
PBS/0.1% Triton-X-100 (2 ml). The homogenate was then aliquoted and stored at
-40°C.
A Lowry Test was done on the brain homogenates to determine protein
concentration. Reactions were performed in 2 ml tubes in duplicate. 0, 10, 20, 40,
60, 80 and 100 |ig of BSA (Bovine serum albumen) standard samples were made up
to 100 pi with lx PBS/0.1% Triton-X-100 (since this is the buffer in which the rat
brain tissue samples were homogenised). The brain homogenates to be measured
were diluted 1:10 with lx PBS/0.1% Triton-X-100 in a final volume of 100 pi.
Freshly prepared reagent A (1 M NaOH/0.25% SDS) (125 pi) was added to each,
mixed and incubated at 60°C for 15 min. Freshly prepared reagent B (250 pi 2% K,
Na tartrate; 250 pi 1% CuS04; 24.5 ml 2% Na2C03) (1.25 ml) was added to each,
mixed and left at RT for 15 min. 125 pi of Folin reagent (which had been diluted
1:1 with dH20) was then added to each reaction, mixing immediately and then left
on ice for 45 min. The absorbance at 750 nm was measured for each sample. A
reference curve was constructed by plotting the absorbance readings of the standard
BSA samples against their protein concentrations. From this standard curve and
their absorbance readings the protein concentrations for each brain homogenate was
deduced, (see Figure 2.4)
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Figure 2.4. Lowry Test standard curve constructed by plotting absorbance readings
at 750 nm of standard BSA samples against protein concentration (|lg). Using this




2.8.2 SDS Polyacrvlamide Gel Electrophoresis (SDS PAGE)
A 10% polyacrv I amide denaturing gel was prepared:-
13.3 ml 30% stock acrylamide
10 ml 4x stock solution OA (1.5 M Tns-HCl. pH 8.9)
21.4uiTEMED
202 |il 20% SDS
150 ul 10% ammonium persulfate (w/v). Freshly prepared.
dH20 to a final volume of 40 ml.
A 10 cm x 12 cm slab gel was poured in a vertical position. Butanol (0.5 ml) was
overlaved on the top surface of the gel to maintain a level surface. Once the gel had
polymerised, the butanol was rinsed away with dEbO. A stacking gel was then
poured on top:-2.25 ml 30% acrylamide
1.875 ml 5.7% Tris-HCl. pH 6.7 (w/v)
75 |ul TEMED
150 pi 10% ammonium persulfate (w/v)
dEbO to a final volume of 15 ml.
A 15 well comb was inserted and the gel allowed to polymerise.
Brain homogenate samples for loading were prepared in a volume containing
lx sample buffer (3x stock = 20% glycerol, 2.28% Tris-HCl pH 6.7 (w/v), 8% SDS)
and 67 mM DTT. They were boiled for 5 min to denature the proteins then loaded
onto the gel together with pre-stained SDS molecular weight markers (27,000-
180,000 MW, Sigma). The gel was run in lx running buffer (25 mM Tris, 250 mM
glycine pH 8.3. 0.5% SDS) at 30 mA for 3-4 h. (20x stock running buffer = 15g tris,
72 g glycine. dHoO to 500 mis, pH 8.4).
2.8.3 Preparation of filters for Western blotting
Once the SDS PAGE gel had run sufficiently to separate the proteins it was
removed from the glass plates and the proteins transferred onto a nitrocellulose
membrane (Protran Nitrocellulose BA85 0.45 mm Nucleic acid and protein transfer
membrane, Schleicher and Schuell) in 20% methanol/2x running buffer (see 2.8.2) at
0.5 A for 1.5 h. The transfer was then placed in blocking buffer (0.2% gelatin (w/v),
0.1% Triton-X-100 (v/v), lx PBS) for 3 h at RT. It was then dried and stored
between two sheets of 3MM filter paper until required. The gel was stained with
Comassie Blue and destained in 45% methanol/10% glacial acetic acid to determine
how successful transfer had been.
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2.8.4 Western blotting of filters
The filter was wet with Ix PBS briefly, then washed twice for 5 min in
blocking buffer (see 2.8.3) with agitation. The primary antibody (Ab755) diluted
1:500 in blocking buffer was applied and incubated with the filter at RT for 1 h with
agitation. The filter was then washed 3x for 5 min in blocking buffer with agitation.
The secondary antibody conjugated to horseradish peroxidase (donkey anti rabbit
HRP) was applied at an approriate dilution (1:500) in blocking buffer and left to
incubate with the filter for 1 h at RT with agitation but in darkness. The filter was
washed 3x 5 min in blocking buffer then for 5 min in lx PBS. A solution of DAB
(diaminobenzidine) dissolved in 50 mM Tris-HCl pH 7.4 (1 mg/ml) was applied to
the filter and 1-2 pi of hydrogen peroxide per ml of DAB solution was added to
activate a colour reaction allowing visualisation of proteins which had reacted with
the primary antibody. SDS solution (20%) was added to stop the reaction when
sufficient. The filter was washed in tap water, dried and stored.
2.9 DEPHOSPHORYLATION OF PROTEINS
To 100 pg of brain homogenate. lOx buffer (5 jll), 20 mM MnCD (5 pi),
BSA (0.5 pg) and a lOx cocktail of protease inhibitors (5 mM PMSF, 0.01 mg/ml
antipain. 0.05 mg/ml chymostatin. 20 mg/ml TLCK and 0.01 mg/ml leupeptin) (5 (il)
were added in a final volume of 50 ul. To this mixture X phosphatase (800 U) (New
England Bioiabs) was added, mixed and incubated at 30°C for 30 min. A control
reaction was set up with all the same reagents except no phosphatase was added. 3x
sample buffer (25 |ll) (see 2.8.2) and 1 M DTT (5 pi) were then added. The samples
were boiled and run on a 10% SDS PAGE gel. The proteins were transferred onto a
nitrocellulose membrane and incubated with Ab755 at a 1:500 dilution as a Western
blot (see 2.8.4).
2.10. DEGLYCOSYLATION OF PROTEINS
To 300 pg of brain homogenate 3 pi of 20% SDS (final 1%), 3 pi of 20%
mercaptoethanol (final 1%) and lOx protease inhibitors cocktail (see 2.9) were added
in a final volume of 60 pi. This mixture was boiled for 2.5 min. To it were added
12 pi of 0.5 M EDTA (final 0.02 M), 30 pi of 10% Tnton-X-100 (final 1%), 30 pi of
1 M phosphate buffer pH 6.3 (final 0.1 M), 30 pi of lOx protease inhibitors cocktail
(see 2.9) and N-Glycosidase F (1.2 U) (Boehringer Mannheim) in a final volume of
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300 ill. The reaction was mixed and left at RT overnight. A control reaction was set
up with the same reagents but no enzyme was added.
Since the maximum possible volume loaded onto an SDS PAGE gel is
approximately 150 ul it was necessary to concentrate the samples by precipitation
first. The samples were placed on ice and 30 ul of dHoO were added. Then 30 ill of
0.18% sodiumdeoxvcholate (final 0.015%) and 120 ul of 24% TCA (final 6%) were
added to give a final volume of 480 (il. This was mixed and left on ice for 15-20
min to precipitate the proteins. After centrifugation at 13.000 g for 5 min at RT the
supernatant was discarded and the pellet washed with 6% TCA (1 ml). After further
centrifugation at 13,000 g for 5 min at RT the supernatant was discarded and the
pellet washed with coid acetone (-20°C) (1 ml). Again the sample was centrifuged
at 13,000 g for 5 min at RT, the supernatant discarded and the pellet allowed to dry
at 37°C for 15-20 min. The pellet was resuspended in dHoO (50 p.1) and added to it
were 3x sample buffer (25 (il) (see 2.9) and 1 M DTT (5 ui). Dropwise addition of 1
M Tris-HCl pH 7.5 brought the acidic pH (yellow in colour) back to neutral (just
turned blue again). Approximately 10 (il was required. The samples were then
boiled and loaded onto a 10% SDS PAGE gel. Transfer of the proteins onto a
nitrocellulose membrane was followed by Western blotting with Ab755.
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CHAPTER 3. RESULTS
3.1 Identification of novel nervous system specific cDNA clones
As a prelude to the project, a number of cDNA clones were isolated from a
differentiated glial subtractive library with a complexity of approximately 300,000.
Those plasmids containing insert DNA fragments which were larger than 0.6 kb
were partially sequenced. Comparisons "with the Genbank and EMBL databases
identified the cDNA clones which had no sequence counterparts in the databases. At
the time this project was initiated, the characterisation of the clones can be
summarised as below
Total number of isolated clones analysed 1003
Number of clones with inserts < 0.6 kb 667
Number of clones with inserts > 0.6 kb and therefore partially sequenced 336
Number of ribosomal sequences identified 170
Number of known sequences identified 80
Number of novel sequences identified 86
Many of the known sequences identified included well characterised clones
such as those encoding the myelin basic proteins and proteolipid proteins (see Table
3.1) Their presence indicated that the subtraction process had been successful in
isolating clones specific to differentiated glial cells. Bacterial sequences and cloning
artefacts were also identified.
The next stage of selection was to identify which of the novel cDNA clones
had a pattern of expression specific to the nervous system. This was achieved by
Northern blotting. Total RNA was extracted from the following rat tissues:-
postnatal day 1 (PI) and P10 brain, then P10 heart, lung, spleen, kidney, thymus,
skeletal muscle, liver and testis. PI is a time in development just before myelination
by oligodendrocytes begins in the brain and the genes which are specifically
involved are switched on. At P10 active myelination is occurring and such genes are
highly expressed. Northern blotting of brain RNA from these two time points
allowed the identification of mRNAs whose expression may be upregulated during
this time indicating possible involvement in the process of myelination.
Total RNA (10 fig) from each of the different rat tissues were run out on a
0.8% formaldehyde agarose electrophoresis gel to separate the different RNA
molecules according to size. Figure 3.1 shows a representative gel demonstrating
approximately equal loadings for each of the tissues analysed. The large (28S) and
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Table 3.1 List of known sequences isolated from the subtractive library.
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Ferritin light chain gene
fyn proto-oncogene
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Human ras-like protein
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Figure 3.1 A representative 0.8% formaldehyde agarose Northern gel before
transfer demonstrating equal loadings of total RNA for each rat tissue analysed. The
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small (18S) ribosomal subunits are clearly visible indicating that the RNA was
intact.
Figure 3.2 shows six Northern blots with different cDNA probes. Probe
OLOOIO is clearly identifying an mRNA of approximately 4.4 kb which is present in
all the tissues analysed. However, five of the 86 novel cDNA clones analysed
hybridised only to RNA molecules present in brain and hence proved to be specific
to the nervous system by not hybridising with mRNAs from any other tissue. These
five clones were also hybridised with total RNA isolated from sciatic nerve of the
peripheral nervous system (PNS), to deduce if any exhibited CNS specific
expression. Optic nerve total RNA was analysed too. The optic nerve has been
described as the simplest part of the CNS since there are no neuronal cell bodies
present and no mRNAs in the nerve axons (Raff, 1989; Raff et al., 1987). Therefore
it is reasonable to deduce that any signal detected from the hybridisation of clones
with optic nerve total RNA indicates expression in glial cells.
Clone OL0003 identifies a very large mRNA molecule with a size in excess
of 9.5 kb and which may be upregulated in brain from PI to P10. Its presence in
sciatic nerve indicates expression in the PNS and a signal in optic nerve indicates
expression in CNS glial cells. Clone OL0587 identifies an mRNA between 7.5 kb
and 9.5 kb which is present in sciatic and optic nerves and is therefore expressed by
glial cells of both the peripheral and central nervous systems.
Clone OL0755, however, is expressed exclusively in the central nervous
system; there is no indication of it in the sciatic nerve. The expression in optic nerve
implicates its presence in CNS glial cells i.e. in oligodendrocytes and/or astrocytes.
It is an interesting clone in the fact that it recognises more than a single mRNA
molecule. At least two mRNAs of approximately 2 kb and 3 kb are identified by it.
Possibly a third species of about 4 kb is also detected although this may be due to
non-specific signal from the large ribosomal subunit.
Clones OL0816 and OL0848 both identify single mRNAs of between 4.4 kb
and 7.5 kb and show a pattern of expression which is specific to the central nervous
system.
Summary
From the Northern blot analysis it can be deduced that clone OL0003 is
expressed by glial cells because of signal in optic and sciatic nerves. It may also be
expressed by neurons due to signal in brain. Clone OL0587 is also expressed in glial
cells but may also be expressed by neurons. Clone OL0755 is expressed by CNS
glia but possibly also by neurons. This clone identifies two mRNAs which may be
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Figure 3.2 Northern blots of total RNA from a variety of rat tissues, transferred to
Hybond-N membrane and probed with 6 different cDNA probes which had been 32p
labelled by random priming. Clone OLOOIO is clearly present in ail tissues analysed.
Clones OL0003, OL0587, OL0755, OL0816 and OL0848 are all clearly shown to be
nervous system specific.
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related by alternative splicing mechanisms. Clone OL0816 must only be expressed
by neurons since there was no signal in optic or sciatic nerves. Clone OL0848 is
expressed by CNS glia but possibly also by neurons.
62
3.2 Expression of the novel nervous system specific cDNA clones in cultured
glial cells as deduced by ISH studies
Having established that 5 of the clones have an expression pattern specific to
the nervous system, investigations were carried out to deduce if any of these clones
were expressed by specific cell types. From the Northern blot data, the signals in
optic nerve and/or sciatic nerve already suggest that all the clones, except OL0816,
are expressed by glial cells. Expression of clone OL0816 specifically in brain and
not in either of the two nerves, implicates expression by neurons. In situ
hybridisation (ISH) studies on cultured glial cells were used to investigate this
question.
The five clones have different sized inserts as clearly shown in Figure 3.3.
The approximate sizes of the inserts for clones OL0003, OL0587, OL0755, OL0816
and OL0848 are 1.2 kb, 2.4 kb, 1.1 kb, 0.8 kb and 1.1 kb respectively. Riboprobes
were prepared from the purified plasmid DNA for each clone. As an indication of
the success of transcription the amount of incorporated radioactivity into the newly
synthesised riboprobe was calculated. Table 3.2 shows representative radioactive
readings for the five riboprobes that were made and indicate high incorporation of
radiolabel. From these figures the volume of 0.01 M DTT in which to resuspend the
probe to give a concentration of 1 ng/pl/kb could be calculated, as described in the
Materials and Methods.
Figures 3.4 and 3.5 show the results of the ISH experiments done on the
cultured glial cells. The antibody against the 04 surface antigen is clearly labelling
cells of the oligodendrocyte lineage. These cells show the characteristic morphology
of many highly branched processes extending and radiating from the cell body. In
some cases the early stages of myelin sheet production is apparent at the ends of
processes.
Astrocytes present in the cultures have also been clearly defined with the
anti-GFAP monoclonal antibody GA5, although it is not able to distinguish between
type 1 and type 2 astrocytes. A typical astrocytic morphology is apparent in these
cells with much longer, less branched and fewer processes radiating from their cell
bodies than observed in oligodendrocytes. It is also possible to see filamentous
staining in some of these cells.
In figure 3.4 it can be seen that clone OL0003 is expressed by 04+
oligodendrocytes by the clustering of silvergrains around the cell body. The silver
grains are indicative of radioactive antisense riboprobe that has hybridised with
native mRNA molecules present in the cell. This clone does not, however, appear to
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Figure 3.3 Restriction digests of piasmid DNAs for the 5 brain specific clones of
interest. The purified piasmid DNAs were digested with the restriction enzymes
NotI and Sail to release the inserts from the pSPORTl vector and then run out on a
1% agarose electrophoresis gel. pSPORTl runs as a band at 4 kb. The 5 clones
clearly have different inserts with differing sizes.
63 f(i)
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Table 3.2 Representative radioactive readings for the 5 riboprobes synthesised.
From the measured counts per minute (CPM) of precipitated RNA solution (Total),
resuspended pelleted RNA (Pellet) and the supernatant (Supernatant) the
incorporation of [35s]-UTP during transcription was calculated. As can be seen
from the table, incorporation was high.
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Clone CPM CPM CPM 5k 5k
Total Pellet Supernatant Unincoruorated Incorporated
003 AS 414497 103283 51845 12.5 87.5
003 S 743234 175273 73969 10.0 90
587 AS 412923 173834 34887 8.4 91.6
587 S 713069 377761 52623 7.4 92.6
755 AS 405312 203875 61076 15.0 85
755 S 411120 172459 31915 7.7 92.3
816 AS 539615 131253 23478 4.35 95.65
816 S 785840 931132 61824 7.9 92.1
848 AS 265320 126993 71311 26.9 73.1
848 S 379457 359931 111254 29.3 70.7
Figure 3.4 Double label immunocytochemistry and ISH analysis of glial cells in
culture. 35§.labelled riboprobes prepared from each cDNA were used to detect
mRNA in cultures of glial progenitor cells which had been allowed to differentiate
for four days. Cells of the oligodendrocyte lineage are fluorescently labelled with
the monoclonal antibody 04 coupled to TRITC (red colour) and astrocytes are
labelled by a monoclonal antibody against GFAP (GA5) which was also coupled to
TRITC. Clones OL0003, OL0587 and OL0848 show expression specific to
oligodendrocytes by a clustering of silver grains over their cell bodies (yellow/green




Figure 3.5 Double label immunocytochemistry and ISH analysis of glial cells in
culture. 35g.labelled riboprobes prepared for each cDNA were used to detect
mRNA in cultures of glial progenitor cells which had been allowed to differentiate
for four days. Cells of the oligodendrocyte lineage are fluorescently labelled with
the monoclonal antibody 04 coupled to TRITC (red colour) and an anti-GFAP
monoclonal antibody (GA5) coupled to TRITC labels astrocytes. Clones OL0755
and OL0816 appear to be expressed by both oligodendrocytes and astrocytes. Clone
OL0816 is also labelling a cell which is not fluorescently labelled with 04 (indicated
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label GFAP+ astrocytes. Clones OL0587 and OL0848 also appear to be expressed
only by oligodendrocytes ana not by astrocytes.
Figure 3.5 shows that clones OL0755 and OL0816 are expressed by both
oligodendrocytes and astrocytes in culture although clone OL0816 is very much
more weakly expressed. There are clear-clusterings of silver grains over the cell
bodies of both cell types when using these 2 nboprobes.
Conclusions
Clone OL0003 is expressed by cultured oligodendrocytes but not by
astrocytes. Combined with the results from the Northern blot this indicates
expression by myelinating CNS glia (oligodendrocytes) and possibly also neurons.
Clone OL0587 is also expressed by oligodendrocytes in culture but not astrocytes.
Therefore results so far indicate expression by oligodendrocytes and possibly also
neurons. This is also the case for clone OL0848.
Clone OL0755 is expressed by both oligodendrocytes and astrocytes in
culture. Therefore results so far indicate expression by glia and possibly also by
neurons. Clone OL0816 is also expressed by oligodendrocytes and astrocytes in
culture, however this result does not agree with the Northern blot which implicated
expression only by neurons. This conflict in results may indicate a difference in
sensitivity between the two techniques or a difference in the expression in vitro
(cultured cells) from in vivo (dissected nerves).
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3.3. Isolation of a full length cDNA for clone OL0755
At this stage of the work it was decided to focus on a single clone. Clone
OL0755 was chosen for two main reasons. First, it is an interesting clone in that it is
expressed by both oligodendrocytes and astrocytes in culture as seen by ISH.
Secondly, the pattern of expression as deduced by Northern blotting is unique in that
it is the only one of the Five brain specific clones to identify more than a single
mRNA molecule. Therefore for these reasons clone OL0755 was chosen for further
investigation.
Clone OL0755 has an insert which is approximately 1 kb and yet it identifies
mRNA molecules on Northern blots which are approximately 2 kb and 3 kb. There
is a possible third species identified at about 4 kb. although this may be due to
background signal from the large ribosomal subunit. Clone OL0755 therefore
cannot be a full length cDNA since the mRNA molecules it identifies on Northern
blots are clearly greater in size.
To obtain a full length cDNA. clone OL0755 was used to probe a cDNA
library. The cDNA library analysed was an oligo dT primed, directionallv cloned
(NotI -> Sail), mixed age (1 day. 15 day and 16 weeks) rat brain library in A.gt22A.
A library constructed from rat brains of these ages was considered a good source of
related clones since clone OL0755 identifies mRNAs expressed at PI and P10 in rat
brain on Northern blots. Partial sequencing of clone OL0755 shows that the extreme
3' end is complete since it includes a polvadenvlation signal and a polyA tail.
Therefore an oiigo dT primed library is a good source of larger cDNAs with
additional 5' sequence and complete 3' sequence.
In the first round of hybridisation screening the entire cDNA library was
plated on four plates each with 60.000 clones. Filter lifts were taken which were
then all hybridised with clone OL0755 which had been radioactively labelled with
[a-3dpj dCTP by random priming. Autoradiography of the hybridised filters
allowed identification of the plaques which contained cDNA clones which had
hybridised with clone OL0755 and hence appeared to have the same DNA sequence.
From the autoradiographs 28 positive plaques were identified and 25 plugs
containing positive plaques were isolated from the plates.
The resultant plug lvsates were analysed by PCR as an additional test for the
presence of clone OL0755 sequence. Primers 1 IF and 7R were used to amplify a
342 bp fragment found at the 5' end of clone OL0755 (see Materials and Methods
for details). These primers were chosen from the partial sequence obtained for clone
OL0755. Of the 25 plug lysates from the primary hybridisation screen only 15
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amplified a band of approximately 300 bp during PCR with these primers as can be
seen in Figure 3.6A. Therefore only 15 out of the 25 plug lysates definitely contain
cDNA clones with the same sequence as clone OL0755. The other lysates may
contain cDNA clones which are smaller. Since the library was oligo dT primed the
extreme 5' end sequence of clone OL0755 may not be present in these clones and
therefore the PCR amplification with pritners 1 IF and 7R would not be possible.
Alternatively the lysates may not contain cDNA clones with the same sequence as
OL0755.
In an attempt to estimate the amount of additional 5' sequence present in
clones related to OL0755, a PCR amplification was done with these plug lysates
using primer 601, a forward primer which is present in the Xgt22A vector sequence,
and primer 7R. Not all the 15 plug lysates amplified. The largest DNA fragment
amplified was approximately 500-600 bp indicating an extra 200-300 bp of 5'
sequence. It is possible, however, that some clones did not amplify because
conditions were unsuitable. Figure 3.6B shows the amplification of potential
additional 5' sequence.
Six plug lysates, 2, 3, 12, 13, 19 and 22, were chosen for the next round of
screening. 200 plaque forming units of each were plated out and the filter lifts from
each plate were hybridised this time with digoxigenin labelled clone OL0755.
Positive plaques were identified following a colour reaction. Of the six plates in the
second round of screening plate 12 had no positive plaques, plate 2 had three
positives, plate 22 had two positives, and plates 3, 13, and 19 had only one each.
Plug lysates from the eight positive plaques were amplified by PCR with primers
11F and 7R to confirm the presence of clone OL0755 sequence. Figure 3.7 shows
this amplification. Only the plug lysates from plates 3, 19 and one from 22
amplified.
High titre lysates were prepared from these three and the phage DNA isolated
from each. Digestion of the purified DNA with the restriction enzymes NotI and
Sail led to estimation of the size of the inserts and therefore whether any were
possible full length cDNAs for clone OL0755. Figure 3.8 shows the digests of the
phage DNA for the three clones. From this point these 3 clones will be called 3, 19
and 22 respectively. The insert of clone 3 is about 2 kb, that of clone 19 is about 1.5
kb and clone 22 has one of approximately 3 kb. These insert DNA fragments were
purified and ligated into the vector pSPORTl and then sequenced.
The clones were sequenced at both ends using the T7 and M13F primers.
Clone 19 was discarded as an artefact since its sequence did not match clone
OL0755 and other clone OL0755 primers produced no sequence at all. Clone 3
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Figure 3.6 PCR amplification of plug lysates from the primary hybridisation screen
of the cDNA library.
A shows the amplification with primers 1 IF and 7R to confirm the presence of clone
OL0755 sequence. 15 of the 25 plug lysates have amplified clone OL0755 sequence.
The negative control which had no template DNA added is clear.
B shows the amplification of those plug lysates positive for clone OL0755 sequence
with primers 601 and 7R to estimate the amount of additional 5' sequence. Not all
lysates have amplified, possibly because conditions were not optimal. Again the
negative control is clear.
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A. Primers 11F and 7R
1 2 3 5 7 8 9 10 11 12 13 14 15 16 17 18 19 20
0.5 kbi
21 22 24 25 26 27 28 -ve
0.5 kbi
B. Primers 601 and 7R
2 3 5 7 9 10 12 13 15 17 18 19 20 22 27 -ve
1.0 kb ►
0.5 kb ►
Figure 3.7 PCR amplification of the plug lysates from the secondary hybridisation
screen of the cDNA library. Amplification was done with primers 1 IF and 7R to
confirm the presence of clone OL0755 sequence. Only plug lysates 3, 19 and 22a
amplified clone OL0755 sequence.
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Primers 11F and 7R
13 19 2b 2c 22a22b-ve
0.5 kb ►
Figure 3.8 Digests of purified Aphage DNA with the restriction enzymes NotI and
Sail to release insert DNA fragments. The uppermost bands on the gel are the
digested Agt22A phage DNA. Clone 3 has an insert of about 2 kb. clone 19 an insert









produced unreadable sequence and so was also discarded as an artefact. Clone 22,
however produced sequence that matched clone OL0755 at the 3' end. including a
polyadenviation signai and polyA tail, and clear readable sequence at the 5' end.
Therefore it appeared that this 3 kb clone 22 could be a full-length cDN'A for clone
OL0755 since it agrees in size with the 3_kb mRNA identified on the Northern blot.
It was named OL0755-A.
Since a smaller mRNA molecule of about 2 kb was also identified on the
Northern blot it was decided to repeat the secondary hybridisation screen in the hope
of isolating a second potential full length cDNA. The plug lvsates 2. 3. 13 and 20
from the primary screen were chosen for a second round of screening. These lysates
all amplified a band of about 300 bp with primers 1 IF and 7R indicating the
presence of clone OL0755 sequence. Although lysates 2 and 3 had already
undergone a secondary screen yielding no full length clones they were chosen again
to see if sensitivity of the screen was improved by using radioactively labelled probe
instead of digoxigenin labelled probe.
The secondary hybridisation screen using radioactively labelled clone
OL0755 as the probe identified at least one positive plaque on each of the four
piates. Plate 2 had six positives, plate 3 had three, plate 13 had one and plate 20 had
six positive plaques. The plug lysates from the plaques with the strongest signal on
each plate were taken through a third hybridisation screen to ensure purification of
the plaques of interest. High titre lysates were prepared from a positive plaque on
each plate and the phage DNA purified from each. Following digestion with the
restriction enzymes NotI and Sail to release the inserts, only lysates from plates 13
and 20 appeared to contain cDNA inserts of 2-2.5 kb as shown in Figure 3.9. From
now on they will be referred to as clones 13 and 20.
The purified insert DNA fragments were ligated into PGEMllzf and
sequenced. When sequenced with the primers T7 and M13F clone 20 produced
sequence which did not relate to clone OL0755 or clone OL0755-A and so was
discarded as an artefact. Clone 13 did produce related sequence to clone OL0755
and clone OL0755-A agreeing exactly at the 3' end and possessing a
polyadenylation signal and polyA tail. The 5' end gave clear readable sequence
which matched exactly with clone OL0755-A 5' sequence. It therefore appeared that
clone 13 was probably the full length cDNA of clone OL0755 encoding the 2 kb
mRNA molecule detected on the Northern blot and was therefore named clone
OL0755-B.
Clones OL0755, OL0755-A and OL0755-B were all fully sequenced from
both directions giving the nucleotide compositions for both DNA strands. Clone
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Figure 3.9 Digests of purified Xphage DNA with the restriction enzymes NotI and
Sail to release insert DNA fragments. The uppermost bands on the gel are the






OL0755-A is 277Ibp in size and clone OL0755-B is 2050bp. Both these sizes
compare well with the mRNAs identified by Northern blotting and thus support the
view that these clones are full length. Both clones have a polyadenylation signal
(AATAAA.) followed by a poly A tail 13 bp downstream which confirms that the 3'
ends of the clones are complete.
Figures 3.10 and 3.11 show the full nucleotide sequences for each clone.
Sequence analysis predicts that clone OL0755-A has 127 bp of untranslated 5'
sequence followed by a 1605 nucleotide open reading frame (ORF) encoding a
protein of 535 amino acids. Clone OL0755-B has 247 bp of 5' non-coding sequence
followed by an ORF of 1311 nucleotides encoding a protein of 437 amino acids.
Both clones have a common start site for translation. The initiation codon is
preceded by at least one in frame stop codon 15 bp upstream suggesting that this is
the correct initiation site. Comparison with the Kozak consensus sequence for the
start of translation (GCCGCCi A/G)CCATGG) (Kozak. 1987; Kozak. 1989)
however, does not show great similarity (clones OL0755-A and OL0755-B:-
ACATCTGGATGG), but of the two positions postulated to be of particular
importance. -3 and +4, one is in agreement (G at position +4). Clones OL0755-A
and OL0755-B are related to each other at the nucleotide level in a manner
suggestive of possible alternative splicing of a common gene. High similarity at the
amino acid level also supports this likelihood. Figure 3.12 shows schematically how
these clones are related to one another and to clone OL0755.
Analysis of the translated products for each clone was done using MacVector
software. Clone OL0755-A has a predicted MW of 59690 and a pi of 6.59. A
hydrophilicity profile (Kyte and Doolittle. 1982) (see Figure 3.13) was done with
constants averaged over 7 amino acids and showed the protein to be mostly
hydrophilic in nature except for a significantly hydrophobic 13 amino acid stretch
from Ser-457 to Gln-469 which has predicted beta-sheet secondary structure An
extended beta strand requires only 9 residues to span a lipid bilayer (Gardinier et al.,
1992) and so this region may be a potential transmembrane sequence. Clone
OL0755-A also has one predicted ATP/GTP binding motif (GEVLDGKT) at amino
acid 263, a TGF binding motif (CAPAGPVSWF) at amino acid 118 and 7 possible
N-glycosylation sites at positions 159, 191, 441, 492, 527, 532 and 540.
Clone OL0755-B has a predicted MW of 49252 and a pi of 5.23. It. like
clone OL0755-A. is mostly hydrophilic in nature except for one potential membrane
spanning region at Thr-168 to Glu-188 which has possible a-helix structure. Figure
3.13 shows the plot. One ATP/GTP binding motif was identified at amino acid 270,
a TGF binding motif at amino acid 158 and two N-glycosylation sites were
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Figure 3.10 The complete nucleotide and deduced amino acid sequence of clone
OL0755-A. The protein has 535 amino acids (including the initiation methionine)
and a calculated molecular weight of 59,690. The sequence in bold type (AATAAA)
indicates the polyadenylation signal. The underlined amino acid sequence denotes a
23 amino acid peptide used to raise a polyclonal antibody against. Primers 16F and
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Figure 3.11 The complete nucleotide and deduced amino acid sequence of clone
OL0755-B. The protein has 437 amino acids (including the initiation methionine)
and a calculated molecular weight of 49,252. The sequence in bold type (AATAAA)
indicates the polyadenylation signal. The underlined amino acid sequence denotes a
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Figure 3.12 A schematic representation of how clones OL0755-A. OL0755-B and
OL0755 are related at the nucleotide level, possibly by alternative splicing of a
common gene. The figures are drawn to scale with respect to clone sizes and blocks
of sequence indicated by solid black represent sequence which is unique and specific
to each clone. Hence clone OL0755-A has 3 unique segments of sequence,
including one segment of about 600 bp in size, and clone OL0755-B has one unique
segment of sequence. Blocks of sequence with the same shade of grey represent
identical sequence common to the clones. The thick black lines under clones
OL0755-A and OL0755-B indicate the locations of clone OL0755 sequence. The
locations of the start and stop codons giving rise to the encoded proteins are also
indicated for clones OL0755-A and OL0755-B. Hence the proteins encoded by












Figure 3.13 Hydrophilicity plots for the proteins encoded by clones OL0755-A and
OL0755-B.
Clone OL0755-A is mostly hydrophilic in nature except for the 13 amino acid
stretch from Ser-457 to Gln-469 which also has predicted beta-sheet secondary
structure and may therefore be a potential transmembrane domain.
Clone OL0755-B is also mostly hydrophilic except for the region from Thr-168 to
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identified at amino acids 199 and 231. The glycosylation sites present in both clones,
however, are apparently not used i see 3.4 ) supporting the view that these clones do
not encode integral membrane proteins.
The only significant similarity of these clones to any other sequence in the
Genbank or EMBL databases is a 95.69c identity of 201 nucleotides (bp 1956-2157
in clone OL0755-A. which is also present in clone OL0755-B) with a R. norvegicus
partial brain mRNA named clone sap37f. This clone was isolated from an
expression cDNA library with antisera raised against a synaptic protein preparation,
the postsynaptic density fraction (Langnaese et al.. 1996).
Conclusions and mini discussion
During hybridisation screening of the library. PCR amplification was a useful
way to confirm that clones were present which were related to clone OL0755.
Amplification with the primers specific to clone OL0755. 1 IF and 7R, was a reliable
reaction. PCR amplifications to estimate the amount of additional 5' sequence
present in clones related to OL0755 was not as reliable probably because conditions
were not optimal for many of the template clones.
Two related clones. OL0755-A and OL0755-B. were isolated from this
library. Clone OL0755-A was identified by digoxigenin labelled clone OL0755 and
clone OL0755-B by 32p radiolabeled probe. Digoxigenin labelling was initially
used as an alternative to radioactivity and therefore as way to avoid the additional
hazards associated. However it does appear to be less sensitive since from six plates
in a secondary hybridisation screen only eight positive plaques were identified with a
digoxigenin labelled probe compared to 17 positive plaques from only four plates
when a radiolabelled probe was used. Also, when comparing plates 2 and 3 which
were analysed by both methods, three positive plaques were identified on plate 2 and
one positive on plate 3 by the digoxigenin labelled probe as opposed to six and three
positive plaques identified with radioactively labelled probe.
The sizes of clones OL0755-A and OL0755-B compare well with the two
mRNAs identified on the Northern blot and sequence analysis shows their 3' ends to
be complete with polyadenylation signal and poly A tail. Therefore it appears that
both clones are full length cDNAs. Sequence analysis predicts that clone OL0755-A
encodes a protein of about 60 kD and clone OL0755-B one of about 50 kD. Both
proteins are mostly hydrophilic but do contain potential membrane spanning
domains, although since the glycosylation sites present in the proteins are apparendy
not used (see 3.4) it seems unlikely that these proteins are integral membrane
proteins. A small, 201 bp fragment present in both clones is almost identical to a
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region of a clone. sap37f. isolated from an expression cDNA library with antisera
raised against a synaptic protein preparation, the postsynaptic density fraction
(Langnaese et al.. 1996). It is possible therefore that the proteins encoded by
OL0755-A and OL0755-B could be associated with synaptic elements of the CNS.
Sequence analysis shows that clones OL0755-A and OL0755-B are closely
related and are possibly the products of alternative splicing of a primary transcript
encoded by a common gene. However, the relationship of these two clones with
clone OL0755 is less straightforward. It is possible that clone OL0755 represents
the partial sequence of a third related clone. If this were the case, however,
explaining the relationship of all three clones by alternative splicing mechanisms
would be difficult. It is perhaps more probable that clone OL0755 is a truncated
form of clone OL0755-B resulting from an error of the reverse transcription of
polyA RNA during the construction of the original cDNA library (see chapter 4 for a
more detailed discussion).
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3.4 Expression patterns of clones OL0755-A and OL0755-B
3.4.1 Northern blot analysis with a clone OL0755-A specific probe
Clone OL0755-A has a 624 bp fragment of sequence (nucleotides 1286-
1910) which is not present in clone OL0755-B and therefore is ideal for use as a
probe specific for clone OL0755-A. PCR amplification using primers 16F
(5'GATCATGAGGACATC3') and 21R (5 'AGAGGGAAGCAAGTCTCAGC3')
was used to isolate a 534 bp fragment from this region (see Figure 3.10). Figure
3.14 shows a 1% agarose gel with the 534 bp amplified product. The negative
control which had no template DNA is clear giving confidence that the DNA of
interest was amplified and not an artefact. Ligation of the PCR product into the TA
vector was followed by sequencing of the insert with the T7 and M13F primers to
confirm that the sequence was correct. This isolated fragment specific to clone
OL0755-A will be called clone OL0755-A(S).
A Northern blot experiment was done using clones OL0755 and OL0755-
A(S) to probe 15 day old rat brain total RNA (15 pg). Plasmid DNA for clones
OL0755 and OL0755-A(S) were radioactively labelled with [a-32p] dCTP by
random priming and hybridised with the filters at 65°C. Autoradiography of the
filters (Figure 3.15) showed that clone OL0755 hybridised with at least two mRNAs
as shown before but clone OL0755-A(S) hybridised specifically to the 3 kb mRNA
which provides good evidence that clone OL0755-A correlates to this mRNA.
3.4.2 Developmental Northern blot
A developmental Northern blot was done using clone OL0755 to probe equal
amounts of total RNA from rat brains of different ages to give an indication of the
levels of expression during postnatal development of the central nervous system.
Total RNA was isolated from whole brains of rats aged 1, 3, 5, 7, 9, 11, 15, 21days
and adult (16 weeks old) and an equal amount (10 pg) of each was run on a 0.8%
formaldehyde agarose gel and transferred onto a nylon membrane. Figure 3.16
shows the autoradiograph of the filter with equal loadings of these different aged rat
brain RNAs after being hybridised with clone OL0755. The 2 mRNAs of about 2 kb
and 3 kb are clearly identified at every age examined. Expression of the smaller
mRNA increases over time during development until postnatal day 21. The larger 3
kb mRNA is not as abundant as the smaller one but increases in amount with
developmental age until P21, although not as dramatically. There may be a third
mRNA band present at 4 kb although it is difficult to discern it from non-specific
signal associated with the large ribosomal subunit.
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Figure 3.14 PCR amplification of clone OL0755-A(S), the 534 bp fragment specific
to clone OL0755-A. Primers 16F and 21R were used to amplify up this region of the




Figure 3.15 Northern blot of 15 day-old rat brain total RNA probed with clones
OL0755 and OL0755-A(S). The autoradiograph clearly shows that probe OL0755-
A(S) is specifically hybridising with the mRNA of about 3 kb recognised by clone
OL0755. Hence this band correlates well with clone OL0755-A (2.7 kb).
71f(ii)
 
Figure 3.16 A developmental Northern blot to investigate expression levels of clone
OL0755 related mRNAs during development. Total RNA (10 |lg) from rat brains of
different ages were run out on a 0.8% formaldehyde agarose gel, transferred onto
Hybond-N nylon membrane and hybridised with radiolabeled probe OL0755. The
resultant autoradiograph clearly shows an increase in expression of both the 2.7 kb
and 2 kb mRNAs, correlating with clones OL0755-A and OL0755-B respectively,
during development until postnatal day 21 (P21).
71f(iii)






3.4.3 Production of a polyclonal antibody against an N-terminus peptide
Clones OL0755-A and B have common N-terminus amino acid sequence. A
polyclonal antibody was raised against a 23 amino acid peptide at the extreme N-
terminus. The peptide sequence was EASFVQTTMALGLPSKKASSRNV. A
reactive antibody was produced which recognises a single protein with a similar size
to actin (the control reaction), as seen in Figure 3.17. Actin is approximately 43 kD
in size and therefore it is possible that the protein being identified by the anti-peptide
antibody is that encoded by clone OL0755-B with a predicted size of about 50 kD.
The full bleed sample clearly recognises the same proteins as the test bleed and there
is little evidence of background signal although the titre of the antibody does appear
to have decreased slightly. There is a very faint band above the stronger one which
may correspond to the 60 kD (approximately) protein encoded by clone OL0755-A.
The abundance of this clone is less than for clone OL0755-B as shown by the
developmental Northern blot so it seems no surprise that the encoded protein may
also be less abundant than that encoded by clone OL0755-B. This antibody will be
called Ab755 since it was raised against a peptide common to both clones OL0755-
A and B just as clone OL0755, when used as a probe, recognises both.
3.4.4 Developmental Western blot with Ab755
Western blotting of brain homogenates from rats of different ages with
Ab755 was used to investigate expression of the proteins encoded by clones
OL0755-A and B during development. Equal amounts of protein (100 fig) for each
brain homogenate sample were loaded onto a 10% SDS PAGE gel which separated
the proteins according to size. The proteins were then transferred onto a
nitrocellulose membrane which was incubated with Ab755 at a dilution of 1:500.
Figure 3.18 shows the developmental Western blot. Expression of the small 50 kD
protein is increasing significantly with developmental age until postnatal day 21.
This pattern compares well with the developmental expression of the mRNA
encoding clone OL0755-B (see the developmental Northern blot). The larger 60 kD
protein is much less abundant and expression appears to decrease slightly with age
unlike expression of the mRNA which increases slightly.
3.4.5 ISH studies on rat brain sagittal sections
Attempts were made to use Ab755 in immunofluoresence studies on rat brain
sagittal sections to investigate expression patterns of the proteins in vivo. However
these proved to be unsuccessful. This may possibly be due to the native proteins
having a conformation which does not allow access by the antibody to the correct
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Figure 3.17 Test Western blots with Ab755 against rat brain homogenate. Strips of
a filter on which the proteins of rat brain homogenate were separated were incubated
with Ab755 at two dilutions (1:500 and 1:1000). Both the antisera from the test
bleed and the full bleed are clearly reacting with a protein a little larger than actin
(43 kD) which may correlate with the 50 kD protein encoded by clone OL0755-B.
There is also a weaker reaction with a larger protein which may correlate with the 60
kD protein encoded by clone OL0755-A. Unfortunately the titre of Ab755 has
decreased from the test bleed to the full bleed.
72f(i)
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Figure 3.18 Developmental Western blot to investigate expression of the proteins
encoded by clones OL0755-A and OL0755-B during development. Protein (100 (ig)
from brain homogenates of different aged rats were run on a 10% SDS PAGE gel,
transferred onto a nitrocellulose membrane and incubated with Ab755 diluted 1:500.
Expression of the 50 kD protein encoded by clone OL0755-B is increasing with age
until postnatal day 21 (P21). Expression of the 60 kD protein encoded by clone
OL0755-A decreases during development.
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epitope. Therefore further attempts were made following treatment of sections with
SDS according to the method of Miner et ah. 1997, in the hope that these denaturing
conditions might expose the epitope on the proteins which reacts with Ab755.
Again, however, this approach proved unsuccessful. Therefore ISH studies were
performed as an alternative in order to investigate expression patterns in the rat brain
of the mRNAs encoding the proteins.
ISH employed clone OL0755 as a riboprobe since its sequence is common to
both clones OL0755-A and OL0755-B and 21 dav-old rat sagittal brain sections
were used since this age corresponds to the maximum expression of both the clones
as deduced from the developmental Northern blot. Immunofluoresence with
antibodies against GFAP to identify astrocytes and against MBP to identify
oligodendrocytes was also performed on the same sections in an attempt to
investigate whether clone OL0755 was expressed by a specific cell type in vivo and
if this expression correlated with expression in cultured oligodendrocytes and
astrocytes. Unfortunately morphological preservation of these cell types was not
good.
Figure 3.19 shows the results of ISH of clone OL0755 on 21 day-old rat
brain sagittal sections. It is highly expressed in cells of the granule cell layer in the
cerebellum. At higher magnification expression is seen in the cerebellar nuclei and
possibly also in some cells of the molecular layer. There is strong expression in the
hippocampal CA1, CA2 and CAS regions as well as in the dentate gyrus, and
throughout the fore-brain there is also expression. The labelling in the granule cells
of the cerebellum, the cerebellar nuclei and the hippocampus strongly indicate
expression of clone OL0755 by neurons, however MBP and GFAP antibody staining
in the fore-brain region seems to correlate in some cells with ISH labelling by clone
OL0755 (as shown more clearly in Figure 3.20) and therefore suggests expression by
glial cells as does the possible labelling of some cells in the molecular layer of the
cerebellum.
ISH was also done on 21 day-old rat brain sagittal sections with clone
OL0755-A(S) as the riboprobe to see if there is a different pattern of expression for
clone OL0755-A alone. Figure 3.21 shows the results. Clone OL0755-A apparendy
has a similar pattern of expression to clone OL0755, although perhaps not as strong.
It strongly labels cells of the granule cell layer in the cerebellum and the
hippocampus and dentate gyrus but does not seem to be as abundantly expressed in
fore-brain as clone OL0755.
73
Figure 3.19 ISH of 21 day-old rat brain sagittal sections with clone OL0755. Panel
A shows the complete sagittal brain section indicating ISH labelling in the
cerebellum (CB), hippocampus (HP) and fore-brain (FB). Panels B. C and D show
ISH labelling in the granule cell layer (GL) of the cerebellum. Panel C also shows
labelling of the cerebellar nuclei (CN). Panel E shows labelling in the hippocampus.
The regions CA1, CA2 and CA3 are indicated, as is the dentate gyrus (DG). Panel F
shows ISH labelling in the granule cell layer of the cerebellum by epifluorescence.




Figure 3.20 21 day-old rat brain sagittal section immunologically labelled with
antibodies against GFAP and MBP and ISH with clone OL0755. Panel A shows
immunocytochemical labelling of astrocytes in the forebrain with the anti-GFAP
monoclonal antibody GA5. There is a correlation of some cells with ISH labelling
by clone OL0755, panel B, indicated by an asterisk. ISH labelling of other cells
shown in panel B correlate with oligodendrocytes labelled by an anti-MBP antibody
shown in panel C, an example of which is indicated by an arrow.
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Figure 3.21 ISH of 21 day-old rat brain sagittal sections with clone OL0755-A(S).
Panel A shows the complete sagittal brain section indicating ISH labelling in the
cerebellum (CB) and in the hippocampus (HP). Panels B and C both show granule
cell layer (GL) labelling in the cerebellum. There also appears to be weak staining
in the cerebellar nuclei (CN) in panel C. Panel D shows labelling of the
hippocampal CA1. CA2 and CA3 regions, as well as the dentate gyrus (DG).
FB=fore-brain, ML=molecular layer, MT=myelinated tract.
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3.4.6 ISH studies on rat optic nerve sections
As previously described, the optic nerve is the simplest part of the CNS and
does not contain any neuronal cell bodies. It was therefore decided to do an ISH
study with clones OL0755 and OL0755-A(S) on 21 day rat optic nerve transverse and
longitudinal sections in the hope of confirming expression by glial cells. Figure 3.22
shows the results. There is clear labelling of the optic nerve by clones OL0755 and
OL0755-A(S) antisense riboprobes as compared with the sense controls. Therefore
it can be deduced that the mRNAs for these clones are expressed by glial cells .
3.4.7 Investigations to deduce whether the proteins encoded by clones OL0755-
A and B are phosphorylated and/or glycosylated
Figure 3.23 shows samples of brain homogenate from 5 day and 21 day-old
rats which had been treated with and without dephosphatase enzyme and then run on
a 10% SDS PAGE gel, transferred onto a nitrocellulose membrane and incubated
with Ab755. A shift in the mobility of the proteins identified by Ab755 compared
with untreated proteins would be indicative that they had been dephosphorylated by
the enzyme and that in vivo they are phosphorylated. However it appears that
treatment of these proteins with the dephosphatase enzyme has not caused them to
run differently on the gel by comparison with the untreated proteins. This lack of
mobility shift does not however prove that the proteins are not phosphorylated. It is
only possible to state that a shift in mobility confirms phosphorylation of the native
proteins but no shift in mobility does not exclude this possibility.
The same 5 day and 21 day-old rat brain homogenates were also treated with
the de-glycosylation enzyme N-Glycosidase F. Glvcosylation of a protein is
indicative of localisation to the plasma membrane of a cell. The deglycosylated
form of a normally glycosylated protein has an increased mobility on an SDS PAGE
gel compared with untreated protein as can be seen in Figure 3.24 with MAG. Brain
homogenate which had been treated with and without N-Glycosidase F was
incubated with an antibody against MAG (diluted at 1:2000). This acted as a control
for the deglycosylation reaction and it can clearly be seen that there is an increase in
the mobility of MAG on the gel following deglycosylation. The diffuse band of the
native glycosylated protein changes to a sharper band following deglycosylation.
However, it appears that the proteins recognised by Ab755 are not glycosylated in
their native form since there is clearly no shift in mobility for either protein on the
gel.
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Figure 3.22 ISH of 21 day-old rat optic nerve sections with clones OL0755 and
OL0755-A(S). Bright field images are shown on the left and dark field images on
the right of each pair. Panels A show longitudinal sections and panels B transverse
sections of the nerve labelled with antisense riboprobes for clone OL0755-A(S) and
OL0755 as indicated. Panels C show transverse sections hybridised with sense
control riboprobes for each clone. Clone OL0755-A(S) and OL0755 both clearly
label the optic nerve by comparison to the sense controls, although labelling by clone
OL0755 is slightly stronger than by clone OL0755-A(S). Panel D shows labelling of
a transverse section of nerve by clone OL0755. viewed by epifluorescence.
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Figure 3.23 Neither protein encoded by clones OL0755-A (60 kD) or OL0755-B
(50 kD) change their electrophoretic mobility following dephosphorylation. Brain
homogenates from 5 day and 21 day rat brains were incubated with (+) or without (-)
^phosphatase and then run on a 10% SDS PAGE gel before transfer to a
nitrocellulose membrane and incubation with Ab755 diluted 1:500. A shift in
mobility would confirm phosphorylation of the native proteins but an absence of a
shift does not exclude the possibility.
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Figure 3.24 Neither protein encoded by clones OL0755-A (60 kD) or OL0755-B
(50 kD) change their electrophoretic mobility following deglycosylation. Brain
homogenates from 5 day and 21 day rat brains were incubated with (+) or without (-)
N-glycosidase F (as described in Materials and Methods) and then run on a 10%
SDS PAGE gel before transfer to a nitrocellulose membrane and incubation with
Ab755 diluted 1:500. An increase in mobility would confirm the presence of N-
linked oligosaccharide chains in the native proteins. This can be seen with MAG














The Northern blot with a probe specific to clone OL0755-A demonstrates
that this clone directly correlates with the mRNA of about 3 kb identified by clone
OL0755. It was not possible to repeat this experiment with a probe specific to clone
OL0755-B since it only contains a small 50 bp segment which is not also present in
clone OL0755-A.
The anti-peptide antibody generated against the N-terminus, common to both
encoded proteins, reacted with two proteins a little larger than actin (43 kD).
Unfortunately the titre of the full bleed was a little less than in the test bleed. In a
developmental Western blot the two proteins which reacted with Ab755 were of a
size which correlated well with that predicted from sequence analysis of clones
OL0755-A and OL0755-B. This gave support to the notion that clones OL0755-A
and OL0755-B were full length cDNAs.
Both the mRNAs and encoded proteins are developmentallv regulated with
peak expression at P21. The smaller clone and associated protein is consistently less
abundant than the larger throughout development.
It was not possible to investigate protein expression patterns but mRNA
expression in P21 rat brain is predominantly neuronal with some expression in glial
cells which was confirmed by ISH studies on optic nerve. Neither protein appears to
be phosphorylated or glycosylated so it is difficult to assign a particular role for
these proteins although their developmental profile and specificity to the CNS
suggest a potential role in nervous system development.
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CHAPTER 4. DISCUSSION
4.1 Was subtractive hybridisation a successful approach to identifying novel
components involved in the development of the nervous system?
Subtractive hybridisation is a powerful technique for identifying genes which
demonstrate cell type or developmental stage specific expression (Watson and
Marguiles, 1993). A glial progenitor cDNA library was used to remove common
sequences from a differentiated glial library. The remaining sequences were
subcloned to prepare the subtracted cDNA library comprising clones which are
specific to differentiated glia. The complexity of this library was approximately
300,000. Many of the known sequences identified included the well characterised
myelin proteins such as MBP and PLP (see Table 3.1) These proteins are expressed
by differentiated glia and therefore indicate that the subtraction process has been
successful in screening out sequences also expressed by progenitor cells. Of the
1003 clones analysed, 86 proved to be novel when their partial sequences were
compared with the EMBL and Genbank databases. This is 8.6% of the clones
analysed. Five clones, 0.5% of the total, were novel and specific to the nervous
system. A particularly important feature of subtractive hybridisation is that it greatly
enhances the probability of isolating sequences encoding rare mRNAs which are the
ones most likely to be cell specific. It has been suggested that this technique is able
to detect transcripts with an abundance of less than 0.001% in an mRNA population
in vivo (Ausubel et al. 1992). Therefore the five brain specific clones isolated, with
an abundance of 0.5% of the total number of clones analysed, are likely to be rare
mRNAs present in differentiated glia which have been enriched for during the
subtraction process and indicate that the subtractive hybridisation approach was a
successful means of identifying novel genes possibly involved in nervous system
development. They also indicate that the differentiated glial subtractive library is a
rich resource of additional novel nervous system clones for future investigations.
4.2 Deductions about the five novel clones from Northern blots and ISH studies
on cultured glial cells.
When the expression patterns of the five novel cDNA clones were examined
by Northern blotting they all identified mRNAs which were large in size, except
clone OL0755 which was also the only clone to identify more than one mRNA. Two
clones were expressed in both the PNS and CNS indicating expression by a cell
type(s) common to both such as neurons or myelinating glia. Clone OL0816 was
only expressed in brain. It was not detected in either optic nerve or sciatic nerve, so
this indicates possible expression by a subset of neurons present only in brain tissue.
Clones OL0755 and OL0848 both showed a pattern of expression specific to the
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CNS. Signal detected in optic nerve indicates expression by glial cells i.e.
oligodendrocytes and/or astrocytes. Since it is generally accepted that neuronal
axons do not contain mRNAs and there are no neuronal cell bodies in optic nerve,
signal in optic nerve on the Northern blot cannot arise from expression by neurons.
Northern blot results therefore indicate that clones OL0755 and OL0848 are
expressed by neurons and/or glial cells. ;
Clone OL0003 appears to demonstrate an upregulation in expression from PI
to P10. In the rat CNS PI corresponds to a time just before oligodendrocytes first
appear and begin to myelinate nerve axons. This time would also correspond to the
switching on of genes required for the process of myelination. By P10 myelination
is well underway and there is generally high expression of proteins involved such as
MBP and PLP etc. There is considerably more than residual expression of clone
OL0003 at PI so it appears unlikely that this clone is expressed exclusively by
differentiated glia, unlike MBP. The expression pattern for MBP (not shown)
demonstrates no signal at all at PI and intense signal at P10 corresponding to the
change from undifferentiated progenitor cells present at around the time of birth and
which do not express MBP, to differentiated oligodendrocytes expressing MBP as
they synthesise myelin.
Clone OL0003 was subsequently proved to encode the 3'-untranslated region
of neurofascin by M. Collinson. This protein is a member of a subgroup of the Ig
superfamily called the LI CAMS and has been implicated in neurite outgrowth,
fasciculation and inter-neuronal adhesion (Grumet et al., 1991; Rathjen and
Schachner, 1984; Volkmer et al., 1992). It is widely recognised as a neuronal cell
adhesion molecule (CAM) but recent studies have also shown it to be expressed by
oligodendrocytes (Moscoso and Sanes, 1995) as did the ISH studies carried out on
cultured glial cells in this study. Neurofascin is developmentally regulated in
oligodendrocytes with mRNA first detectable when the gene for PLP becomes
transcriptionally active. Expression declines when ensheathment of the target axon
begins, therefore neurofascin appears not to be involved in compaction or
stabilisation of the myelin sheath (Collinson et al, 1997). Although expression
declines in oligodendrocytes it continues to be expressed by neurons into adulthood.
Neurofascin has been implicated as a candidate cell surface molecule mediating and
signalling axon-glial interaction during the first stages of myelination (Collinson et
al., 1997). Therefore the significant signal at PI on the Northern blot probed with
clone OL0003 is most likely due to expression of neurofascin by neurons before
myelination begins. By P10 the signal is due to both neurons and oligodendrocytes
which are actively interacting during the first stages of myelination. It could be
77
noted that the subtraction process should have removed all sequences expressed by
progenitor cells and therefore no clones with expression at PI should have been
identified. However, perhaps the low abundance of these clones in the cDNA
libraries could explain how they managed to avoid the subtraction process. Possibly
if the subtraction had been performed more than twice, such clones would have been
removed.
When expression of the five clones was analysed more closely by ISH
experiments on cultured glial cells, all five clones appeared to be expressed by cells
of the oligodendrocyte lineage which were labelled immunocytochemically by the
monoclonal antibody 04. Clone OL0755 showed expression by both
oligodendrocytes and astrocytes. This result agrees with the Northern blotting
analysis in which a signal was evident in optic nerve indicating expression by glial
cells. Interestingly, clone OL0816 is the only other clone to show expression by
both glial cell types, although weakly. However no signal was detected in optic
nerve on the Northern blot. This may reflect a difference in sensitivity between the
two techniques. Alternatively the results from ISH experiments on cultured cells
may be less representative of what actually occurs in vivo. It is possible that cells in
culture are induced to express some proteins artificially. An example is MAP5, also
known as MAP IB (Vouyiouklis and Brophy, 1993), which has been shown to be
expressed in cultured oligodendrocytes but in vivo is expressed primarily in neurons
(Fischer et al., 1990; Schoenfeld et al., 1989). Hence it is important to employ
caution when interpreting results obtained from an in vitro environment and
extrapolating them to an in vivo situation.
4.3 The relationship of clones OL0755-A and OL0755-B to OL0755.
Clone OL0755 was chosen for further investigation. Since this cDNA clone
contained an insert of about 1 kb in size and yet identified mRNAs on Northern blots
of around 2 and 3 kb, it could not possibly be full length. It was therefore used to
screen a cDNA library to obtain related clones which could be full length. The
library screened was oligo dT primed since from the partial sequence it was known
that the 3' end of clone OL0755 was complete and included a polyadenylation signal
and a polyA tail. The library was also directionally cloned in the NotI to Sail
direction to ensure that any related sequences identified by clone OL0755 could be
correctly oriented. The cDNAs from mixed aged rat brains enhanced the chances of
identifying related clones since from the Northern blot it was known that clone
OL0755 related mRNAs were expressed at PI and P10. Two clones, OL0755-A and
OL0755-B, were isolated from this library.
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Sequence analysis of clones OL0755-A and OL0755-B showed them to be
closely related. The pattern of similarity between them suggests that they are likely
to have arisen from the alternative splicing of a primary transcript encoded by a
common gene. Alternative splicing is a common phenomenon amongst proteins
involved in myelination. MBP has at least six different isoforms which are all
products of alternative splicing mechanisms. PLP, MAG and CNPase also use
alternative splicing as a way to increase protein variation in the nervous system.
Related proteins with the same N-terminus and different C-termini, as occurs with
clones OL0755-A and OL0755-B, is also not unusual as illustrated by MOBP.
The relationship of clones OL0755-A and OL0755-B with clone OL0755 is
less straightforward. Comparing clone OL0755 with OL0755-B, it appears that
three sections of sequence present in OL0755-B are missing from OL0755; a large
section of about 600 bp towards the 3' end, a very small 10 bp section towards the 5'
end and the 5' terminal sequence. These identical sections of sequence are,
however, present in clone OL0755-A, although they are also interspersed by
sequence unique and specific to clone OL0755-A. There are two possible
explanations for the relationship between OL0755 and the other two clones. The
first is that OL0755 represents the partial 3' sequence of a third related clone. This
clone could possibly correspond to a signal at around 4 kb on the Northern blot
probed by OL0755, although it has been speculated that this signal is due to non¬
specific binding by the ribosomal subunit. If clone OL0755 does represent another
4 kb variant then a further 3 kb of 5' sequence is missing. It would also be much
more difficult to explain the relationship of all three clones by alternative splicing
mechanisms. The second possibility, which is probably the more plausible, is that a
mistake occurred during the construction of the original cDNA libraries used for the
subtractive hybridisation. During the reverse transcription of isolated polyA RNA
sequences the reverse transcriptase enzyme may have skipped over some of the
sequence resulting in a truncated cDNA clone with sections missing. If this has
occurred then clone OL0755 is probably an artificially truncated form of clone
OL0755-B.
4.4 Evidence that clones OL0755-A and OL0755-B correspond to the mRNAs
identified on the Northern blot and that they are full length cDNAs.
The sizes of clones OL0755-A and OL0755-B approximate to the sizes of the
mRNAs identified on the Northern blot probed by OL0755. Hence they are likely to
represent full length cDNAs. Clone OL0755-A, from sequence analysis is 2771 bp
in length and clone OL0755-B is 2050 bp. These correlate with signals at
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approximately 3 kb and 2 kb respectively on the Northern blot. An exact estimation
of the sizes of the mRNAs identified on the Northern blot is difficult since more
accurate size markers were not available. Additional evidence that these two clones
correspond to the signals on the Northern blot is that probe OL0755-A(S), derived
from the 600 bp fragment of sequence specific to clone OL0755-A, clearly identified
a single mRNA molecule corresponding to the band at approximately 3 kb. Since
there is only a very small fragment of sequence which is specific to clone OL0755-B
(approximately 50 bp) is was not possible to repeat this experiment to show that
clone OL0755-B directly correlates with the smaller signal at about 2 kb on the
Northern blot. However, evidence is also provided by the anti-peptide antibody
Ab755 which identifies two proteins with sizes corresponding to those predicted
from sequence analysis of clones OL0755-A and OL0755-B. It was predicted that
clone OL0755-A encoded a protein of about 60 kD (59690 daltons) and clone
OL0755-B encoded one of about 50 kD (49252 daltons). On a Western blot two
proteins with comparable sizes are identified by Ab755. Therefore the evidence
supports the contention that clones OL0755-A and OL0755-B are full length cDNA
clones encoding the mRNAs identified on the original Northern blot.
4,5 What is known about the proteins encoded by clones OL0755-A and
OL0755-B?
When the sequences were compared with the Genbank and EMBL databases,
the only significant similarity was a 95.6% identity of 201 nucleotides (bp 1956-
2157 in clone OL0755-A, which is also present in clone OL0755-B, bp 1247-1448)
with a R. norvegicus brain 262 bp cDNA fragment named clone sap37f which was
isolated from an expression cDNA library with antisera raised against a synaptic
protein preparation, the postsynaptic density fraction (Langnaese et al., 1996). It is
possible therefore that the proteins encoded by clones OL0755-A and OL0755-B
could be associated with synaptic elements of the CNS.
The predicted sequences of the two proteins provide little information about
possible function. From the hydropathy profiles performed on the translated proteins
as predicted by sequence analysis of the cDNA clones, both proteins are mostly
hydrophilic. The 60 kD protein encoded by clone OL0755-A has a 13 amino acid
hydrophobic segment with predicted beta-sheet secondary structure. In theory it is
possible for an extended beta strand of only nine residues to span a lipid bilayer
(Gardinier et al., 1992), so this protein could be a transmembrane protein. The other
50 kD protein has a region of 20 amino acids with potential a-helix structure which
could also span a plasma membrane. However the potential glycosylation sites,
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identified by analysis of the predicted proteins, appear not to be utilised as
demonstrated by the deglycosylation experiments and this suggests that neither of
the proteins are integral membrane proteins. It is not known whether the proteins are
phosphorylated since there was no shift in mobility of the proteins on an
electrophoresis gel following dephosphorylation. A shift in mobility following
dephosphorylation confirms that a protein is phosphorylated but when there is no
shift in mobility the possibility cannot be excluded.
4.6 Expression patterns
mRNA expression for both clones is developmentally regulated as indicated
by a developmental Northern blot. Both clones show peak expression at P21,
although the smaller clone, OL0755-B, is consistently more abundant than the larger
clone, OL0755-A, throughout development. When protein expression is analysed on
a developmental Western blot, the abundance of the smaller protein encoded by
clone OL0755-B increases during development peaking at P21 in complete
agreement with the developmental Northern. However the abundance of the larger
protein encoded by clone OL0755-A appears to decrease as development progresses.
The developmental profiles of both mRNA and protein expression correlate with a
potential role in the development of the nervous system. Neurogenesis primarily
occurs prior to birth in most regions of the brain. Gliogenesis of oligodendrocytes is
principally a postnatal event while for astrocytes it occurs during late foetal
development and postnatally. Since expression of clones OL0755-A and OL0755-B
is detected at PI and they remain constitutively expressed in adults, the encoded
proteins may be important in interactions between glial cells and neurons, perhaps
also in the process of myelination.
When ISH studies were performed on P21 rat sagittal brain sections, an age
corresponding to maximum expression of the mRNAs for clones OL0755-A and
OL0755-B, using clone OL0755 as the probe, since its sequence is common to both
OL0755-A and OL0755-B, strong expression in the granule cell layer of the
cerebellum, the cerebellar nuclei and in the hippocampus indicated a predominantly
neuronal pattern of expression. The granule cell layer of the cerebellum contains
numerous small neurons with non-myelinated axons which pass outwards to the
molecular layer and synapse with the dendrites of Purkinje cells. It is in the granule
cell layer that mRNA expression is strongest.
On closer inspection, however, a few cells in the molecular layer of the
cerebellum also appear to express mRNA detected by clone OL0755. This would
seem to indicate expression by glial cells, although at a lower level than by neurons.
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Further evidence for glial cell expression is present in the forebrain when the brain
sections were double labelled immunocytochemically with antibodies identifying
oligodendrocytes and astrocytes. Although morphological preservation of these cells
in the section is far from ideal, there do appear to be some cells positively labelled
with an anti-MBP antibody (oligodendrocytes) which are also labelled by ISH, and
other cells labelled by an anti-GFAP antibody (astrocytes) which are also indicated
by ISH labelling. The expression of mRNA, identified by clone OL0755, in glial
cells is further supported by the ISH studies on rat optic nerve. Compared to the
sense control, clone OL0755 is definitely identifying mRNA present in optic nerve.
Since, as previously discussed, it is widely accepted that the optic nerve does not
contain neuronal cell bodies then these signals must arise from expression by glial
cells. This is in agreement with the results from ISH studies on cultured glial cells
and Northern blotting of optic nerve. Therefore it appears that mRNAs identified by
clone OL0755 are expressed predominantly by neurons but also to a lesser extent by
glial cells.
When the mRNA expression pattern specific to clone OL0755-A was
investigated using OL0755-A(S) as a probe, a very similar pattern was observed to
that when OL0755 was the probe. Expression was predominantly neuronal again
with strongest expression in the granule cell layer of the cerebellum. Signal was
quite intense in the hippocampus and there was also some labelling of cerebellar
nuclei. Considering that clone OL0755-A mRNA is less abundantly expressed than
OL0755-B as deduced from Northern blots, a weaker signal is expected. When the
same investigation was done on optic nerve, a signal, significantly weaker than that
detected by OL0755 was produced. It therefore appears that the expression pattern
for clone OL0755-A, although less intense, is the same as that detected by clone
OL0755. Unfortunately, as previously discussed, it is not possible to repeat this
experiment with a probe specific to clone OL0755-B so it is unknown whether the
expression pattern for this clone is different. It could be that clone OL0755-B
mRNA is expressed only by one specific cell type as opposed to expression by
neurons and glia as demonstrated by OL0755-A. However when the optic nerve is
probed by OL0755, which is common to both OL0755-A and OL0755-B, the signal
is significantly stronger than when the probe is specific to clone OL0755-A (probe
OL0755-A(S). This indicates that mRNAs in addition to those encoded by clone
OL0755-A are expressed by glial cells in optic nerve and probably correspond to
mRNAs encoded by clone OL0755-B. Therefore it seems likely that mRNA
encoded by clone OL0755-B is expressed at least by glial cells.
Although ISH studies indicate strong expression in neurons and weaker
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expression in glial cells at P21 by clones OL0755-A and OL0755-B this balance of
expression may be different at different ages of development. It could be that at
earlier ages and at times corresponding to active myelination there is a shift of
expression towards glial cells. Further ISH analyses on brain sections of different
ages are required to investigate this possibility.
Attempts were made to investigate the expression patterns of the proteins in
sagittal brain sections using Ab755 but they proved to be unsuccessful possibly
because the epitope is masked somehow by the conformation of the native proteins.
Unsuccessful attempts were also made to denature the proteins in situ and expose the
reacting epitope. Therefore it is not possible at this stage to identify the cellular
locations of these proteins. Work is in progress to generate a fusion protein which
can be used as an antigen. The protein is more likely to be in its natural
conformation and therefore enable an antibody to be raised against an accessible
epitope. Studies can then be carried out to define the cellular localisations of the
proteins which may assist in the elucidation of function.
4.7 Proposed future work
As already discussed, future work should investigate mRNA expression of
each clone in brain sections at different ages to deduce whether there is a shift in
expression towards glial cells at an earlier age. Once a suitable antibody has been
raised, investigations exploring the expression patterns of the encoded proteins can
then proceed. Possibly an antibody specific for the protein encoded by clone
OL0755-A can also be produced. Localisation studies and in situ developmental
profiles of the proteins may suggest potential roles.
Future work could also include the identification of the gene encoding clones
OL0755-A and OL0755-B. Once the encoding gene has been identified, gene
disruption experiments could be performed in a bid to gain information about the
function of the encoded proteins. Fractionation experiments could be performed to
investigate interactions of the proteins with other components of the nervous system.
Identifying binding partners of the proteins may also suggest potential function. The
similarity of a small part of the clones with sap37f which was isolated from an
expression cDNA library with antisera raised against a synaptic protein preparation
(Langnaese et al., 1996) may indicate association of the encoded proteins with
synaptic elements, perhaps as part of some signalling system or transport
mechanism. Investigating potential interactions of the proteins with synaptic
elements may therefore be important. Alternatively interactions with cytoskeletal
elements or extracellular matrix molecules could implicate a structural role. It is
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also possible that these proteins have enzymatic activity and may contribute to the
metabolism of cells in the nervous system. Further investigations in the future will
eventually provide answers about these potentially important and interesting proteins
expressed in the developing CNS.
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